


**CUMULATIVE
SUPPLEMENT 12
DECEMBER 2015**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs**

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

Cumulative Supplement 8

August 2015

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

35th EDITION

**CUMULATIVE SUPPLEMENT 12
December 2015**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2014</u>	<u>MAR 2015</u>	<u>JUN 2015</u>	<u>SEPT 2015</u>	<u>DEC 2015</u>
DRUG PRODUCTS LISTED	16150	16352	16543	16824	17151
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)	2613 (15.5%)	2664 (15.5%)
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)	14211 (84.5%)	14487 (84.5%)
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)	14089 (83.7%)	14366 (83.8%)
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)	122 (0.7%)	121 (0.7%)
EXCEPTIONS ¹	77 (0.5%)	75 (0.5%)	75 (0.5%)	75 (0.4%)	73 (0.4%)
NEW MOLECULAR ENTITIES APPROVED	13	22	12	37	28
NUMBER OF APPLICANTS	927	935	957	975	1011

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
ACETAMINOPHEN

FRESENIUS KABI USA 1GM/100ML (10MG/ML) N204767 001 Oct 28, 2015 Oct NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL

ALLZITAL

LARKEN LABS INC 325MG;25MG A203484 001 Dec 04, 2015 Nov NEWA

BUTALBITAL AND ACETAMINOPHEN

AA LARKEN LABS INC 325MG;50MG A203484 002 Dec 04, 2015 Nov NEWA

AA TEDOR PHARMA INC 325MG;50MG A205120 001 Oct 30, 2015 Oct NEWA

BUTAPAP

AA + MIKART 325MG;50MG A089987 001 Oct 26, 1992 Oct CTEC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORICET

@ ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 Feb CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

FIORICET W/ CODEINE

AB + ACTAVIS LABS UT INC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA SUN PHARM INDS LTD 300MG;30MG A085868 001 Apr CAHN

AA 300MG;60MG A087083 001 Apr CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA + MIKART 325MG;2.5MG A040846 001 Jun 09, 2010 Feb CTEC

@ SUN PHARM INDS LTD 325MG;10MG A040826 001 Aug 16, 2007 Apr CAHN

NORCO

AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Feb NEWA

AA 325MG;5MG A040148 005 Jul 07, 2014 Feb NEWA

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

DIAMOX

AB + TEVA BRANDED PHARM 500MG N012945 001 Jun CAHN

TABLET;ORAL

ACETAZOLAMIDE

@ SUN PHARM INDS 250MG A089753 001 Jun 22, 1988 Nov CAHN

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

@ ANI PHARMS INC 250MG A070869 001 Feb 09, 1987 Jul CAHN

@ 500MG A070870 001 Feb 09, 1987 Jul CAHN

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

AP AKORN INC 6GM/30ML (200MG/ML) A203173 001 Mar 24, 2015 Mar NEWA

AP MYLAN INSTITUTIONAL 6GM/30ML (200MG/ML) A203624 001 Jun 19, 2015 Jun NEWA

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN ALVOGEN INC 10% A204674 001 Feb 11, 2014 Sep CAHN

AN 20% A203853 001 Jun 21, 2012 Sep CAHN

ACITRETINCAPSULE;ORAL
ACITRETIN

AB	MYLAN PHARMS INC	10MG	A202148	001	Sep 10, 2015	Aug NEWA
AB		17.5MG	A203707	001	Sep 10, 2015	Aug NEWA
AB		22.5MG	A203707	002	Sep 10, 2015	Aug NEWA
AB		25MG	A202148	002	Sep 10, 2015	Aug NEWA
AB	SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA
AB		17.5MG	A204633	002	May 22, 2015	May NEWA
AB		22.5MG	A204633	003	May 22, 2015	May NEWA
AB		25MG	A204633	004	May 22, 2015	May NEWA
>A> AB	WATSON LABS INC	10MG	A202552	001	Dec 23, 2015	Dec NEWA
>A> AB		17.5MG	A202552	002	Dec 23, 2015	Dec NEWA
>A> AB		22.5MG	A202552	003	Dec 23, 2015	Dec NEWA
>A> AB		25MG	A202552	004	Dec 23, 2015	Dec NEWA

ACLIDINIUM BROMIDEPOWDER, METERED; INHALATION
TUDORZA PRESSAIR

+	ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN
+		0.4MG/INH	N202450	001	Jul 23, 2012	Aug CPOT

ACYCLOVIRTABLET;ORAL
ACYCLOVIR

AB	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN
AB		800MG	A074980	002	Sep 30, 1998	Apr CAHN

ADAPALENESOLUTION;TOPICAL
ADAPALENE

>A>	+	CALL INC	0.1%	A204593	001	Jan 05, 2016	Dec NEWA
-----	---	----------	------	---------	-----	--------------	----------

ADAPALENE; BENZOYL PEROXIDEGEL;TOPICAL
ADAPALENE AND BENZOYL PEROXIDE

AB		ACTAVIS MID ATLANTIC	0.1%;2.5%	A203790	001	Sep 30, 2015	Sep NEWA
		EPIDUO					
AB	+	GALDERMA LABS LP	0.1%;2.5%	N022320	001	Dec 08, 2008	Sep CFTG
		EPIDUO FORTE					
	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug CAHN
	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Jul NEWA

ADENOSINEINJECTABLE;INJECTION
ADENOSINE

AP	EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun CAHN
	@	3MG/ML	A076501	001	Jun 16, 2004	Sep CAHN
	@ WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May DISC

ALBENDAZOLETABLET, CHEWABLE;ORAL
ALBENZA

>D>	+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Dec DISC
>D>	@		200MG	N207844	001	Jun 11, 2015	Dec DISC
>A>	+		200MG	N207844	001	Jun 11, 2015	Jun NEWA

ALBUTEROL SULFATEPOWDER, METERED; INHALATION
PROAIR RESPICLICK

+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar NEWA
---	--------------------	---------------------	---------	-----	--------------	----------

SYRUP;ORAL

ALBUTEROL SULFATE

AA	G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr CAHN
----	------------------	-----------------	---------	-----	--------------	----------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDEAEROSOL, METERED; INHALATION
COMBIVENT

@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May DISC
---	----------------------	--------------------------------	---------	-----	--------------	----------

>D>	<u>ALCOHOL; DEXTROSE</u>									
>D>	INJECTABLE; INJECTION									
>D>	ALCOHOL 10% AND DEXTROSE 5%									
>D>	+	B BRAUN	10ML/100ML; 5GM/100ML			N004589	006		Dec	DISC
>A>	@		10ML/100ML; 5GM/100ML			N004589	006		Dec	DISC
>D>	ALCOHOL 5% AND DEXTROSE 5%									
>D>	AP	+	B BRAUN	5ML/100ML; 5GM/100ML		N004589	004		Dec	DISC
>A>		@		5ML/100ML; 5GM/100ML		N004589	004		Dec	DISC
>A>	<u>ALECTINIB HYDROCHLORIDE</u>									
>A>	CAPSULE; ORAL									
>A>	ALECENSA									
>A>	+	HOFFMANN-LA ROCHE	EQ 150MG BASE			N208434	001	Dec 11, 2015	Dec	NEWA
	<u>ALFUZOSIN HYDROCHLORIDE</u>									
	TABLET, EXTENDED RELEASE; ORAL									
	ALFUZOSIN HYDROCHLORIDE									
		@	WOCKHARDT LTD	10MG		A090221	001	Aug 10, 2012	Feb	DISC
	UROXATRAL									
AB	+	CONCORDIA PHARMS INC	10MG			N021287	001	Jun 12, 2003	Jun	CAHN
	<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE</u>									
	TABLET; ORAL									
	TEKAMLO									
		@	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE		N022545	001	Aug 26, 2010	May	DISC
		@		EQ 150MG BASE; EQ 10MG BASE		N022545	002	Aug 26, 2010	May	DISC
		@		EQ 300MG BASE; EQ 5MG BASE		N022545	003	Aug 26, 2010	May	DISC
		@		EQ 300MG BASE; EQ 10MG BASE		N022545	004	Aug 26, 2010	May	DISC
	<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE</u>									
	TABLET; ORAL									
	AMTURNIDE									
		@	NOVARTIS	EQ 150MG BASE; EQ 5MG BASE; 12.5MG		N200045	001	Dec 21, 2010	May	DISC
		@		EQ 300MG BASE; EQ 5MG BASE; 12.5MG		N200045	002	Dec 21, 2010	May	DISC
		@		EQ 300MG BASE; EQ 5MG BASE; 25MG		N200045	003	Dec 21, 2010	May	DISC
		@		EQ 300MG BASE; EQ 10MG BASE; 12.5MG		N200045	004	Dec 21, 2010	May	DISC
		@		EQ 300MG BASE; EQ 10MG BASE; 25MG		N200045	005	Dec 21, 2010	May	DISC
	<u>ALMOTRIPTAN MALATE</u>									
	TABLET; ORAL									
	ALMOTRIPTAN MALATE									
AB		MYLAN PHARMS INC	EQ 6.25MG BASE			A205171	001	Nov 09, 2015	Oct	NEWA
AB			EQ 12.5MG BASE			A205171	002	Nov 09, 2015	Oct	NEWA
AB		TEVA PHARMS USA	EQ 6.25MG BASE			A078027	001	Jul 07, 2015	Jun	NEWA
AB			EQ 12.5MG BASE			A078027	002	Jul 07, 2015	Jun	NEWA
	AXERT									
AB		JANSSEN PHARMS	EQ 6.25MG BASE			N021001	001	May 07, 2001	Jun	CFTG
AB	+		EQ 12.5MG BASE			N021001	002	May 07, 2001	Jun	CFTG
	<u>ALOSETRON HYDROCHLORIDE</u>									
	TABLET; ORAL									
	ALOSETRON HYDROCHLORIDE									
AB		ROXANE	EQ 0.5MG BASE			A200652	001	May 04, 2015	Apr	NEWA
AB			EQ 1MG BASE			A200652	002	May 04, 2015	Apr	NEWA
	LOTIRONEX									
AB		PROMETHEUS LABS	EQ 0.5MG BASE			N021107	002	Dec 23, 2003	Apr	CFTG
AB	+		EQ 1MG BASE			N021107	001	Feb 09, 2000	Apr	CFTG
	<u>ALPRAZOLAM</u>									
	TABLET; ORAL									
	ALPRAZOLAM									
		@	ANI PHARMS INC	0.25MG		A074085	001	Feb 16, 1994	Jul	CAHN
		@		0.5MG		A074085	002	Feb 16, 1994	Jul	CAHN
		@		1MG		A074085	003	Feb 16, 1994	Jul	CAHN
		@		2MG		A074085	004	Feb 26, 1996	Jul	CAHN
AB		AUROBINDO PHARMA LTD	0.25MG			A203346	001	Jul 31, 2015	Jul	NEWA
AB			0.5MG			A203346	002	Jul 31, 2015	Jul	NEWA
AB			1MG			A203346	003	Jul 31, 2015	Jul	NEWA
AB			2MG			A203346	004	Jul 31, 2015	Jul	NEWA
AB		NATCO PHARMA LTD	0.25MG			A200739	001	Apr 15, 2015	Mar	NEWA
AB			0.5MG			A200739	002	Apr 15, 2015	Mar	NEWA

TABLET;ORAL									
ALPRAZOLAM									
AB		1MG	A200739	003	Apr 15, 2015	Mar	NEWA		
AB		2MG	A200739	004	Apr 15, 2015	Mar	NEWA		
TABLET, EXTENDED RELEASE;ORAL									
ALPRAZOLAM									
>A>	AB	APOTEX INC	1MG	A078449	004	Dec 23, 2015	Dec	NEWA	
	AB	HERITAGE PHARMS INC	0.5MG	A078489	001	Oct 17, 2008	Sep	CAHN	
	AB		1MG	A078489	002	Oct 17, 2008	Sep	CAHN	
	AB		2MG	A078489	003	Oct 17, 2008	Sep	CAHN	
	AB		3MG	A078489	004	Oct 17, 2008	Sep	CAHN	
<u>AMANTADINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
AMANTADINE HYDROCHLORIDE									
AB		BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN	
SYRUP;ORAL									
AMANTADINE HYDROCHLORIDE									
	@	G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May	CAHN	
	@	SILARX	50MG/5ML	A076352	001	Sep 10, 2004	Oct	DISC	
	@	VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006	Oct	DISC	
<u>AMIKACIN SULFATE</u>									
INJECTABLE;INJECTION									
AMIKACIN SULFATE									
AP		FRESENIUS KABI USA	EQ 50MG BASE/ML	A205605	001	Dec 09, 2015	Nov	NEWA	
AP			EQ 250MG BASE/ML	A205604	001	Dec 09, 2015	Nov	NEWA	
	@	IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN	
	@		EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN	
<u>AMILORIDE HYDROCHLORIDE</u>									
TABLET;ORAL									
AMILORIDE HYDROCHLORIDE									
AB		ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA	
<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
>D>		TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER							
>D>		BAXTER HLTHCARE	5.5%;102MG/100ML;522MG/100ML;431MG	N020173	001	Oct 27, 1995	Dec	DISC	
>A>	@		/100ML;224MG/100ML						
			5.5%;102MG/100ML;522MG/100ML;431MG	N020173	001	Oct 27, 1995	Dec	DISC	
			/100ML;224MG/100ML						
>D>		TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER							
>D>		BAXTER HLTHCARE	8.5%;102MG/100ML;522MG/100ML;594MG	N020173	002	Oct 27, 1995	Dec	DISC	
>A>	@		/100ML;154MG/100ML						
			8.5%;102MG/100ML;522MG/100ML;594MG	N020173	002	Oct 27, 1995	Dec	DISC	
			/100ML;154MG/100ML						
<u>AMINOCAPROIC ACID</u>									
SYRUP;ORAL									
AMINOCAPROIC ACID									
AA		VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN	
TABLET;ORAL									
AMINOCAPROIC									
AB		VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN	
<u>AMIODARONE HYDROCHLORIDE</u>									
TABLET;ORAL									
AMIODARONE HYDROCHLORIDE									
>D>	AB	BARR	200MG	A075389	001	Jan 25, 2001	Dec	CAHN	
>A>	AB	SWAN PHARMS LLC	200MG	A075389	001	Jan 25, 2001	Dec	CAHN	
<u>AMITRIPTYLINE HYDROCHLORIDE</u>									
TABLET;ORAL									
AMITRIPTYLINE HYDROCHLORIDE									
	@	ANI PHARMS INC	10MG	A084910	003		Aug	CAHN	
	@		25MG	A085031	001		Aug	CAHN	
	@		50MG	A085032	001		Aug	CAHN	
	@		75MG	A085030	001		Aug	CAHN	

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

LIMBITROL

@ HERITAGE PHARMS INC EQ 12.5MG BASE;5MG

N016949 001

Jul CAHN

LIMBITROL DS

@ HERITAGE PHARMS INC EQ 25MG BASE;10MG

N016949 002

Jul CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

AB ASCENT PHARMS INC EQ 2.5MG BASE

A206367 001 Dec 10, 2015 Nov NEWA

AB EQ 5MG BASE

A206367 002 Dec 10, 2015 Nov NEWA

AB EQ 10MG BASE

A206367 003 Dec 10, 2015 Nov NEWA

AB CHINA RESOURCES EQ 5MG BASE

A090752 001 Apr 15, 2011 Mar CAHN

AB EQ 10MG BASE

A090752 002 Apr 15, 2011 Mar CAHN

AB MYLAN PHARMS INC EQ 2.5MG BASE

A078224 001 Feb 27, 2008 Sep CAHN

AB EQ 5MG BASE

A078224 002 Feb 27, 2008 Sep CAHN

AB EQ 10MG BASE

A078224 003 Feb 27, 2008 Sep CAHN

AB SOVEREIGN PHARMS EQ 2.5MG BASE

A204900 001 Jul 23, 2015 Jul NEWA

AB EQ 5MG BASE

A204900 002 Jul 23, 2015 Jul NEWA

AB EQ 10MG BASE

A204900 003 Jul 23, 2015 Jul NEWA

AB SUN PHARM INDS LTD EQ 2.5MG BASE

A077974 001 Jul 09, 2007 Apr CAHN

AB EQ 5MG BASE

A077974 002 Jul 09, 2007 Apr CAHN

AB EQ 10MG BASE

A077974 003 Jul 09, 2007 Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB LUPIN LTD 5MG;12.5MG;160MG

A200797 001 Jun 03, 2015 May NEWA

AB 5MG;25MG;160MG

A200797 002 Jun 03, 2015 May NEWA

AB 10MG;12.5MG;160MG

A200797 003 Jun 03, 2015 May NEWA

AB 10MG;25MG;160MG

A200797 004 Jun 03, 2015 May NEWA

AB 10MG;25MG;320MG

A200797 005 Jun 03, 2015 May NEWA

AB PAR PHARM 5MG;12.5MG;160MG

A201087 001 Jun 01, 2015 May NEWA

AB 5MG;25MG;160MG

A201087 002 Jun 01, 2015 May NEWA

AB 10MG;12.5MG;160MG

A201087 003 Jun 01, 2015 May NEWA

AB 10MG;25MG;160MG

A201087 004 Jun 01, 2015 May NEWA

AB 10MG;25MG;320MG

A201087 005 Jun 01, 2015 May NEWA

AB TEVA PHARMS 5MG;12.5MG;160MG

A200435 001 Sep 25, 2012 May CAIN

AB 5MG;25MG;160MG

A200435 002 Sep 25, 2012 May CAIN

AB 10MG;12.5MG;160MG

A200435 005 Sep 25, 2012 May CAIN

AB 10MG;25MG;160MG

A200435 003 Sep 25, 2012 May CAIN

AB 10MG;25MG;320MG

A200435 004 Sep 25, 2012 May CAIN

AB TORRENT PHARMS LTD 5MG;12.5MG;160MG

A201593 001 Jun 03, 2015 Sep CMS1

AB 5MG;12.5MG;160MG

A201593 001 Jun 04, 2015 May NEWA

AB 5MG;25MG;160MG

A201593 002 Jun 03, 2015 Sep CMS1

AB 5MG;25MG;160MG

A201593 002 Jun 04, 2015 May NEWA

AB 10MG;12.5MG;160MG

A201593 003 Jun 03, 2015 Sep CMS1

AB 10MG;12.5MG;160MG

A201593 003 Jun 04, 2015 May NEWA

AB 10MG;25MG;160MG

A201593 004 Jun 03, 2015 Sep CMS1

AB 10MG;25MG;160MG

A201593 004 Jun 04, 2015 May NEWA

AB 10MG;25MG;320MG

A201593 005 Jun 03, 2015 Sep CMS1

AB 10MG;25MG;320MG

A201593 005 Jun 04, 2015 May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

SYMPLMED PHARMS LLC EQ 2.5MG BASE;3.5MG

N205003 001 Jan 21, 2015 Jan NEWA

EQ 5MG BASE;7MG

N205003 002 Jan 21, 2015 Jan NEWA

+ EQ 10MG BASE;14MG

N205003 003 Jan 21, 2015 Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB ALEMBIC PHARMS LTD EQ 5MG BASE;160MG

A202713 001 Apr 03, 2015 Mar NEWA

AB EQ 5MG BASE;320MG

A202713 003 Apr 03, 2015 Mar NEWA

AB EQ 10MG BASE;160MG

A202713 002 Apr 03, 2015 Mar NEWA

AB EQ 10MG BASE;320MG

A202713 004 Apr 03, 2015 Mar NEWA

AB LUPIN EQ 5MG BASE;160MG

A090245 001 Mar 30, 2015 Mar NEWA

AB EQ 5MG BASE;320MG

A090245 003 Mar 30, 2015 Mar NEWA

AB EQ 10MG BASE;160MG

A090245 002 Mar 30, 2015 Mar NEWA

AB EQ 10MG BASE;320MG

A090245 004 Mar 30, 2015 Mar NEWA

TABLET;ORAL

AMLODIPINE BESYLATE AND VALSARTAN

AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015	Apr	CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015	Apr	CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015	Apr	CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

AP	3D IMAGING DRUG	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203779	001	Oct 19, 2015	Oct	NEWA
AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr	NEWA
	@ CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Nov	DISC
		3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun	NEWA
>A>	ESSENTIAL ISOTOPES	3.75-260mCi/ML	A205687	001	Dec 17, 2015	Dec	NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr	NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
AP	PETNET	30mCi-300mCi (3.75-37.5mCi/ML)	A204510	001	Nov 02, 2015	Oct	NEWA
	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug	NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL

AMOXICILLIN

@ SUN PHARM INDS LTD

@

200MG/5ML

400MG/5ML

A065113 001 Nov 29, 2002 Apr CAHN

A065113 002 Nov 29, 2002 Apr CAHN

TABLET;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr	CAHN
	@	200MG	A065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr	CAHN
	@	400MG	A065060	002	Nov 29, 2000	Apr	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD

AB		500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL
DYANA VEL XR

+ TRIS PHARMA INC EQ 2.5MG BASE/ML N208147 001 Oct 19, 2015 Oct NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A 040444	005	Nov 03, 2014	May NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040444	006	Nov 03, 2014	May NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040444	007	Nov 03, 2014	May NEWA
AB	MYLAN PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 206721	001	Nov 10, 2015	Oct NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A 206721	002	Nov 10, 2015	Oct NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 206721	003	Nov 10, 2015	Oct NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 206721	004	Nov 10, 2015	Oct NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 206721	005	Nov 10, 2015	Oct NEWA
AB		5MG;5MG;5MG;5MG	A 206721	006	Nov 10, 2015	Oct NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 206721	007	Nov 10, 2015	Oct NEWA
AB	SUN PHARM INDS	1.25MG;1.25MG;1.25MG;1.25MG	A 040480	001	Sep 09, 2003	Nov CAHN
AB		1.875MG;1.875MG;1.875MG;1.875MG	A 040480	002	Sep 09, 2003	Nov CAHN
AB		2.5MG;2.5MG;2.5MG;2.5MG	A 040480	003	Sep 09, 2003	Nov CAHN
AB		3.125MG;3.125MG;3.125MG;3.125MG	A 040480	004	Sep 09, 2003	Nov CAHN
AB		3.75MG;3.75MG;3.75MG;3.75MG	A 040480	005	Sep 09, 2003	Nov CAHN
AB		5MG;5MG;5MG;5MG	A 040480	006	Sep 09, 2003	Nov CAHN
AB		7.5MG;7.5MG;7.5MG;7.5MG	A 040480	007	Sep 09, 2003	Nov CAHN

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

	ARBOR PHARMS LLC	5MG	A 200166	001	Aug 09, 2012	Mar CTNA
+		10MG	A 200166	002	Aug 09, 2012	Mar CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

AP	HOSPIRA INC	EQ 250MG BASE/VIAL	A 202864	001	Sep 04, 2015	Aug NEWA
AP		EQ 500MG BASE/VIAL	A 202864	002	Sep 04, 2015	Aug NEWA
AP		EQ 1GM BASE/VIAL	A 202864	003	Sep 04, 2015	Aug NEWA
AP		EQ 2GM BASE/VIAL	A 202864	004	Sep 04, 2015	Aug NEWA
AP		EQ 10GM BASE/VIAL	A 202865	001	Sep 04, 2015	Aug NEWA
AP	SAGENT PHARMS	EQ 125MG BASE/VIAL	A 090583	001	Nov 27, 2015	Nov NEWA
AP		EQ 250MG BASE/VIAL	A 090583	002	Nov 27, 2015	Nov NEWA
AP		EQ 500MG BASE/VIAL	A 090583	003	Nov 27, 2015	Nov NEWA
AP		EQ 1GM BASE/VIAL	A 090583	004	Nov 27, 2015	Nov NEWA
AP		EQ 2GM BASE/VIAL	A 090583	005	Nov 27, 2015	Nov NEWA
AP		EQ 10GM BASE/VIAL	A 090581	001	Oct 20, 2015	Oct NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

AMPICILLIN AND SULBACTAM

AP	ANTIBIOTICS SA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 201406	001	Dec 07, 2015	Nov NEWA
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 201406	002	Dec 07, 2015	Nov NEWA
>A> AP	SAGENT PHARMS	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A 090579	001	Jan 08, 2016	Dec NEWA
>A> AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A 090579	002	Jan 08, 2016	Dec NEWA
>A> AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A 090578	001	Jan 11, 2016	Dec NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

@	G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A 061741	001		Apr CAHN
---	------------------	---------------------------	----------	-----	--	----------

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

@	KREMERS URBAN PHARMS	1MG	A 091331	001	Jan 05, 2011	Mar CAHN
---	----------------------	-----	----------	-----	--------------	----------

APREPITANT

>A> FOR SUSPENSION; ORAL

>A> EMEND

>A> + MSD MERCK CO 125MG/KIT N207865 001 Dec 17, 2015 Dec NEWA

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML)

N201811 001 Mar 23, 2015 Apr CDFR

AP + PFIZER 250MG/2.5ML (100MG/ML)

N020883 001 Jun 30, 2000 Aug CTNA

INJECTABLE; IV (INFUSION)

ARGATROBAN

AP FRESENIUS KABI USA 250MG/2.5ML (100MG/ML)

N201811 001 Mar 23, 2015 Mar NEWA

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

AA AMNEAL PHARMS 1MG/ML

A203906 001 Aug 14, 2015 Aug NEWA

AA APOTEX INC 1MG/ML

A204094 001 Sep 30, 2015 Sep NEWA

AA SILARX PHARMS INC 1MG/ML

A204171 001 Aug 14, 2015 Aug NEWA

TABLET; ORAL

ABILIFY

AB OTSUKA

2MG

N021436 006 Nov 15, 2002 Apr CFTG

AB +

5MG

N021436 005 Nov 15, 2002 Apr CFTG

AB +

10MG

N021436 001 Nov 15, 2002 Apr CFTG

AB

15MG

N021436 002 Nov 15, 2002 Apr CFTG

AB

20MG

N021436 003 Nov 15, 2002 Apr CFTG

AB

30MG

N021436 004 Nov 15, 2002 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD

2MG

A202101 001 Apr 28, 2015 Apr NEWA

AB

5MG

A202101 002 Apr 28, 2015 Apr NEWA

AB

10MG

A202101 003 Apr 28, 2015 Apr NEWA

AB

15MG

A202101 004 Apr 28, 2015 Apr NEWA

AB

20MG

A202101 005 Apr 28, 2015 Apr NEWA

AB

30MG

A202101 006 Apr 28, 2015 Apr NEWA

AB APOTEX INC

2MG

A078583 001 Jul 24, 2015 Jul NEWA

AB

5MG

A078583 002 Jul 24, 2015 Jul NEWA

AB

10MG

A078583 003 Jul 24, 2015 Jul NEWA

AB

15MG

A078583 004 Jul 24, 2015 Jul NEWA

AB

20MG

A078583 005 Jul 24, 2015 Jul NEWA

AB

30MG

A078583 006 Jul 24, 2015 Jul NEWA

AB AUROBINDO PHARMA LTD

2MG

A203908 001 Oct 08, 2015 Sep NEWA

AB

5MG

A203908 002 Oct 08, 2015 Sep NEWA

AB

10MG

A203908 003 Oct 08, 2015 Sep NEWA

AB

15MG

A203908 004 Oct 08, 2015 Sep NEWA

AB

20MG

A203908 005 Oct 08, 2015 Sep NEWA

AB

30MG

A203908 006 Oct 08, 2015 Sep NEWA

AB HETERO LABS LTD V

2MG

A205064 001 Apr 28, 2015 Apr NEWA

AB

5MG

A205064 002 Apr 28, 2015 Apr NEWA

AB

10MG

A205064 003 Apr 28, 2015 Apr NEWA

AB

15MG

A205064 004 Apr 28, 2015 Apr NEWA

AB

20MG

A205064 005 Apr 28, 2015 Apr NEWA

AB

30MG

A205064 006 Apr 28, 2015 Apr NEWA

AB TEVA PHARMS USA

2MG

A078607 001 Apr 28, 2015 Apr NEWA

AB

5MG

A078607 002 Apr 28, 2015 Apr NEWA

AB

10MG

A078608 001 Apr 28, 2015 Apr NEWA

AB

15MG

A078708 001 Apr 28, 2015 Apr NEWA

AB

20MG

A078708 002 Apr 28, 2015 Apr NEWA

AB

30MG

A078708 003 Apr 28, 2015 Apr NEWA

AB TORRENT PHARMS LTD

2MG

A201519 001 Apr 28, 2015 Apr NEWA

AB

10MG

A201519 003 Apr 28, 2015 Apr NEWA

AB

5MG

A201519 002 Apr 28, 2015 Apr NEWA

AB

15MG

A201519 004 Apr 28, 2015 Apr NEWA

AB

20MG

A201519 005 Apr 28, 2015 Apr NEWA

AB

30MG

A201519 006 Apr 28, 2015 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

ABILIFY

AB + OTSUKA

10MG

N021729 002 Jun 07, 2006 Apr CFTG

AB

15MG

N021729 003 Jun 07, 2006 Apr CFTG

ARIPIPIRAZOLE

AB ALEMBIC PHARMS LTD

10MG

A202102 001 Apr 28, 2015 Apr NEWA

AB

15MG

A202102 002 Apr 28, 2015 Apr NEWA

ARIPIPRAZOLE LAUROXILSUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
ARISTADA

ALKERMES INC	441MG/1.6ML (275.63MG/ML)	N207533	001	Oct 05, 2015	Oct NEWA
	662MG/2.4ML (275.83MG/ML)	N207533	002	Oct 05, 2015	Oct NEWA
+	882MG/3.2ML (275.63MG/ML)	N207533	003	Oct 05, 2015	Oct NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

@ IGI LABS INC

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL	N018933	002	Aug 08, 1985	Jun CAHN
---	---------	-----	--------------	----------

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

@ NOVEL LABS INC

4.7GM; 100GM; 1.015GM; 5.9GM; 2.691GM; 7.5GM	A090145	001	Jan 25, 2012	Aug CTNA
--	---------	-----	--------------	----------

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

FOREST LABS LLC

EQ 5MG BASE

N022117	001	Aug 13, 2009	Jun CAHN
---------	-----	--------------	----------

+

EQ 10MG BASE

N022117	002	Aug 13, 2009	Jun CAHN
---------	-----	--------------	----------

ASPIRIN

CAPSULE, EXTENDED RELEASE; ORAL

DURLAZA

+ NEW HAVEN PHARMS

162.5MG

N200671	001	Sep 04, 2015	Sep NEWA
---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

FIORINAL

AA + ACTAVIS LABS UT INC

325MG; 50MG; 40MG

N017534	005	Apr 16, 1986	Jan CAHN
---------	-----	--------------	----------

TABLET; ORAL

FIORINAL

@ ACTAVIS LABS UT INC

325MG; 50MG; 40MG

N017534	003	Apr 16, 1986	Jan CAHN
---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE

AB COASTAL PHARMS

325MG; 50MG; 40MG; 30MG

A203335	001	Oct 30, 2015	Oct NEWA
---------	-----	--------------	----------

FIORINAL W/CODEINE

AB + ACTAVIS LABS UT INC

325MG; 50MG; 40MG; 30MG

N019429	003	Oct 26, 1990	Jan CAHN
---------	-----	--------------	----------

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

SYNALGOS-DC

+ SUN PHARM INDS

356.4MG; 30MG; 16MG

N011483	004	Sep 06, 1983	Aug CAHN
---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

SANDOZ

385MG; 30MG; 25MG

A074654	001	Dec 31, 1996	Mar CTEC
---------	-----	--------------	----------

+

770MG; 60MG; 50MG

A074654	002	Dec 31, 1996	Mar CTEC
---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA ACTAVIS LABS FL INC

325MG; 4.8355MG

A090084	001	Mar 22, 2011	Mar CAHN
---------	-----	--------------	----------

ATAZANAVIR SULFATE; COBICISTAT

TABLET; ORAL

EVOTAZ

+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan NEWA
---	----------------------	---------------------	---------	-----	--------------	----------

ATENOLOL

TABLET; ORAL

ATENOLOL

AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jul CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jul CAHN
	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun DISC
AB	SUN PHARM INDS	25MG	A074499	001	Jul 30, 1997	Nov CAHN
AB		50MG	A073475	001	Mar 30, 1993	Nov CAHN
AB		100MG	A073476	001	Mar 30, 1993	Nov CAHN
	TENORMIN					
AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb CAHN
AB		50MG	N018240	001		Feb CAHN
AB	+	100MG	N018240	002		Feb CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul CAHN	
AB		100MG;25MG	A072302	001	May 31, 1990	Jul CAHN	
	TENORETIC 100						
AB	+	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb CAHN
	TENORETIC 50						
AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb CAHN	

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar NEWA
----	-------------------	-------------	---------	-----	--------------	----------

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar NEWA
	ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar NEWA

ATROPINE SULFATE

SOLUTION/DROPS; OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May CRLD
---	-------	----	---------	-----	--------------	----------

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET; ORAL

MOTOFEN

+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN
	MOTOFEN HALF-STRENGTH					
	@ SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ ANI PHARMS INC

0.025MG; 2.5MG

A086727 001

Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER; IV (INFUSION)

AVYCAZ

+ CEREXA INC

EQ 0.5GM BASE; 2GM/VIAL

N206494 001 Feb 25, 2015

Feb NEWA

AZELAIC ACID

AEROSOL, FOAM; TOPICAL

FINACEA

+ BAYER HLTHCARE

15%

N207071 001 Jul 29, 2015

Jul NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTEPRO

AB + MEDA PHARMS

EQ 0.1876MG BASE/SPRAY

N022203 002 Aug 31, 2009

Nov CMS1

AZELASTINE HYDROCHLORIDE

AB BRECKENRIDGE PHARMS

EQ 0.125MG BASE/SPRAY

A090176 001 Jul 28, 2015

Jul NEWA

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 100MG BASE/5ML

A065488 001 May 15, 2015

May NEWA

AB

EQ 200MG BASE/5ML

A065488 002 May 15, 2015

May NEWA

INJECTABLE; INJECTION

AZITHROMYCIN

AP AUROBINDO PHARMA LTD

EQ 500MG BASE/VIAL

A203294 001 Jun 19, 2015

Jun NEWA

TABLET; ORAL

AZITHROMYCIN

AB LUPIN LTD

EQ 250MG BASE

A065398 001 May 15, 2015

May NEWA

AB

EQ 500MG BASE

A065399 001 May 15, 2015

May NEWA

AB

EQ 600MG BASE

A065400 001 May 15, 2015

May NEWA

BALSALAZIDE DISODIUM

CAPSULE; ORAL

COLAZAL

AB + VALEANT PHARMS INTL

750MG

N020610 001 Jul 18, 2000

Jul CAHN

TABLET; ORAL

BALSALAZIDE DISODIUM

AB PAR PHARM INC

1.1GM

A206336 001 Sep 08, 2015

Aug NEWA

GIAZO

AB + VALEANT PHARMS INTL

1.1GM

N022205 001 Feb 03, 2012

Aug CFTG

+

1.1GM

N022205 001 Feb 03, 2012

Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB AMNEAL PHARMS LLC

5MG

A076820 001 Feb 03, 2006

Jan CAHN

AB

10MG

A076820 002 Feb 03, 2006

Jan CAHN

AB

20MG

A076820 003 Feb 03, 2006

Jan CAHN

AB

40MG

A076820 004 Feb 03, 2006

Jan CAHN

AB SUN PHARM INDS LTD

5MG

A076344 001 Feb 11, 2004

Apr CAHN

AB

10MG

A076344 002 Feb 11, 2004

Apr CAHN

AB

20MG

A076344 003 Feb 11, 2004

Apr CAHN

AB

40MG

A076344 004 Feb 11, 2004

Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB SUN PHARM INDS LTD

5MG; 6.25MG

A077483 001 Sep 08, 2005

Apr CAHN

AB

10MG; 12.5MG

A077483 002 Sep 08, 2005

Apr CAHN

AB

20MG; 12.5MG

A077483 003 Sep 08, 2005

Apr CAHN

AB

20MG; 25MG

A077483 004 Sep 08, 2005

Apr CAHN

BENDAMUSTINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

>A> BENDEKA

>A> EAGLE PHARMS 100MG/4ML (25MG/ML) N208194 001 Dec 07, 2015 Dec NEWA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
AA		200MG	A091310	002	Jan 16, 2015	Jan NEWA
AA	BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan CAHN
AA	CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
AA	STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Jul NEWA
AA		200MG	A091133	002	Jul 30, 2015	Jul NEWA
AA	STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
AA		200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

ACANYA

AB	+ DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG
	CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE					
AB	ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA
AB	PERRIGO ISRAEL	5%;EQ 1% BASE	A202440	001	Sep 21, 2015	Sep NEWA
	ONEXTON					
	+ DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

ERYTHROMYCIN AND BENZOYL PEROXIDE

AB	LYNE	5%;3%	A065385	001	Sep 18, 2015	Sep NEWA
----	------	-------	---------	-----	--------------	----------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	50MG	A090346	001	Dec 15, 2015	Nov NEWA
AA	+ KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD
AA	TEDOR PHARM	25MG	A040747	002	Nov 20, 2015	Nov NEWA

BENZTROPINE MESYLATE

TABLET; ORAL

BENZTROPINE MESYLATE

AA	NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
AA		1MG	A204713	002	Apr 14, 2015	Mar NEWA
AA		2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

AB	G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
	@	EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM; TOPICAL

ENSTILAR

	+ LEO PHARMA AS	0.064%;0.005%	N207589	001	Oct 16, 2015	Oct NEWA
--	-----------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION; TOPICAL

TACLONEX

	+ LEO PHARMA AS	0.064%;0.005%	N022185	002	Oct 29, 2015	Nov NEWA
--	-----------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS LTD	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Oct NEWA
----	---------------------	------------------	---------	-----	--------------	----------

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETA-VAL

AB	G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN
	LOTION; TOPICAL					
	BETA-VAL					

AB	G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN
	OINTMENT; TOPICAL					
	BETA-VAL					

AB	G AND W LABS INC	EQ 0.1% BASE	A070069	001	Dec 19, 1985	Oct CAHN
----	------------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

AA	HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
AA		10MG	A091256	002	May 04, 2010	Mar CAHN
AA		25MG	A091256	003	May 04, 2010	Mar CAHN
AA		50MG	A091256	004	May 04, 2010	Mar CAHN
AA	LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
AA		50MG	A040677	001	Mar 27, 2008	Feb CMFD
	DUVOID					
AA	WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
AA		25MG	A086263	001		May CMFD
AA		50MG	A085882	003		May CMFD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

>D>	AB	BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Dec CAHN
	AB		75MG	A203174	001	Aug 12, 2014	Jun CMFD
		@	75MG	A203174	001	Aug 12, 2014	Jan CAHN
>A>	AB	BIONPHARMA INC	75MG	A203174	001	Aug 12, 2014	Dec CAHN
		TARGETETIN					
	AB	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
AB	STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
AT	APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
AT	+ LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+	0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+	0.03%	A203991	001	Feb 20, 2015	Feb NEWA

BIPERIDEN HYDROCHLORIDE

TABLET; ORAL

AKINETON

@ ABBVIE

2MG

N012003	001		Aug DISC
---------	-----	--	----------

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL

PYLERA

+	FOREST LABS LLC	140MG; 125MG; 125MG	N050786	001	Sep 28, 2006	Jul CAHN
---	-----------------	---------------------	---------	-----	--------------	----------

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

AP	HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun NEWA
AP		250MG/VIAL	A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATE

TABLET; ORAL

BOSULIF

+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
		EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

BREXPIRAZOLE

TABLET; ORAL

REXULTI

	OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul NEWA
		0.5MG	N205422	002	Jul 10, 2015	Jul NEWA
		1MG	N205422	003	Jul 10, 2015	Jul NEWA
		2MG	N205422	004	Jul 10, 2015	Jul NEWA
		3MG	N205422	005	Jul 10, 2015	Jul NEWA
+		4MG	N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMFENAC SODIUM

AT2	APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC	
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDE

AEROSOL, FOAM; RECTAL

UCERIS

+	VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr CAHN
---	---------------------	---------------	---------	-----	--------------	----------

SPRAY, METERED; NASAL

BUDESONIDE

	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar CTEC
--	------------	-------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

UCERIS

+	VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Aug CAHN
---	---------------------	-----	---------	-----	--------------	----------

BUMETANIDE

INJECTABLE; INJECTION

BUMETANIDE

AP	EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun CAHN
----	--------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

BUMEX

AB	VALIDUS PHARMS INC	0.5MG	N018225	002	Feb 28, 1983	Oct CMFD
AB		1MG	N018225	001	Feb 28, 1983	Oct CMFD
AB		2MG	N018225	003	Jun 14, 1985	Oct CMFD

BUPRENORPHINE HYDROCHLORIDE

FILM; BUCCAL

BELBUCA

	ENDO PHARMS INC	EQ 0.075MG BASE	N207932	001	Oct 23, 2015	Nov CPOT
		EQ 0.15MG BASE	N207932	002	Oct 23, 2015	Nov CPOT
		EQ 0.3MG BASE	N207932	003	Oct 23, 2015	Nov CPOT
		EQ 0.45MG BASE	N207932	004	Oct 23, 2015	Nov CPOT
		EQ 0.6MG BASE	N207932	005	Oct 23, 2015	Nov CPOT
		EQ 0.75MG BASE	N207932	006	Oct 23, 2015	Nov CPOT
+		EQ 0.9MG BASE	N207932	007	Oct 23, 2015	Nov CPOT
		75MCG	N207932	001	Oct 23, 2015	Oct NEWA
		150MCG	N207932	002	Oct 23, 2015	Oct NEWA
		300MCG	N207932	003	Oct 23, 2015	Oct NEWA
		450MCG	N207932	004	Oct 23, 2015	Oct NEWA
		600MCG	N207932	005	Oct 23, 2015	Oct NEWA
		750MCG	N207932	006	Oct 23, 2015	Oct NEWA
		900MCG	N207932	007	Oct 23, 2015	Oct NEWA

INJECTABLE; INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul NEWA
----	----------------------	------------------	---------	-----	--------------	----------

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb NEWA
AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE							
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL, SUBLINGUAL

SUBOXONE

INDIVIOR INC		EQ 2MG BASE;EQ 0.5MG BASE	N022410	001	Aug 30, 2010	Sep	CDFR
		EQ 4MG BASE;EQ 1MG BASE	N022410	003	Aug 10, 2012	Sep	CDFR
		EQ 8MG BASE;EQ 2MG BASE	N022410	002	Aug 30, 2010	Sep	CDFR
+		EQ 12MG BASE;EQ 3MG BASE	N022410	004	Aug 10, 2012	Sep	CDFR

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE							
AB	ETHYPHARM USA CORP	EQ 2MG BASE;EQ 0.5MG BASE	A204431	001	Oct 16, 2015	Oct	NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A204431	002	Oct 16, 2015	Oct	NEWA
ZUBSOLV							
	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

VALEANT PHARMS NORTH		174MG	N022108	001	Apr 23, 2008	Feb	CAHN
		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+		522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE							
AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
AB1		150MG	A202304	002	May 26, 2015	May	NEWA
AB1		200MG	A202304	003	May 26, 2015	May	NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
	@	150MG	A201331	002	Aug 30, 2012	May	DISC
	@	200MG	A201331	003	Aug 30, 2012	May	DISC

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE							
AB	EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Sep	NEWA
AB		10MG	A204582	002	Sep 18, 2015	Sep	NEWA
AB		15MG	A204582	003	Sep 18, 2015	Sep	NEWA
AB		30MG	A204582	004	Sep 18, 2015	Sep	NEWA
AB	ORION CORP ORION	5MG	A202087	001	Dec 16, 2015	Nov	NEWA
AB		10MG	A202087	002	Dec 16, 2015	Nov	NEWA
AB		15MG	A202087	003	Dec 16, 2015	Nov	NEWA
AB		30MG	A202087	004	Dec 16, 2015	Nov	NEWA

BUSULFAN

INJECTABLE;INJECTION

BUSULFAN							
>A>	PHARMAFORCE	6MG/ML	A202259	001	Dec 22, 2015	Dec	NEWA
BUSULFEX							
>D>	+ OTSUKA PHARM	6MG/ML	N020954	001	Feb 04, 1999	Dec	CFTG
>A>	AP +	6MG/ML	N020954	001	Feb 04, 1999	Dec	CFTG

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM							
	@ MEDA PHARMS	30MG/5ML	A085380	001		Jul	DISC
TABLET;ORAL							
BUTISOL SODIUM							
	@ MEDA PHARMS	50MG	N000793	003		May	DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE							
	@ ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May	CTNA
GYNAZOLE-1							
	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun	CTNA

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFFEINE CITRATE

AP	AUROBINDO PHARMA LTD	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A205013	001	Sep 22, 2015	Sep NEWA
----	----------------------	------------------------------------	---------	-----	--------------	----------

CALCIPOTRIENECREAM;TOPICAL
CALCIPOTRIENE

AB	GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May NEWA
----	---------------------	--------	---------	-----	--------------	----------

CALCITONIN SALMONINJECTABLE;INJECTION
CALCITONIN-SALMON

	@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar CAHN
--	----------------	-----------	---------	-----	--------------	----------

MIACALCIN

	@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug CAHN
--	---------------------	-----------	---------	-----	--------------	----------

+ 200 IU/ML

N017808	002	Mar 29, 1991	Aug CAHN
---------	-----	--------------	----------

SPRAY, METERED;NASAL

MIACALCIN

AB	+ MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug CAHN
----	---------------------	--------------	---------	-----	--------------	----------

CALCITRIOLCAPSULE;ORAL
CALCITRIOL

AB	BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan CAHN
----	----------------------	---------	---------	-----	--------------	----------

AB		0.5MCG	A091174	002	May 24, 2013	Jan CAHN
----	--	--------	---------	-----	--------------	----------

AB	STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan CAHN
----	----------------	---------	---------	-----	--------------	----------

AB		0.5MCG	A091356	002	Dec 12, 2014	Jan CAHN
----	--	--------	---------	-----	--------------	----------

INJECTABLE;INJECTION

CALCIJEX

	@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun DISC
--	----------	------------	---------	-----	--------------	----------

	@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun DISC
--	---	------------	---------	-----	--------------	----------

CALCITRIOL

	@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun DISC
--	---------	------------	---------	-----	--------------	----------

	@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun DISC
--	----------------------	------------	---------	-----	--------------	----------

	@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun DISC
--	---	------------	---------	-----	--------------	----------

	@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun DISC
--	-------------------	------------	---------	-----	--------------	----------

	@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun DISC
--	---	------------	---------	-----	--------------	----------

	@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun DISC
--	------------	------------	---------	-----	--------------	----------

	@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun DISC
--	---	------------	---------	-----	--------------	----------

	@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun DISC
--	-----------------	------------	---------	-----	--------------	----------

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Sep CAHN
----	---------------------	------------------	---------	-----	--------------	----------

AB	LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun NEWA
----	-----------	------------------	---------	-----	--------------	----------

AB	NOSTRUM LABS INC	EQ 169MG CALCIUM	A203179	001	Oct 26, 2015	Oct NEWA
----	------------------	------------------	---------	-----	--------------	----------

AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun NEWA
----	----------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

CALCIUM ACETATE

AB	HERITAGE PHARMS INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Sep CAHN
----	---------------------	------------------	---------	-----	--------------	----------

AB	ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan NEWA
----	----------------------	------------------	---------	-----	--------------	----------

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Oct CAHN
---	-----------------	---	---------	-----	--------------	----------

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan CPOT
---	--------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Oct CAHN
---	-----------------	--	---------	-----	--------------	----------

@	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4	N021703	012	Oct 10, 2008	Jan CPOT
---	--------------------	-------------------------------	---------	-----	--------------	----------

INJECTABLE; INJECTION

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER							
GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)							
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Oct	CAHN
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Oct	CAHN
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Oct	CAHN
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Oct	CAHN
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Oct	CAHN
+	GAMBRO RENAL PRODS	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0 IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Oct	CAHN
@	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Oct	CAHN
+	GAMBRO RENAL PRODS	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan	CPOT
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Oct	CAHN
+	GAMBRO RENAL PRODS	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan	CPOT
PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER							
@	BAXTER HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML	N021703	008	Oct 25, 2006	Oct	CAHN

INJECTABLE;INJECTION

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

	GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)						
@ GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan	CPOT	

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Oct	CAHN	
-------------------	--	---------	-----	--------------	-----	------	--

@ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan	CPOT	
----------------------	--	---------	-----	--------------	-----	------	--

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Oct	CAHN	
-------------------	--	---------	-----	--------------	-----	------	--

+ GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan	CPOT	
----------------------	--	---------	-----	--------------	-----	------	--

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+ BAXTER HLTHCARE	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Oct	CAHN	
-------------------	---	---------	-----	--------------	-----	------	--

+ GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan	CPOT	
----------------------	---	---------	-----	--------------	-----	------	--

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Oct	CAHN	
-------------------	---	---------	-----	--------------	-----	------	--

@ GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan	CPOT	
----------------------	---	---------	-----	--------------	-----	------	--

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan	NEWA	
-----------------	---	---------	-----	--------------	-----	------	--

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+ GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan	NEWA	
-----------------	--	---------	-----	--------------	-----	------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@ ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008	Jun	DISC	
--------------------	---	---------	-----	--------------	-----	------	--

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>							
>D>	+ B BRAUN	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993	Dec	DISC
>A>	@	37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML	N019864	001	Jun 10, 1993	Dec	DISC

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

		INJECTABLE;INJECTION							
>D>		DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER							
>D>	+	B BRAUN	20MG/100ML;5GM/100ML;30MG/100ML;38	N018258	001			Dec	DISC
			0MG/100ML;600MG/100ML						
>A>	@		20MG/100ML;5GM/100ML;30MG/100ML;38	N018258	001			Dec	DISC
			0MG/100ML;600MG/100ML						

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

		INJECTABLE;INJECTION							
>D>		ISOLYTE E IN PLASTIC CONTAINER							
>D>	+	B BRAUN	35MG/100ML;30MG/100ML;74MG/100ML;6	N019718	001	Sep 29, 1989		Dec	DISC
			40MG/100ML;500MG/100ML;74MG/100ML						
>A>	@		35MG/100ML;30MG/100ML;74MG/100ML;6	N019718	001	Sep 29, 1989		Dec	DISC
			40MG/100ML;500MG/100ML;74MG/100ML						

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1	N207026	002	Jan 13, 2015	Oct	CAHN
		000ML;2.21GM/1000ML;6.95GM/1000ML;					
		0.187GM/1000ML (5000ML)					

+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1	N207026	002	Jan 13, 2015	Feb	CAIN
		000ML;2.21GM/1000ML;6.95GM/1000ML;					
		0.187GM/1000ML (5000ML)					

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314G	N207026	001	Jan 13, 2015	Oct	CAHN
		M/1000ML					

+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314G	N207026	001	Jan 13, 2015	Feb	CAIN
		M/1000ML					
		;3.09GM/1000ML;6.34GM/1000ML;0.187					

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML;	N019933	001	Aug 29, 1989	Sep	DISC
		310MG/100ML					

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	16MG;12.5MG	A204100	001	Feb 27, 2015	Feb	NEWA
AB		32MG;12.5MG	A204100	002	Feb 27, 2015	Feb	NEWA
AB		32MG;25MG	A204100	003	Feb 27, 2015	Feb	NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB	ACCORD HLTHCARE	150MG	A202593	001	Apr 23, 2015	Apr	NEWA
AB		500MG	A202593	002	Apr 23, 2015	Apr	NEWA

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

	@ G AND W LABS INC	12.5MG	A074433	001	Feb 13, 1996	Jul	CAHN
	@	12.5MG	A074462	001	Feb 13, 1996	Apr	CAHN
	@	12.5MG	A074483	001	Feb 13, 1996	Jul	CAHN
	@	25MG	A074433	002	Feb 13, 1996	Jul	CAHN
	@	25MG	A074462	002	Feb 13, 1996	Apr	CAHN
	@	25MG	A074483	002	Feb 13, 1996	Jul	CAHN
	@	50MG	A074433	003	Feb 13, 1996	Jul	CAHN
	@	50MG	A074462	003	Feb 13, 1996	Apr	CAHN
	@	50MG	A074483	003	Feb 13, 1996	Jul	CAHN
	@	100MG	A074433	004	Feb 13, 1996	Jul	CAHN
	@	100MG	A074462	004	Feb 13, 1996	Apr	CAHN
	@	100MG	A074483	004	Feb 13, 1996	Jul	CAHN
AB	+	MYLAN	A074434	004	Feb 13, 1996	May	CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	G AND W LABS INC	25MG;15MG	A074827	001	Dec 29, 1997	Apr CAHN
AB		25MG;25MG	A074827	002	Dec 29, 1997	Apr CAHN
AB		50MG;15MG	A074827	004	Dec 29, 1997	Apr CAHN
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May CAHN
AB		200MG	A076697	002	May 20, 2011	May CAHN
AB		300MG	A076697	003	May 20, 2011	May CAHN

CARBIDOPA

TABLET; ORAL

CARBIDOPA

>A> AB	ALVOGEN MALTA	25MG	A204291	001	Jan 08, 2016	Dec NEWA
--------	---------------	------	---------	-----	--------------	----------

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE; ORAL

RYTARY

	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan NEWA

SUSPENSION; ENTERAL

DUOPA

+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan NEWA
---	------------	-------------------	---------	-----	--------------	----------

CARIPRAZINE HYDROCHLORIDE

CAPSULE; ORAL

VRAYLAR

	FOREST RES INST INC	EQ 1.5MG BASE	N204370	001	Sep 17, 2015	Sep NEWA
		EQ 3MG BASE	N204370	002	Sep 17, 2015	Sep NEWA
		EQ 4.5MG BASE	N204370	003	Sep 17, 2015	Sep NEWA
+		EQ 6MG BASE	N204370	004	Sep 17, 2015	Sep NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun NEWA
AB	SHASUN PHARMS LTD	250MG	A205513	001	Nov 12, 2015	Oct NEWA
AA		350MG	A205513	002	Nov 12, 2015	Oct NEWA
AA	SUN PHARM INDS	350MG	A089346	001	Oct 17, 1991	Nov CAHN
	SOMA					
AB	+ MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun CTEC

CARVEDILOL

TABLET; ORAL

CARVEDILOL

	@ HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun DISC
	@	25MG	A077887	004	Sep 07, 2007	Jun DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr CAHN

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL

CEFADROXIL

	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION
CEFAZOLIN SODIUM

AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan CAHN
AP	+	EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan CAHN
>A> AP	QILU PHARM CO LTD	EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Dec NEWA

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

	BAXTER HLTHCARE	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Sep CAHN
	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug NEWA

CEFIXIME

FOR SUSPENSION;ORAL
CEFIXIME

AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr NEWA
	SUPRAX					
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION
CEFOTAN

@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN
	CEFOTAN IN PLASTIC CONTAINER					
@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFOXITIN SODIUM

POWDER;IV (INFUSION)

CEFOXITIN IN PLASTIC CONTAINER

	SAMSON MEDCL	EQ 100GM BASE	A200938	001	Nov 16, 2015	Nov NEWA
--	--------------	---------------	---------	-----	--------------	----------

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL
CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB		EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB	SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB		EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE;INJECTION
FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN
AP	+	IGI LABS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Oct CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Oct CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Oct CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Oct CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN
@	IGI LABS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Oct CAHN
+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Oct CAHN

INJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

+ EQ 40MG BASE/ML N050634 003 Apr 28, 1989 Oct CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER; IV (INFUSION)
ZERBAXA

+ CUBIST PHARMS LLC EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL N206829 001 Dec 19, 2014 Aug CAHN

CEFTRIAZONE SODIUM

INJECTABLE;INJECTION
CEFTRIAZONE

AP FACTA FARMA EQ 10GM BASE/VIAL A065269 001 Feb 28, 2007 Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFTRIAZONE

@ FACTA FARMA EQ 1GM BASE/VIAL A065268 001 Feb 28, 2007 Jan CAHN

@ EQ 2GM BASE/VIAL A065268 002 Feb 28, 2007 Jan CAHN

@ FRESENIUS KABI USA EQ 250MG BASE/VIAL A065245 001 Feb 15, 2006 Jul DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL
CEFUROXIME AXETIL

AB SUN PHARM INDS LTD EQ 125MG BASE/5ML A065323 001 Feb 05, 2008 Apr CAHN

AB EQ 250MG BASE/5ML A065323 002 Feb 05, 2008 Apr CAHN

TABLET;ORAL
CEFUROXIME AXETIL

AB ANI PHARMS INC EQ 250MG BASE A065190 001 Oct 18, 2004 Jul CAHN

AB EQ 500MG BASE A065190 002 Oct 18, 2004 Jul CAHN

AB SUN PHARM INDS LTD EQ 125MG BASE A065118 001 Apr 25, 2003 Apr CAHN

AB EQ 250MG BASE A065118 002 Apr 25, 2003 Apr CAHN

AB EQ 500MG BASE A065118 003 Apr 25, 2003 Apr CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION
CEFUROXIME SODIUM

AP FACTA FARMA EQ 1.5GM BASE/VIAL A064125 002 May 30, 1997 Jan CAHN

AP EQ 7.5GM BASE/VIAL A064124 001 May 30, 1997 Jan CAHN

ZINACEF

AP + CONCORDIA PHARMS INC EQ 1.5GM BASE/VIAL N050558 003 Oct 19, 1983 Jun CAHN

AP + EQ 7.5GM BASE/VIAL N050558 004 Oct 23, 1986 Jun CAHN

ZINACEF IN PLASTIC CONTAINER

@ CONCORDIA PHARMS INC EQ 15MG BASE/ML N050643 001 Apr 28, 1989 Jun CAHN

+ EQ 30MG BASE/ML N050643 002 Apr 28, 1989 Jun CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
CEFUROXIME SODIUM

AB FACTA FARMA EQ 750MG BASE/VIAL A064125 001 May 30, 1997 Jan CAHN

ZINACEF

AB + CONCORDIA PHARMS INC EQ 750MG BASE/VIAL N050558 002 Oct 19, 1983 Jun CAHN

CELECOXIB

CAPSULE;ORAL
CELECOXIB

AB ALEMBIC PHARMS LTD 50MG A204519 001 Aug 21, 2015 Aug NEWA

AB 100MG A204519 002 Aug 21, 2015 Aug NEWA

AB 200MG A204519 003 Aug 21, 2015 Aug NEWA

AB 400MG A204519 004 Aug 21, 2015 Aug NEWA

AB APOTEX INC 50MG A204197 001 Jun 02, 2015 May NEWA

AB 100MG A204197 002 Jun 02, 2015 May NEWA

AB 200MG A204197 003 Jun 02, 2015 May NEWA

AB CIPLA LTD 50MG A207446 001 Sep 23, 2015 Sep NEWA

AB 100MG A207446 002 Sep 23, 2015 Sep NEWA

AB 200MG A207446 003 Sep 23, 2015 Sep NEWA

AB 400MG A207446 004 Sep 23, 2015 Sep NEWA

AB LUPIN LTD 100MG A202240 002 Jun 09, 2015 May NEWA

AB 200MG A202240 003 Jun 09, 2015 May NEWA

AB 400MG A202240 004 Jun 09, 2015 May NEWA

AB MYLAN PHARMS INC 100MG A078857 002 Feb 11, 2015 Jan NEWA

AB 200MG A078857 003 Feb 11, 2015 Jan NEWA

AB 400MG A078857 004 Feb 11, 2015 Jan NEWA

>A> AB TORRENT PHARMS LTD 50MG A207677 001 Dec 23, 2015 Dec NEWA

>A> AB 100MG A207677 002 Dec 23, 2015 Dec NEWA

CAPSULE;ORAL
CELECOXIB

>A>	AB		200MG	A207677	003	Dec 23, 2015	Dec NEWA
>A>	AB		400MG	A207677	004	Dec 23, 2015	Dec NEWA
	AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
	AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB			EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN

FOR SUSPENSION;ORAL
CEPHALEXIN

		@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
		@	EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CETIRIZINE HYDROCHLORIDESYRUP;ORAL
ZYRTEC

AA	+	J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN
----	---	----------------------	---------	---------	-----	--------------	----------

CHLOROTHIAZIDE SODIUMINJECTABLE;INJECTION
CHLOROTHIAZIDE SODIUM

AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA
----	--	---------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATETABLET, EXTENDED RELEASE;ORAL
CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE
SPRIASO LLC 8MG;54.3MG

N206323	001	Jun 22, 2015	Jun NEWA
---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATESOLUTION;ORAL
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE

AA		TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
----	--	-----------------	-----------------	---------	-----	--------------	----------

AA	+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG
----	---	---------------	-----------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDESOLUTION;ORAL
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul NEWA
----	--	----------------	--------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREXSUSPENSION, EXTENDED RELEASE;ORAL
TUZISTRA XR

+		TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr NEWA
+		VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun CAHN

CHLORPROMAZINE HYDROCHLORIDECONCENTRATE;ORAL
CHLORPROMAZINE HYDROCHLORIDE INTENSOL

@		CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun CAHN
@			100MG/ML	A088158	001	Apr 27, 1983	Jun CAHN

INJECTABLE;INJECTION
CHLORPROMAZINE HYDROCHLORIDE

+		EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb CAHN
---	--	--------------------	---------	---------	-----	--	----------

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

@		CYCLE PHARMS LTD	10MG	A085331	001		Jun CAHN
@			25MG	A085331	002		Jun CAHN
@			50MG	A085331	003		Jun CAHN
@			100MG	A085331	004		Jun CAHN
@			200MG	A085331	005		Jun CAHN
@		SANDOZ	10MG	A080439	001		May DISC
@			25MG	A080439	002		May DISC
@			50MG	A080439	003		May DISC

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

@ 100MG

A080439 004

May DISC

@ 200MG

A080439 005

May DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

@ G AND W LABS INC 50MG

A088651 001 May 30, 1985 Apr CAHN

AB + MUTUAL PHARM 50MG

A089286 001 Jul 21, 1986 Mar CMFD

AB MYLAN 50MG

A086831 001 Jun CTEC

AB SUN PHARM INDS 50MG

A089286 001 Jul 21, 1986 Nov CAHN

THALITONE

@ CITRON PHARMA LLC 15MG

N019574 001 Dec 20, 1988 Jun DISC

CHLORZOXAZONE

TABLET;ORAL

PARAFON FORTE DSC

@ JANSSEN R AND D 500MG

N011529 002 Jun 15, 1987 Nov DISC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

@ ANI PHARMS INC EQ 4GM RESIN/PACKET

A074554 001 Oct 02, 1996 Aug CAHN

@ EQ 4GM RESIN/SCOOPFUL

A074554 002 Oct 02, 1996 Aug CAHN

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

ASKLEPION PHARMS LLC 50MG

N205750 001 Mar 17, 2015 Mar NEWA

+ 250MG

N205750 002 Mar 17, 2015 Mar NEWA

RTRX 50MG

N205750 001 Mar 17, 2015 Apr CAHN

+ 250MG

N205750 002 Mar 17, 2015 Apr CAHN

CHOLINE C-11

INJECTABLE;INTRAVENOUS

CHOLINE C-11

AP GLOBAL ISOTOPES LLC 4-33.1mCi/ML

A206319 001 Nov 13, 2015 Nov NEWA

AP + MCRPF 4-33.1mCi/ML

N203155 001 Sep 12, 2012 Oct CFTG

AP UNIV TX MD ANDERSON 4-33.1mCi/ML

A205690 001 Oct 29, 2015 Oct NEWA

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

FENOFIBRIC ACID

AB ACTAVIS ELIZABETH EQ 45MG FENOFIBRIC ACID

A200920 001 Oct 07, 2015 Sep NEWA

AB EQ 135MG FENOFIBRIC ACID

A200920 002 Oct 07, 2015 Sep NEWA

CHROMIC PHOSPHATE P-32

INJECTABLE;INJECTION

PHOSPHOCOL P32

>D> @ MALLINKRODT 5mCi/ML

N017084 001

Dec CAHN

>A> @ MALLINKRODT NUCLEAR 5mCi/ML

N017084 001

Dec CAHN

CICLOPIROX

SOLUTION;TOPICAL

CICLOPIROX

AT APOTEX INC 8%

A078172 001 Sep 18, 2007 Sep CMFD

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP + MYLAN INSTITUTIONAL EQ 75MG BASE/ML

A201276 001 Jun 27, 2012 May CRLD

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

@ G AND W LABS INC EQ 300MG BASE/5ML

A074176 001 Jun 01, 1994 Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION
CIPROFLOXACIN

AP	CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A 078062	001	Apr 29, 2008	Apr CAHN
AP		400MG/40ML (10MG/ML)	A 078062	002	Apr 29, 2008	Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML	A 078024	001	Mar 18, 2008	Apr CAHN
AP		400MG/200ML	A 078024	002	Mar 18, 2008	Apr CAHN

INJECTABLE, SUSPENSION;OTIC

>A> OTIPRIO

>A>	+	OTONOMY INC	6% (60MG/ML)	N 207986	001	Dec 10, 2015	Dec NEWA
-----	---	-------------	--------------	----------	-----	--------------	----------

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

AT	RISING PHARMS INC	EQ 0.3% BASE	A 077689	001	Dec 13, 2006	Oct CAHN
----	-------------------	--------------	----------	-----	--------------	----------

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 250MG BASE	A 075747	001	Jun 09, 2004	Apr CAHN
AB		EQ 500MG BASE	A 075747	002	Jun 09, 2004	Apr CAHN
AB		EQ 750MG BASE	A 075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION
CISATRACURIUM BESYLATE

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A 203183	001	Feb 26, 2015	Feb NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					

AP	FRESENIUS KABI USA	EQ 2MG BASE/ML	A 203182	001	Feb 26, 2015	Feb NEWA
AP		EQ 10MG BASE/ML	A 203182	002	Feb 26, 2015	Feb NEWA

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

AP	ACCORD HLTHCARE	1MG/ML	A 206774	001	Aug 18, 2015	Aug NEWA
----	-----------------	--------	----------	-----	--------------	----------

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL
CITALOPRAM HYDROBROMIDE

AA	HETERO LABS LTD III	EQ 10MG BASE/5ML	A 201450	001	Dec 15, 2015	Nov NEWA
----	---------------------	------------------	----------	-----	--------------	----------

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB	G AND W LABS INC	EQ 10MG BASE	A 077048	001	Nov 16, 2004	Apr CAHN
AB		EQ 20MG BASE	A 077048	002	Nov 16, 2004	Apr CAHN
AB		EQ 40MG BASE	A 077048	003	Nov 16, 2004	Apr CAHN
>A> AB	JUBILANT GENERICS	EQ 10MG BASE	A 205407	001	Dec 23, 2015	Dec NEWA
>A> AB		EQ 20MG BASE	A 205407	002	Dec 23, 2015	Dec NEWA
>A> AB		EQ 40MG BASE	A 205407	003	Dec 23, 2015	Dec NEWA

CLARITHROMYCIN

FOR SUSPENSION;ORAL
CLARITHROMYCIN

AB	SUN PHARM INDS LTD	125MG/5ML	A 065382	001	Aug 30, 2007	Apr CAHN
AB		250MG/5ML	A 065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB	HEC PHARM USA INC	250MG	A 203584	001	Sep 28, 2015	Sep NEWA
AB		500MG	A 203584	002	Sep 28, 2015	Sep NEWA
AB	SUN PHARM INDS LTD	250MG	A 065174	001	Sep 24, 2004	Apr CAHN
AB		500MG	A 065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL
CLARITHROMYCIN

AB	LUPIN LTD	500MG	A 202532	001	Sep 15, 2015	Aug NEWA	
AB	+	TEVA	500MG	A 065154	001	May 18, 2005	Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION
TIMENTIN

@ GLAXOSMITHKLINE EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL
@ EQ 100MG BASE/VIAL;EQ 3GM
BASE/VIAL

A 062691	001	Dec 19, 1986	May DISC
N 050590	001	Apr 01, 1985	May DISC

INJECTABLE; INJECTION

TIMENTIN

@	EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N050590	002	Apr 01, 1985	May DISC
@	EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N050590	003	Aug 18, 1987	May DISC
TIMENTIN IN PLASTIC CONTAINER					
@ GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET; ORAL

CLEMASTINE FUMARATE

@ ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul CAHN
------------------	--------	---------	-----	--------------	----------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP	ALVOGEN INC	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Sep CAHN
AP		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Sep CAHN
AP		EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Sep CAHN
	@ IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar CAHN

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

	@ BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan CAHN
AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun NEWA
	ZIANA					
AB	+ MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun CTEC

CLOBETASOL PROPIONATE

CREAM; TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	+ FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May CRLD
	CORMAX					

AB1	+ HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun CRLD
-----	------------------	-------	---------	-----	--------------	----------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	+ FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May CRLD
----	------------------	-------	---------	-----	--------------	----------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb CAHN
----	------------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar CMFD
AT	NOVEL LABS INC	0.05%	A206075	001	Nov 23, 2015	Nov NEWA

CLOMIPHENE CITRATE

TABLET; ORAL

SEROPHENE

@ EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun DISC
--------------	------	---------	-----	--------------	----------

CLONIDINE

FILM, EXTENDED RELEASE; TRANSDERMAL

CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar CAHN

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE							
	@ DAVA PHARMS INC	0.1MG	A 071783	001	Apr 05, 1988	May	DISC
	@	0.2MG	A 071784	001	Apr 05, 1988	May	DISC
	@	0.3MG	A 071785	001	Apr 05, 1988	May	DISC
AB	SUN PHARM INDS	0.1MG	A 070925	001	Sep 04, 1987	Nov	CAHN
AB		0.2MG	A 070924	001	Sep 04, 1987	Nov	CAHN
AB		0.3MG	A 070923	001	Sep 04, 1987	Nov	CAHN

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE							
AB2	ACTAVIS ELIZABETH	0.1MG	A 202792	001	May 15, 2015	May	NEWA
AB1		0.1MG	A 203320	001	May 15, 2015	May	NEWA
	@	0.2MG	A 202792	002	May 15, 2015	Aug	DISC
AB2		0.2MG	A 202792	002	May 15, 2015	May	NEWA
	@	0.2MG	A 203320	002	May 15, 2015	Aug	DISC
AB1		0.2MG	A 203320	002	May 15, 2015	May	NEWA
	@ ANCHEN PHARMS	0.1MG	A 202983	001	Apr 02, 2014	Aug	DISC
AB2		0.1MG	A 202983	001	Apr 02, 2014	May	CTEC
	@	0.2MG	A 202983	002	Apr 02, 2014	Aug	DISC
AB2		0.2MG	A 202983	002	Apr 02, 2014	May	CTEC
CLONIDINE HYDROCHLORIDE							
AB1	ANCHEN PHARMS	0.1MG	A 202984	001	Sep 30, 2013	May	CTEC
	@	0.2MG	A 202984	002	Sep 30, 2013	Aug	DISC
AB1		0.2MG	A 202984	002	Sep 30, 2013	May	CTEC
KAPVAY							
AB1	+ CONCORDIA PHARMS INC	0.1MG	N 022331	003	Sep 28, 2010	Aug	CRLD
AB1		0.1MG	N 022331	003	Sep 28, 2010	Jun	CRLD
AB1	+	0.1MG	N 022331	003	Sep 28, 2010	May	CTEC
	@	0.2MG	N 022331	004	Sep 28, 2010	Aug	DISC
AB1	+	0.2MG	N 022331	004	Sep 28, 2010	Jun	CRLD
AB1		0.2MG	N 022331	004	Sep 28, 2010	May	CTEC

CLOPIDOGREL

TABLET; ORAL

>D>	CLOPIDOGREL						
>D> AB	AMNEAL PHARMS	75MG	A 203751	001	Apr 11, 2014	Dec	CTNA

CLOPIDOGREL BISULFATE

TABLET; ORAL

>A>	CLOPIDOGREL BISULFATE						
>A> AB	AMNEAL PHARMS	EQ 75MG BASE	A 203751	001	Apr 11, 2014	Dec	CTNA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM							
AB	SUN PHARM INDS LTD	3.75MG	A 076911	001	Sep 29, 2004	Apr	CAHN
AB		7.5MG	A 076911	002	Sep 29, 2004	Apr	CAHN
AB		15MG	A 076911	003	Sep 29, 2004	Apr	CAHN

CLOZAPINE

TABLET; ORAL

CLOZAPINE							
AB	ACCORD HLTHCARE	25MG	A 202873	001	Nov 25, 2015	Nov	NEWA
AB		100MG	A 202873	002	Nov 25, 2015	Nov	NEWA
AB	ACTAVIS LABS FL INC	25MG	A 203807	001	Sep 17, 2015	Sep	NEWA
AB		100MG	A 203807	002	Sep 17, 2015	Sep	NEWA
CLOZARIL							
AB	HERITAGE LIFE	25MG	N 019758	001	Sep 26, 1989	Aug	CAHN
AB	+	100MG	N 019758	002	Sep 26, 1989	Aug	CAHN
TABLET, ORALLY DISINTEGRATING; ORAL							
CLOZAPINE							
AB	BARR LABS INC	25MG	A 090308	001	Nov 25, 2015	Nov	NEWA
AB		100MG	A 090308	002	Nov 25, 2015	Nov	NEWA
AB	MYLAN PHARMS INC	25MG	A 201824	002	Sep 15, 2015	Aug	NEWA
AB		100MG	A 201824	003	Sep 15, 2015	Aug	NEWA
AB	TEVA PHARMS USA	150MG	A 203039	001	Nov 25, 2015	Nov	NEWA
AB		200MG	A 203039	002	Nov 25, 2015	Nov	NEWA
FAZACLO ODT							
AB	JAZZ PHARMS III	25MG	N 021590	001	Feb 10, 2004	Aug	CFTG
AB	+	100MG	N 021590	002	Feb 10, 2004	Aug	CFTG

TABLET, ORALLY DISINTEGRATING;ORAL									
FAZACLO ODT									
AB		150MG		N021590	005	Jul 09, 2010		Nov	CTEC
AB		200MG		N021590	006	Jul 09, 2010		Nov	CTEC
<u>COBICISTAT; DARUNAVIR ETHANOLATE</u>									
TABLET;ORAL									
PREZCOBIX									
+	JANSSEN PRODS	150MG;EQ 800MG BASE		N205395	001	Jan 29, 2015		Jan	NEWA
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE</u>									
TABLET;ORAL									
GENVOYA									
+	GILEAD SCIENCES INC	150MG;150MG;200MG;EQ 10MG BASE		N207561	001	Nov 05, 2015		Nov	NEWA
<u>COBIMETINIB FUMARATE</u>									
TABLET;ORAL									
COTELLIC									
+	GENENTECH INC	EQ 20MG BASE		N206192	001	Nov 10, 2015		Nov	NEWA
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
AA	AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML		A200963	001	Aug 26, 2015		Aug	NEWA
<u>CODEINE SULFATE</u>									
SOLUTION;ORAL									
CODEINE SULFATE									
@	ROXANE	30MG/5ML		N202245	001	Jun 30, 2011		Jan	DISC
<u>COLCHICINE</u>									
CAPSULE;ORAL									
MITIGARE									
	HIKMA INTL PHARMS	0.6MG		N204820	001	Sep 26, 2014		Jan	CAHN
<u>COLISTIMETHATE SODIUM</u>									
INJECTABLE;INJECTION									
COLISTIMETHATE SODIUM									
AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL		A205356	001	May 29, 2015		May	NEWA
<u>CORTICOTROPIN</u>									
INJECTABLE;INJECTION									
H.P. ACTHAR GEL									
@	MALLINCKRODT ARD	40 UNITS/ML		N008372	006			Aug	CAHN
+		80 UNITS/ML		N008372	008			Aug	CAHN
<u>CYANOCOBALAMIN</u>									
INJECTABLE;INJECTION									
CYANOCOBALAMIN									
@	EUROHLTH INTL SARL	1MG/ML		A080515	002			Feb	CAHN
AP	GAVIS PHARMS LLC	1MG/ML		A206503	001	Dec 11, 2015		Nov	NEWA
<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>									
TABLET;ORAL									
CYCLOBENZAPRINE HYDROCHLORIDE									
AB	ORIT LABS LLC	5MG		A078218	002	Jun 19, 2015		Jun	NEWA
AB	SUN PHARM INDS	5MG		A073541	002	Apr 06, 2006		Nov	CAHN
AB		10MG		A073541	001	May 23, 1995		Nov	CAHN
AB	SUN PHARM INDS LTD	5MG		A078722	001	May 12, 2008		Apr	CAHN
AB		7.5MG		A078722	002	May 12, 2008		Apr	CAHN
AB		10MG		A078722	003	May 12, 2008		Apr	CAHN
<u>CYCLOPENTOLATE HYDROCHLORIDE</u>									
SOLUTION/DROPS;OPHTHALMIC									
CYCLOGYL									
AT	+	ALCON	0.5%	A084109	001			Nov	CFTG
CYCLOPENTOLATE HYDROCHLORIDE									
AT		AKORN INC	0.5%	A205937	001	Dec 09, 2015		Nov	NEWA

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA	MIRROR PHARMS LLC	4MG	A205087	001	Sep 23, 2015	Sep NEWA
----	-------------------	-----	---------	-----	--------------	----------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE; ORAL

PRADAXA

BOEHRINGER INGELHEIM EQ 110MG BASE

N022512	003	Nov 20, 2015	Nov NEWA
---------	-----	--------------	----------

DABRAFENIB MESYLATE

CAPSULE; ORAL

TAFINLAR

NOVARTIS PHARMS CORP EQ 50MG BASE

N202806	001	May 29, 2013	Mar CAHN
---------	-----	--------------	----------

+ EQ 75MG BASE

N202806	002	May 29, 2013	Mar CAHN
---------	-----	--------------	----------

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

BRISTOL-MYERS SQUIBB EQ 30MG BASE

N206843	001	Jul 24, 2015	Jul NEWA
---------	-----	--------------	----------

+ EQ 60MG BASE

N206843	002	Jul 24, 2015	Jul NEWA
---------	-----	--------------	----------

DALTEPARIN SODIUM

INJECTABLE; INJECTION

FRAGMIN

@ PFIZER INC 7,500 IU/0.75ML

N020287	008	Apr 04, 2002	Jun CAHN
---------	-----	--------------	----------

@ PHARMACIA AND UPJOHN 7,500 IU/0.75ML

N020287	008	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

INJECTABLE; SUBCUTANEOUS

FRAGMIN

PFIZER INC 2,500IU/0.2ML (12,500IU/ML)

N020287	001	Dec 22, 1994	Jun CAHN
---------	-----	--------------	----------

5,000IU/0.2ML (25,000IU/ML)

N020287	003	Mar 18, 1996	Jun CAHN
---------	-----	--------------	----------

7,500IU/0.3ML (25,000IU/ML)

N020287	005	Apr 04, 2002	Jun CAHN
---------	-----	--------------	----------

@ 10,000IU/0.4ML (25,000IU/ML)

N020287	002	May 01, 2007	Jun CAHN
---------	-----	--------------	----------

10,000IU/ML (10,000IU/ML)

N020287	004	Jan 30, 1998	Jun CAHN
---------	-----	--------------	----------

12,500IU/0.5ML (25,000IU/ML)

N020287	009	May 01, 2007	Jun CAHN
---------	-----	--------------	----------

15,000IU/0.6ML (25,000IU/ML)

N020287	010	May 01, 2007	Jun CAHN
---------	-----	--------------	----------

18,000IU/0.72ML (25,000IU/ML)

N020287	011	May 01, 2007	Jun CAHN
---------	-----	--------------	----------

+ 95,000IU/3.8ML (25,000IU/ML)

N020287	006	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

@ 95,000IU/9.5ML (10,000IU/ML)

N020287	007	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

PHARMACIA AND UPJOHN 2,500IU/0.2ML (12,500IU/ML)

N020287	001	Dec 22, 1994	Apr CAHN
---------	-----	--------------	----------

5,000IU/0.2ML (25,000IU/ML)

N020287	003	Mar 18, 1996	Apr CAHN
---------	-----	--------------	----------

7,500IU/0.3ML (25,000IU/ML)

N020287	005	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

@ 10,000IU/0.4ML (25,000IU/ML)

N020287	002	May 01, 2007	Apr CAHN
---------	-----	--------------	----------

10,000IU/ML (10,000IU/ML)

N020287	004	Jan 30, 1998	Apr CAHN
---------	-----	--------------	----------

12,500IU/0.5ML (25,000IU/ML)

N020287	009	May 01, 2007	Apr CAHN
---------	-----	--------------	----------

15,000IU/0.6ML (25,000IU/ML)

N020287	010	May 01, 2007	Apr CAHN
---------	-----	--------------	----------

18,000IU/0.72ML (25,000IU/ML)

N020287	011	May 01, 2007	Apr CAHN
---------	-----	--------------	----------

+ 95,000IU/3.8ML (25,000IU/ML)

N020287	006	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

@ 95,000IU/9.5ML (10,000IU/ML)

N020287	007	Apr 04, 2002	Apr CAHN
---------	-----	--------------	----------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

AB	ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
----	----------------	------	---------	-----	--------------	----------

AB		50MG	A076686	002	Oct 24, 2005	May CAHN
----	--	------	---------	-----	--------------	----------

AB		100MG	A076686	003	Oct 24, 2005	May CAHN
----	--	-------	---------	-----	--------------	----------

DAPSONE

TABLET; ORAL

DAPSONE

>A>						
-----	--	--	--	--	--	--

>A>	AB	FERA PHARMS LLC	25MG	A205429	001	Jan 07, 2016	Dec NEWA
-----	----	-----------------	------	---------	-----	--------------	----------

>A>	AB		100MG	A205429	002	Jan 07, 2016	Dec NEWA
-----	----	--	-------	---------	-----	--------------	----------

>D>		JACOBUS	25MG	A086841	001		Dec CFTG
-----	--	---------	------	---------	-----	--	----------

>A>	AB		25MG	A086841	001		Dec CFTG
-----	----	--	------	---------	-----	--	----------

>D>	+		100MG	A086842	001		Dec CFTG
-----	---	--	-------	---------	-----	--	----------

>A>	AB	+	100MG	A086842	001		Dec CFTG
-----	----	---	-------	---------	-----	--	----------

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL
DARIFENACIN HYDROBROMIDE

AB	ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB		EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
	ENABLEX					
AB	WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG

DASATINIB

TABLET;ORAL
SPRYCEL

+	BRISTOL MYERS SQUIBB	100MG	N021986	004	May 30, 2008	Sep CRLD
		140MG	N021986	006	Oct 28, 2010	Sep CRLD

DECITABINE

INJECTABLE;INTRAVENOUS
DACOGEN

AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
----	---	---------------------	-----------	---------	-----	--------------	----------

DEFERASIROX

TABLET;ORAL
JADENU

	NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
		180MG	N206910	002	Mar 30, 2015	Mar NEWA
+		360MG	N206910	003	Mar 30, 2015	Mar NEWA

DEFERIPRONE

SOLUTION;ORAL
FERRIPROX

+	AOPHARMA INC	100MG/ML	N208030	001	Sep 09, 2015	Sep NEWA
---	--------------	----------	---------	-----	--------------	----------

DEMECLOCYCLINE HYDROCHLORIDE

TABLET;ORAL
DEMECLOCYCLINE HYDROCHLORIDE

AB	EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug NEWA
AB		300MG	A065447	002	Aug 18, 2015	Aug NEWA

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS
KYBELLA

+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
---	-------------------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL
DESIPRAMINE HYDROCHLORIDE

	ANI PHARMS INC	25MG	A071803	002	Dec 08, 1987	Sep CMS1
		50MG	A071803	003	Dec 08, 1987	Sep CMS1
		75MG	A071803	004	Dec 08, 1987	Sep CMS1
		150MG	A071803	005	May 29, 1997	Sep CMS1

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS
IPRIVASK

+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
---	----------------------	-----------	---------	-----	--------------	----------

DESLORATADINE

SOLUTION;ORAL
CLARINEX

AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
		DESLORATADINE					
AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA

DESMOPRESSIN ACETATE

TABLET;ORAL
DDAVP

AB	FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+	0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
	DESMOPRESSIN ACETATE					
AB	GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB		0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28
BEKYREE

AB	LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul	NEWA
AB	+ CYCLESSA						
AB	+ ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
AB	ISIBLOOM						
AB	SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul	NEWA
AB	KARIVA						
AB	+ BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC
AB	KIMIDESS						
AB	VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE

CREAM; TOPICAL
DESONIDE

AB	TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL
DESOXIMETASONE

AB	ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug	NEWA
AB	VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA

OINTMENT; TOPICAL
DESOXIMETASONE

AB	PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA
----	------------------	-------	---------	-----	--------------	-----	------

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE; ORAL
DESVENLAFAXINE SUCCINATE

AB	ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
AB	LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
AB	MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA
AB	SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun	NEWA
AB		EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun	NEWA
AB	PRISTIQ						
AB	+ WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun	CFTG
AB	+	EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun	CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

AP	AUROBINDO PHARMA LTD	EQ 4MG PHOSPHATE/ML	A206781	001	Dec 01, 2015	Nov	NEWA
AP	BD RX	EQ 4MG PHOSPHATE/ML	A203129	001	Sep 30, 2015	Sep	NEWA
AP	@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
AP	+	EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
MAXITROL

AT	+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN
----	------------------	---------------------------------------	---------	-----	--	-----	------

SUSPENSION/DROPS; OPHTHALMIC
MAXITROL

AT	+ ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN
----	------------------	---------------------------------------	---------	-----	--	-----	------

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXMEDETOMIDINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A201072	001	Sep 18, 2015	Sep	NEWA
AP	SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug	NEWA
AP	PRECEDEX						
AP	HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA

SOLUTION; IV (INFUSION)

DEXMEDETOMIDINE HYDROCHLORIDE

+	HQ SPCLT PHARMA	EQ 1MG BASE/10ML (EQ 100MCG BASE/ML)	N206628	002	Oct 21, 2015	Oct NEWA
		EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML)	N206628	001	Oct 21, 2015	Oct NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug NEWA
AB		10MG	A204266	002	Aug 25, 2015	Aug NEWA
AB		15MG	A204266	003	Aug 25, 2015	Aug NEWA
>A>	AB	20MG	A204266	004	Dec 21, 2015	Dec NEWA
AB		40MG	A204266	007	Aug 25, 2015	Aug NEWA
AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul NEWA
AB		10MG	A079108	002	Aug 05, 2015	Jul NEWA
>A>	AB	20MG	A079108	004	Dec 21, 2015	Dec NEWA

TABLET; ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	ABHAI INC	2.5MG	A206931	001	Dec 04, 2015	Nov NEWA
AB		5MG	A206931	002	Dec 04, 2015	Nov NEWA
AB		10MG	A206931	003	Dec 04, 2015	Nov NEWA
AB	NOVEL LABS INC	2.5MG	A204534	001	Dec 04, 2015	Nov NEWA
AB		5MG	A204534	002	Dec 04, 2015	Nov NEWA
AB		10MG	A204534	003	Dec 04, 2015	Nov NEWA
AB	SUN PHARM INDS LTD	2.5MG	A201231	001	Sep 24, 2015	Sep NEWA
AB		5MG	A201231	002	Sep 24, 2015	Sep NEWA
AB		10MG	A201231	003	Sep 24, 2015	Sep NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	AVANTHI INC	5MG	A203548	001	Nov 23, 2015	Nov NEWA
AA		10MG	A203548	002	Nov 23, 2015	Nov NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH W/ DEXTROMETHORPHAN

AA	G AND W LABS INC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Nov CMFD
	@	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	May CAHN

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 50%

>A>	HOSPIRA	500MG/ML	N019445	003	Sep 03, 2014	Dec NEWA
	DEXTROSE 50% IN PLASTIC CONTAINER					
>D>	AP	HOSPIRA	N019445	001	Jun 03, 1986	Dec CTEC
>A>		500MG/ML	N019445	001	Jun 03, 1986	Dec CTEC
	@	50GM/100ML	N019894	001	Dec 26, 1989	Nov DISC

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE; INJECTION

ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	B BRAUN	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843	001	Aug 09, 1993	Dec DISC
>A>	@	5GM/100ML; 30MG/100ML; 37MG/100ML; 370MG/100ML; 530MG/100ML; 500MG/100ML	N019843	001	Aug 09, 1993	Dec DISC

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

>D>	AP	BAXTER HLTHCARE	N017634	004		Dec CTEC
>A>		5GM/100ML; 75MG/100ML	N017634	004		Dec CTEC
	POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	AP	B BRAUN	N018744	001	Nov 09, 1982	Dec DISC
>A>	@	5GM/100ML; 75MG/100ML	N018744	001	Nov 09, 1982	Dec DISC
	POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER					
>D>	AP	B BRAUN	N018744	002	Nov 09, 1982	Dec DISC
>A>	@	5GM/100ML; 150MG/100ML	N018744	002	Nov 09, 1982	Dec DISC

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>	AP	B BRAUN	5GM/100ML; 300MG/100ML	N018744	004	Nov 09, 1982	Dec	DISC
>A>		@	5GM/100ML; 300MG/100ML	N018744	004	Nov 09, 1982	Dec	DISC

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO 75 IN PLASTIC CONTAINER

>D>		BAXTER HLTHCARE	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983	Dec	DISC
>A>		@	5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML	N018840	001	Jun 29, 1983	Dec	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

MD-76R

AP	+	LIEBEL-FLARSHEIM	66%; 10%	N019292	001	Sep 29, 1989	Feb	CAHN
		SOLUTION; ORAL, RECTAL						
		MD-GASTROVIEW						
AA		LIEBEL-FLARSHEIM	66%; 10%	A087388	001		Jan	CAHN

DICHLORPHENAMIDE

TABLET; ORAL

KEVEYIS

TARO

50MG

N011366 002 Aug 07, 2015 Aug NEWA

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB		ACTAVIS MID ATLANTIC	3%	A206493	001	Dec 02, 2015	Nov	NEWA
		VOLTAREN						
	+	GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug	CAHN
		SOLUTION; TOPICAL						
		DICLOFENAC SODIUM						
AT		IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun	NEWA
AT		LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug	NEWA
AT		NOVEL LABS INC	1.5%	A205878	001	Dec 09, 2015	Nov	NEWA
		SOLUTION/DROPS; OPHTHALMIC						
		DICLOFENAC SODIUM						
AT		ALTAIRE PHARMS INC	0.1%	A203383	001	Nov 16, 2015	Nov	NEWA
		TABLET, EXTENDED RELEASE; ORAL						
		DICLOFENAC SODIUM						
AB		VPNA	100MG	A075492	001	Feb 11, 2000	Oct	CAHN

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

TENUATE

AA	+	ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
AB	+	ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN

DIFLORASONE DIACETATE

OINTMENT; TOPICAL

DIFLORASONE DIACETATE

AB		VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul	NEWA
----	--	----------------	-------	---------	-----	--------------	-----	------

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

AB		HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN
----	--	-----------------	-------	---------	-----	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN
		TABLET; ORAL						
		DIGOXIN						
AB		MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
AB			0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
AB		SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD

TABLET;ORAL							
DIGOXIN							
AB		0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD
LANOXIN							
	CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
AB		0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN
		0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
AB	+	0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
	@	0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
	@	0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL								
DILT-CD								
	@	APOTEX	120MG	A076151	001	May 20, 2004	Oct	DISC
	@		180MG	A076151	002	May 20, 2004	Oct	DISC
	@		240MG	A076151	003	May 20, 2004	Oct	DISC
	@		300MG	A076151	004	May 20, 2004	Oct	DISC
DILTIAZEM HYDROCHLORIDE								
AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD
TIAZAC								
AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
AP	EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION							
DIPHENHYDRAMINE HYDROCHLORIDE							
AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION							
DIPYRIDAMOLE							
AP	EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun	CAHN

DISULFIRAM

TABLET;ORAL								
DISULFIRAM								
AB	MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA	
AB		500MG	A203916	002	Mar 04, 2015	Feb	NEWA	

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL								
DIVALPROEX SODIUM								
AB	AMNEAL PHARMS		EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA
	@	G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION									
DOBUTAMINE HYDROCHLORIDE									
@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN		

DOCETAXEL

INJECTABLE;INJECTION							
DOCETAXEL							
AP	TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug	NEWA
AP		80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug	NEWA
SOLUTION;IV (INFUSION)							
DOCETAXEL							
>A>	TEIKOKU PHARMA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Dec	NEWA
>A>		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Dec	NEWA
>A>		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Dec	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	AB	ACTAVIS ELIZABETH	23MG	A202415	001	Dec 17, 2015	Dec	NEWA
	AB	HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
	AB		10MG	A203034	002	Jan 30, 2015	Jan	NEWA
	AB	LUPIN LTD	23MG	A202782	001	Oct 30, 2015	Oct	NEWA
	AB	MYLAN PHARMS INC	23MG	A202656	001	Oct 22, 2015	Oct	NEWA
	AB	SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
	AB		10MG	A076786	002	Nov 26, 2010	Apr	CAHN
	AB		23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

NAMZARIC

		FOREST LABS LLC	10MG; 14MG	N206439	001	Dec 23, 2014	Mar	CAHN
	+		10MG; 28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

	@	IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
	@		40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
	@		80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
	@		80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
	@		80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
	@		160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
	@		160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
	@		160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+	EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN
----	---	--------------------	---------	---------	-----	--	-----	------

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	+	MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+	PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM; TOPICAL

ZONALON

	+	DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN
--	---	-------------------	----	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP		AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA
----	--	-----------	--------------------	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	+	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Nov	CRLD	
AP	+		200MG/100ML	A203622	002	Jun 27, 2014	Nov	NEWA	
AP		EUROHLTH INTL SARL	2MG/ML	A062975	001	Mar 17, 1989	Nov	CRLD	
AP			200MG/100ML	A064097	001	Sep 13, 1994	Nov	CRLD	
>D>	AP	+	PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	Dec	CRLD
>A>	AP		2MG/ML	N050629	001	Dec 23, 1987	Dec	CRLD	
	AP	+	2MG/ML	N050629	001	Dec 23, 1987	Oct	CMFD	
		@	2MG/ML	N050629	001	Dec 23, 1987	Oct	CTNA	
		@	10MG/VIAL	N050467	001		Oct	CTNA	
		@	20MG/VIAL	N050467	003	May 20, 1985	Oct	CTNA	
		@	50MG/VIAL	N050467	002		Oct	CTNA	
		@	150MG/VIAL	N050467	004	Jul 22, 1987	Oct	CTNA	
			150MG/75ML	N050629	003	Mar 28, 2011	Oct	NEWA	
>D>	AP	+	200MG/100ML	N050629	002	May 03, 1988	Dec	CRLD	
>A>	AP		200MG/100ML	N050629	002	May 03, 1988	Dec	CRLD	
	AP	+	200MG/100ML	N050629	002	May 03, 1988	Oct	CMFD	
		@	200MG/100ML	N050629	002	May 03, 1988	Oct	CTNA	

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr CAHN

TABLET;ORAL
DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr CAHN

DOXYCYCLINE HYCLATECAPSULE;ORAL
VIBRAMYCIN

>D> AB	PFIZER	EQ 50MG BASE	N050007	001		Dec DISC
>A>	@	EQ 50MG BASE	N050007	001		Dec DISC

INJECTABLE;INJECTION
DOXYCYCLINE

@	EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun CAHN
@		EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun CAHN

DRONABINOLCAPSULE;ORAL
DRONABINOL

@	INSYS THERAP	2.5MG	A078501	001	Aug 19, 2011	Nov DISC
@		5MG	A078501	002	Aug 19, 2011	Nov DISC
@		10MG	A078501	003	Aug 19, 2011	Nov DISC

DROPERIDOLINJECTABLE;INJECTION
DROPERIDOL

@	IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072020	001	Oct 19, 1988	Mar CAHN
@		2.5MG/ML	A072021	001	Oct 19, 1988	Mar CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug NEWA
AB	JAI PHARMA LTD	3MG;0.02MG	A202594	001	Oct 22, 2015	Oct NEWA

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug NEWA
AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug NEWA
AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug NEWA
AB	ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	Oct NEWA
AB		EQ 30MG BASE	A090780	002	Oct 28, 2015	Oct NEWA
AB		EQ 60MG BASE	A090780	003	Oct 28, 2015	Oct NEWA
AB	INVENTIA HLTHCARE	EQ 20MG BASE	A202336	001	Oct 28, 2015	Oct NEWA
AB		EQ 30MG BASE	A202336	002	Oct 28, 2015	Oct NEWA
AB		EQ 60MG BASE	A202336	003	Oct 28, 2015	Oct NEWA

DUTASTERIDECAPSULE;ORAL
DUTASTERIDE

AB	ACTAVIS LABS FL INC	0.5MG	A202808	001	Nov 20, 2015	Nov NEWA
AB	AMNEAL PHARMS	0.5MG	A203118	001	Nov 20, 2015	Nov NEWA
AB	APOTEX INC	0.5MG	A204292	001	Nov 24, 2015	Nov NEWA
AB	BANNER PHARMACAPS	0.5MG	A200899	001	Nov 20, 2015	Nov NEWA
AB	BRECKENRIDGE PHARM	0.5MG	A204705	001	Nov 20, 2015	Nov NEWA
AB	RISING PHARMS INC	0.5MG	A202530	001	Nov 20, 2015	Nov NEWA
AB	ROXANE	0.5MG	A202204	001	Nov 23, 2015	Nov NEWA
AB	SANDOZ INC	0.5MG	A202660	001	Nov 20, 2015	Nov NEWA
AB	STRIDES ARCOLAB LTD	0.5MG	A204262	001	Nov 20, 2015	Nov NEWA
AB	VINTAGE PHARMS LLC	0.5MG	A202421	001	Nov 20, 2015	Nov NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE; ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ACTAVIS LABS FL INC	0.5MG; 0.4MG	A202975	001	Nov 20, 2015	Nov	NEWA
----	---------------------	--------------	---------	-----	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar	CRLD
AB	+ PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar	CRLD

EDOXABAN TOSYLATE

TABLET; ORAL

SAVAYSA

DAIICHI SANKYO

EQ 15MG BASE

N206316 001 Jan 08, 2015 Jan NEWA

EQ 30MG BASE

N206316 002 Jan 08, 2015 Jan NEWA

+

EQ 60MG BASE

N206316 003 Jan 08, 2015 Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON

+ MYLAN INSTITUTIONAL

10MG/ML

A088873 001 Aug 06, 1985 Mar CRLD

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

PROMACTA

+ NOVARTIS PHARMS CORP

EQ 25MG ACID/PACKET

N207027 001 Aug 24, 2015 Aug NEWA

TABLET; ORAL

PROMACTA

NOVARTIS PHARMS CORP

EQ 12.5MG ACID

N022291 004 Oct 20, 2011 Mar CAHN

EQ 25MG ACID

N022291 001 Nov 20, 2008 Mar CAHN

EQ 50MG ACID

N022291 002 Nov 20, 2008 May CRLD

+

EQ 50MG ACID

N022291 002 Nov 20, 2008 Mar CAHN

+

EQ 75MG ACID

N022291 003 Sep 08, 2009 May CRLD

EQ 75MG ACID

N022291 003 Sep 08, 2009 Mar CAHN

+

EQ 100MG ACID

N022291 005 Nov 16, 2012 May CRLD

EQ 100MG ACID

N022291 005 Nov 16, 2012 Mar CAHN

ELUXADOLINE

TABLET; ORAL

VIBERZI

FOREST TOSARA LTD

75MG

N206940 001 May 27, 2015 Jul CAHN

+

100MG

N206940 002 May 27, 2015 Jul CAHN

FURIEX PHARMS

75MG

N206940 001 May 27, 2015 May NEWA

+

100MG

N206940 002 May 27, 2015 May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET; ORAL

GLYXAMBI

BOEHRINGER INGELHEIM

10MG; 5MG

N206073 001 Jan 30, 2015 Jan NEWA

+

25MG; 5MG

N206073 002 Jan 30, 2015 Jan NEWA

EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

SYNJARDY

BOEHRINGER INGELHEIM

5MG; 500MG

N206111 001 Aug 26, 2015 Aug NEWA

5MG; 1GM

N206111 002 Aug 26, 2015 Aug NEWA

12.5MG; 500MG

N206111 003 Aug 26, 2015 Aug NEWA

+

12.5MG; 1GM

N206111 004 Aug 26, 2015 Aug NEWA

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

SANDOZ INC

2.5MG

A075496 001 Aug 22, 2000 Mar CMFD

AB

5MG

A075496 002 Aug 22, 2000 Mar CMFD

AB

10MG

A075459 001 Aug 22, 2000 Mar CMFD

AB

20MG

A075459 002 Aug 22, 2000 Mar CMFD

@ SUN PHARM INDS LTD

2.5MG

A075556 001 Aug 22, 2000 Apr CAHN

@

5MG

A075556 002 Aug 22, 2000 Apr CAHN

@

10MG

A075556 003 Aug 22, 2000 Apr CAHN

@

20MG

A075556 004 Aug 22, 2000 Apr CAHN

TABLET; ORAL									
VASOTEC									
AB	VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr	CAHN		
AB		5MG	N018998	001	Dec 24, 1985	Apr	CAHN		
AB		10MG	N018998	002	Dec 24, 1985	Apr	CAHN		
AB	+	20MG	N018998	003	Dec 24, 1985	Apr	CAHN		
<u>ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE</u>									
TABLET; ORAL									
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE									
AB	G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr	CAHN		
AB		10MG;25MG	A075727	002	Sep 18, 2001	Apr	CAHN		
<u>ENTACAPONE</u>									
TABLET; ORAL									
ENTACAPONE									
AB	AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun	NEWA		
<u>ENTECAVIR</u>									
TABLET; ORAL									
ENTECAVIR									
AB	AMNEAL PHARMS	0.5MG	A206652	001	Nov 12, 2015	Oct	NEWA		
AB		1MG	A206652	002	Nov 12, 2015	Oct	NEWA		
AB	AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015	Aug	NEWA		
AB		1MG	A206217	002	Aug 26, 2015	Aug	NEWA		
AB	HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015	Aug	NEWA		
AB		1MG	A205740	002	Aug 21, 2015	Aug	NEWA		
<u>EPINEPHRINE</u>									
INJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS									
ADRENALIN									
+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul	CAIN		
INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS									
ADRENALIN									
+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul	CAIN		
<u>EPINEPHRINE HYDROCHLORIDE</u>									
SOLUTION; IV (INFUSION), INTRAOCULAR									
EPINEPHRINE									
	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Oct	CDFR		
<u>EPINEPHRINE; LIDOCAINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE									
@	EUROHLTH INTL SARL	0.01MG/ML; 1%	A080406	001		Sep	CAHN		
@		0.01MG/ML; 2%	A080406	002		Sep	CAHN		
<u>EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE</u>									
TABLET; ORAL									
TEVETEN HCT									
@	ABBVIE	600MG; 12.5MG	N021268	001	Nov 01, 2001	Jun	DISC		
@		600MG; 25MG	N021268	002	Nov 01, 2001	Jun	DISC		
<u>EPTIFIBATIDE</u>									
INJECTABLE; INJECTION									
EPTIFIBATIDE									
AP	AUROBINDO PHARMA LTD	2MG/ML	A206127	001	Dec 08, 2015	Nov	NEWA		
AP		75MG/100ML	A206127	002	Dec 08, 2015	Nov	NEWA		
AP	TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun	NEWA		
AP		75MG/100ML	A091555	001	Jun 05, 2015	May	NEWA		
INTEGRILIN									
AP	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun	CTEC	
AP	+		75MG/100ML	N020718	002	May 18, 1998	May	CFTG	
<u>ERGOCALCIFEROL</u>									
CAPSULE; ORAL									
VITAMIN D									
AA	BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan	CAHN		

ERGOTAMINE TARTRATETABLET;SUBLINGUAL
ERGOSTAT

@ WATSON LABS INC

2MG

A088337 001 Jun 08, 1984 Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL

ERLOTINIB HYDROCHLORIDE

@ MYLAN PHARMS INC

EQ 25MG BASE

A091002 001 Jun 11, 2014 Sep DISC

@

EQ 100MG BASE

A091002 002 Jun 11, 2014 Sep DISC

@

EQ 150MG BASE

A091002 003 Jun 11, 2014 Sep DISC

@ TEVA PHARMS USA

EQ 100MG BASE

A091059 002 Aug 28, 2015 Oct DISC

AB

EQ 100MG BASE

A091059 002 Aug 28, 2015 Aug NEWA

@

EQ 150MG BASE

A091059 003 Aug 28, 2015 Oct DISC

AB

EQ 150MG BASE

A091059 003 Aug 28, 2015 Aug NEWA

TARCEVA

OSI PHARMS

EQ 25MG BASE

N021743 001 Nov 18, 2004 Sep CTEC

EQ 100MG BASE

N021743 002 Nov 18, 2004 Oct CTEC

+

EQ 150MG BASE

N021743 003 Nov 18, 2004 Oct CTEC

ERYTHROMYCIN

SOLUTION;TOPICAL

ERYTHRA-DERM

>D>

>D> AT

PADDOCK LLC

2%

A062687 001 Feb 05, 1988 Dec DISC

>A>

@

2%

A062687 001 Feb 05, 1988 Dec DISC

ERYTHROMYCIN

>D> AT

+

FOUGERA PHARMS

2%

A064187 001 Sep 30, 1997 Dec CRLD

>A> AT

2%

A064187 001 Sep 30, 1997 Dec CRLD

>D> AT

PERRIGO NEW YORK

2%

A063038 001 Jan 11, 1991 Dec CRLD

>A> AT

+

2%

A063038 001 Jan 11, 1991 Dec CRLD

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

@ G AND W LABS INC

EQ 125MG BASE/5ML

A062169 001 Oct 17, 1990 Apr CAHN

@

EQ 250MG BASE/5ML

A062169 002 Oct 17, 1990 Apr CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

@ ANI PHARMS INC

EQ 200MG BASE/5ML

A062055 001 Jul CAHN

SUSPENSION;ORAL

E.E.S. 200

@ ARBOR PHARMS LLC

EQ 200MG BASE/5ML

A061639 001 Nov DISC

E.E.S. 400

@ ARBOR PHARMS LLC

EQ 400MG BASE/5ML

A061639 002 Nov DISC

PEDIAMYCIN

@ ARBOR PHARMS LLC

EQ 200MG BASE/5ML

A062304 001 Nov DISC

PEDIAMYCIN 400

@ ARBOR PHARMS LLC

EQ 400MG BASE/5ML

A062304 002 Nov DISC

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA

ANTRIM PHARMS LLC

EQ 5MG BASE/5ML

A203967 001 May 26, 2015 May NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB

MYLAN PHARMS INC

EQ 5MG BASE

A077550 001 May 14, 2015 Apr NEWA

AB

EQ 10MG BASE

A077550 002 May 14, 2015 Apr NEWA

AB

EQ 20MG BASE

A077550 003 May 14, 2015 Apr NEWA

AB

PRINSTON INC

EQ 5MG BASE

A078032 001 Aug 28, 2015 Aug NEWA

AB

EQ 10MG BASE

A078032 002 Aug 28, 2015 Aug NEWA

AB

EQ 20MG BASE

A078032 003 Aug 28, 2015 Aug NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP

AUROBINDO PHARMA LTD

10MG/ML

A205520 001 Jul 23, 2015 Jul NEWA

AP

LUITPOLD

10MG/ML

A201126 001 Feb 20, 2015 Feb NEWA

ESOMEPRAZOLE MAGNESIUMCAPSULE, DELAYED REL PELLETS;ORAL
ESOMEPRAZOLE MAGNESIUM

AB	DR REDDYS LABS LTD	EQ 20MG BASE	A078279	001	Sep 25, 2015	Sep NEWA
AB		EQ 40MG BASE	A078279	002	Sep 25, 2015	Sep NEWA
AB	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Sep NEWA
AB		EQ 40MG BASE	A202784	002	Sep 21, 2015	Sep NEWA
AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan NEWA
AB	MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul NEWA
AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A078936	001	Aug 02, 2015	Sep CAHN
AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Sep CAHN
AB	TORRENT PHARMS LTD	EQ 20MG BASE	A203636	001	Oct 19, 2015	Oct NEWA
AB		EQ 40MG BASE	A203636	002	Oct 19, 2015	Oct NEWA
NEXIUM						
AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan CFTG
AB	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan CFTG

ESOMEPRAZOLE SODIUMINJECTABLE;INTRAVENOUS
ESOMEPRAZOLE SODIUM

AP	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	Sep NEWA
----	-----------------	-------------------	---------	-----	--------------	----------

ESOMEPRAZOLE STRONTIUMCAPSULE, DELAYED RELEASE;ORAL
ESOMEPRAZOLE STRONTIUM

	HANMI PHARM CO LTD	24.65MG	N202342	001	Aug 06, 2013	Aug CPOT
+		49.3MG	N202342	002	Aug 06, 2013	Aug CPOT

ESTRADIOLFILM, EXTENDED RELEASE;TRANSDERMAL
ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar CAHN
MINIVELLE						
	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan NEWA
TABLET;ORAL						
ESTRADIOL						
	@ EPIC PHARMA INC	0.5MG	A040275	001	Dec 29, 1998	Oct CAHN
	@	1MG	A040275	002	Dec 29, 1998	Oct CAHN
	@	2MG	A040275	003	Dec 29, 1998	Oct CAHN
TABLET;VAGINAL						
ESTRADIOL						
	@ AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May DISC

ESZOPICLONETABLET;ORAL
ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan NEWA

ETHACRYNATE SODIUMINJECTABLE;INJECTION
EDECRIN

AP	+	ATON	EQ 50MG BASE/VIAL	N016093	001		Jul CFTG
		ETHACRYNATE SODIUM					
AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Jul NEWA

ETHAMBUTOL HYDROCHLORIDETABLET;ORAL
ETHAMBUTOL HYDROCHLORIDE

AB	VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Jan CMFD
AB		400MG	A075095	002	Nov 30, 1999	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

ASHLYNA

AB	GLENMARK GENERICS	0.03MG;0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015	Feb NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB	GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015	Mar NEWA
AB	GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015	Jun NEWA
AB	HAUPT PHARMA	0.03MG;0.15MG	A203871	001	Nov 13, 2015	Nov NEWA
>A> AB		0.03MG,0.01MG;0.15MG,NA	A203872	001	Dec 22, 2015	Dec NEWA
AB	+ WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011	Mar CTEC
	TABLET; ORAL-28					
	ELIFEMME					
AB	SANDOZ INC	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A202507	001	Dec 04, 2015	Nov NEWA
	LEVONORGESTREL AND ETHINYL ESTRADIOL					
AB	LUPIN LTD	0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG	A200248	001	Nov 19, 2015	Nov NEWA
	LEVORA 0.15/30-28					
AB	+ WATSON LABS	0.03MG;0.15MG	A073594	001	Dec 13, 1993	Aug CRLD
	VIENVA					
AB1	SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015	May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

XULANE

AB	+ MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CRLD
----	----------------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BREVICON 21-DAY

@ ACTAVIS LABS UT INC

0.035MG;0.5MG

N017566 001

Mar CAHN

NORINYL 1+35 21-DAY

AB ACTAVIS LABS UT INC

0.035MG;1MG

N017565 001

Feb CAHN

TRI-NORINYL 21-DAY

@ ACTAVIS LABS UT INC

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG

N018977 001 Apr 13, 1984

Feb CAHN

TABLET; ORAL-28

BREVICON 28-DAY

AB ACTAVIS LABS UT INC

0.035MG;0.5MG

N017743 001

Mar CAHN

CYCLAFEM 0.5/35

AB VINTAGE PHARMS

0.035MG;0.5MG

A203413 001 Dec 16, 2015

Nov NEWA

NORETHINDRONE AND ETHINYL ESTRADIOL

AB FAMY CARE LTD

0.035MG;0.4MG

A200897 001 May 11, 2015

Apr NEWA

>A> AB + JAI PHARMA LTD

0.035MG;0.4MG

A200897 001 May 11, 2015

Jul CRLD

>A> AB 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG

A200486 001 Dec 28, 2015

Dec NEWA

AB 0.035MG;0.5MG

A200488 001 Oct 21, 2015

Oct NEWA

AB 0.035MG;1MG

A200489 001 Oct 21, 2015

Oct NEWA

+

0.05MG;1MG

A203006 001 Aug 05, 2013

Jul CTEC

NORINYL 1+35 28-DAY

AB ACTAVIS LABS UT INC

0.035MG;1MG

N017565 002

Feb CAHN

TRI-NORINYL 28-DAY

AB + ACTAVIS LABS UT INC

0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG

N018977 002 Apr 13, 1984

Feb CAHN

TABLET, CHEWABLE; ORAL

>A> KAITLIB FE

>A> AB LUPIN LTD

0.025MG;0.8MG

A203448 001 Dec 17, 2015

Dec NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

BLISOVI 24 FE

AB LUPIN LTD

0.02MG;1MG

A091398 001 Oct 28, 2015

Oct NEWA

FEMHRT

AB WARNER CHILCOTT LLC

0.0025MG;0.5MG

N021065 001 Jan 14, 2005

Mar CTEC

FYAVOLV

AB LUPIN LTD

0.005MG;1MG

A204213 002 Dec 10, 2015

Nov NEWA

AB 0.0025MG;0.5MG

A204213 001 Dec 10, 2015

Nov NEWA

LARIN 24 FE

AB NOVAST LABS LTD

0.02MG;1MG

A202994 001 Feb 18, 2015

Feb NEWA

LOESTRIN 24 FE

>D> @ WARNER CHILCOTT

0.02MG;1MG

N021871 001 Feb 17, 2006

Dec CMFD

TABLET;ORAL

LOESTRIN 24 FE

>A>	AB		0.02MG;1MG	N021871	001	Feb 17, 2006	Dec CMFD
		@	0.02MG;1MG	N021871	001	Feb 17, 2006	Jan DISC
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL					
	AB	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009
	AB		GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015
	AB			0.005MG;1MG	A203038	002	Apr 02, 2015
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
	AB	+	AMNEAL PHARMS	0.02MG;1MG	A078267	001	Sep 01, 2009
		TABLET;ORAL-28					
		BLISOVI FE 1.5/30					
	AB		LUPIN LTD	0.03MG;1.5MG	A201585	001	Nov 18, 2015
		BLISOVI FE 1/20					
	AB		LUPIN LTD	0.02MG;1MG	A201584	001	Nov 18, 2015

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

NORGESTIMATE AND ETHINYL ESTRADIOL

AB			HAUPT PHARMA	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A203870	001	Nov 12, 2015
				15MG,0.25MG			Oct NEWA
AB				0.035MG;0.25MG	A203865	001	Oct 27, 2015
AB			JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A202132	001	Sep 09, 2015
				15MG,0.25MG			Aug NEWA
AB			OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.2	A200383	001	Apr 07, 2015
				15MG;0.25MG			Mar NEWA
AB				0.035MG;0.25MG	A200384	001	Apr 07, 2015
		TRI LO SPRINTec					
AB			BARR LABS INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A076784	001	Jun 29, 2009
				15MG,0.25MG			Nov CMFD
		TRI-LO-ESTARYLLA					
AB			SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A091232	001	Jun 29, 2015
				15MG,0.25MG			Jun NEWA

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-28

LOW-OGESTREL-28

AB			WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999
----	--	--	-------------	--------------	---------	-----	--------------

ETHOSUXIMIDE

CAPSULE;ORAL

ETHOSUXIMIDE

AB			BANNER LIFE SCIENCES	250MG	A040430	001	Oct 28, 2002
AB			HERITAGE PHARMS INC	250MG	A200892	001	Sep 25, 2012

ETODOLAC

TABLET;ORAL

ETODOLAC

			@ LEHIGH VALLEY	400MG	A074927	001	Oct 30, 1997
--	--	--	-----------------	-------	---------	-----	--------------

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

			@ ORGANON USA INC	68MG/IMPLANT	N021529	001	Jul 17, 2006
--	--	--	-------------------	--------------	---------	-----	--------------

EZETIMIBE

TABLET;ORAL

EZETIMIBE

			@ GLENMARK PHARMS LTD	10MG	A078560	001	Jun 26, 2015
AB				10MG	A078560	001	Jun 26, 2015
		ZETIA					
		+	MSD INTL GMBH	10MG	N021445	001	Oct 25, 2002
AB		+		10MG	N021445	001	Oct 25, 2002

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE

AP		+	EUROHLTH INTL SARL	10MG/ML	A075488	001	Apr 16, 2001
			@	10MG/ML	A075799	001	Apr 30, 2002
		FAMOTIDINE PRESERVATIVE FREE					
AP		+	EUROHLTH INTL SARL	10MG/ML	A075486	001	Apr 16, 2001

TABLET;ORAL

FAMOTIDINE

>A>	AB	AUROBINDO PHARMA LTD	20MG	A206530	001	Dec 22, 2015	Dec NEWA
>A>	AB		40MG	A206530	002	Dec 22, 2015	Dec NEWA
		PEPCID					
	AB	VALEANT PHARMS NORTH	20MG	N019462	001	Oct 15, 1986	Feb CAHN
	AB	+	40MG	N019462	002	Oct 15, 1986	Feb CAHN

FELBAMATE

TABLET;ORAL

FELBAMATE

	AB	COREPHARMA	400MG	A202284	001	Nov 04, 2015	Oct NEWA
	AB		600MG	A202284	002	Nov 04, 2015	Oct NEWA
>A>	AB	MYLAN PHARMS INC	400MG	A204595	001	Jan 11, 2016	Dec NEWA
>A>	AB		600MG	A204595	002	Jan 11, 2016	Dec NEWA

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

	AB	ORCHID HLTHCARE	2.5MG	A203032	001	May 21, 2015	May NEWA
	AB		5MG	A203032	002	May 21, 2015	May NEWA
	AB		10MG	A203032	003	May 21, 2015	May NEWA
	AB	SUN PHARM INDS LTD	2.5MG	A091200	001	Dec 13, 2013	Apr CAHN
	AB		5MG	A091200	002	Dec 13, 2013	Apr CAHN
	AB		10MG	A091200	003	Dec 13, 2013	Apr CAHN
		PLENDIL					
		@ ASTRAZENECA	2.5MG	N019834	004	Sep 22, 1994	Nov DISC
		@	5MG	N019834	001	Jul 25, 1991	Nov DISC
		@	10MG	N019834	002	Jul 25, 1991	Nov DISC

FENOFIBRATE

CAPSULE;ORAL

FENOFIBRATE

	AB	SUN PHARM INDS LTD	43MG	A201748	001	Oct 31, 2014	Apr CAHN
	AB		130MG	A201748	002	Oct 31, 2014	Apr CAHN

TABLET;ORAL

FENOFIBRATE

	AB	LUPIN LTD	54MG	A204019	001	Aug 17, 2015	Aug NEWA
	AB		160MG	A204019	002	Aug 17, 2015	Aug NEWA
	AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr CAHN
			107MG	A076635	002	Oct 31, 2005	Apr CAHN
	AB		160MG	A076635	003	Oct 31, 2005	Apr CAHN
	AB	VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug CAHN
	AB		145MG	A090715	002	Apr 05, 2012	Aug CAHN

FENOFIBRIC ACID

TABLET;ORAL

FIBRICOR

		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun CAHN
		+	105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

	AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar CAHN
		FENTANYL-12					
	AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun NEWA
		FENTANYL-25					
	AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar CAHN
		FENTANYL-50					
	AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar CAHN
		FENTANYL-75					
	AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar CAHN

FENTANYL CITRATE

FILM;BUCCAL

ONSOLIS

		@ BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar CAHN
		@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar CAHN
		@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar CAHN
		@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar CAHN
		@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar CAHN

INJECTABLE;INJECTION

FENTANYL CITRATE PRESERVATIVE FREE

AP	+	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb CAHN
		SPRAY, METERED;NASAL					
		LAZANDA					

>A>		DEPOMED INC	EQ 0.3MG BASE	N022569	003	Dec 21, 2015	Dec NEWA
		TABLET;SUBLINGUAL					
		ABSTRAL					

>D>		GALENA BIOPHARMA	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Dec CAHN
>D>			EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Dec CAHN
>D>			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Dec CAHN
>D>	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Dec CAHN
>D>			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Dec CAHN
>D>			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Dec CAHN
>A>		SENTYNL THERAPS INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Dec CAHN
>A>			EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Dec CAHN
>A>			EQ 0.3MG BASE	N022510	003	Jan 07, 2011	Dec CAHN
>A>	+		EQ 0.4MG BASE	N022510	004	Jan 07, 2011	Dec CAHN
>A>			EQ 0.6MG BASE	N022510	005	Jan 07, 2011	Dec CAHN
>A>			EQ 0.8MG BASE	N022510	006	Jan 07, 2011	Dec CAHN

FENTANYL HYDROCHLORIDESYSTEM;IONTOPHORESIS, TRANSDERMAL
IONSYS

		@ THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr CAHN
	+		EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun CMFD

FERRIC CITRATETABLET;ORAL
AURYXIA

	+	KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan CTNA
--	---	-----------------	---------------	---------	-----	--------------	----------

FERRIC PYROPHOSPHATE CITRATESOLUTION;IV (INFUSION)
TRIFERIC

	+	ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan NEWA
			272MG IRON/50ML (5.44MG IRON/ML)	N206317	002	Sep 04, 2015	Oct NEWA

FESOTERODINE FUMARATETABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

AB		ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Nov NEWA
AB			8MG	A204827	002	Dec 10, 2015	Nov NEWA
		TOVIAZ					
AB		PFIZER	4MG	N022030	001	Oct 31, 2008	Nov CFTG
AB	+		8MG	N022030	002	Oct 31, 2008	Nov CFTG

FIDAXOMICINTABLET;ORAL
DIFICID

	+	CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug CAHN
--	---	-------------------	-------	---------	-----	--------------	----------

FLECAINIDE ACETATETABLET;ORAL
FLECAINIDE ACETATE

AB		ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr CAHN
AB			100MG	A075882	002	Oct 28, 2002	Apr CAHN
AB			150MG	A075882	003	Oct 28, 2002	Apr CAHN
AB		AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun NEWA
AB			100MG	A202821	002	Jul 08, 2015	Jun NEWA
AB			150MG	A202821	003	Jul 08, 2015	Jun NEWA
AB		SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr CAHN
AB			100MG	A076421	002	Mar 28, 2003	Apr CAHN
AB			150MG	A076421	003	Mar 28, 2003	Apr CAHN

FLIBANSERINTABLET;ORAL
ADDYI

	+	SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug NEWA
--	---	---------------	-------	---------	-----	--------------	----------

FLUCONAZOLEFOR SUSPENSION; ORAL
FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr CAHN

INJECTABLE; INJECTION

FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr CAHN

TABLET; ORAL

FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May CMFD
AB		100MG	A078423	002	Mar 07, 2011	May CMFD
AB		150MG	A078423	003	Mar 07, 2011	May CMFD
AB		200MG	A078423	004	Mar 07, 2011	May CMFD

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	3D IMAGING DRUG	20-300mCi/ML	A203778	001	Oct 30, 2015	Oct NEWA
AP	CARDINAL HEALTH 414	20-300mCi/ML	A203603	001	Nov 13, 2015	Nov NEWA
AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug NEWA
AP	KETTERING MEDCTR	4-40mCi/ML	A204759	001	Oct 27, 2015	Oct NEWA
AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr NEWA
AP	MIDWEST MEDCL	20-200mCi/ML	A203736	001	Nov 19, 2015	Nov NEWA
AP	MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar NEWA
	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug NEWA
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr NEWA
AP +	UCLA BIOMEDICAL	4-40mCi/ML	A203811	001	Jun 27, 2013	Oct CTEC
AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun NEWA
----	----------------	-------	---------	-----	--------------	----------

SOLUTION; TOPICAL

FLUOCINOLONE ACETONIDE

AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug NEWA
----	------------------	-------	---------	-----	--------------	----------

FLUOCINONIDE

GEL; TOPICAL

FLUOCINONIDE

AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr CAHN
----	------------------	-------	---------	-----	--------------	----------

FLUOROURACIL

CREAM; TOPICAL

CARAC

AB	+ VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr CFTG
	+	0.5%	N020985	001	Oct 27, 2000	Feb CAHN

FLUOROURACIL

AB	SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr NEWA
----	------------------	------	---------	-----	--------------	----------

TOLAK

	+ HILL DERMACEUTICALS	4%	N022259	001	Sep 18, 2015	Sep NEWA
--	-----------------------	----	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL							
FLUOXETINE HYDROCHLORIDE							
	@ ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@	EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
		EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@ SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@	EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1	SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1		EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB		EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

OINTMENT; TOPICAL							
CORDRAN							
+	AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
		0.05%	N012806	001		May	CMFD
TAPE; TOPICAL							
CORDRAN							
+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLURBIPROFEN

TABLET; ORAL							
ANSAID							
	@ PHARMACIA AND UPJOHN	50MG	N018766	002	Oct 31, 1988	Oct	DISC
	@	100MG	N018766	003	Oct 31, 1988	Oct	DISC
	FLURBIPROFEN						
AB	+	MYLAN	100MG	A074358	002	Jun 20, 1994	Oct CRLD

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION							
BREO ELLIPTA							
	GLAXO GRP LTD	0.2MG/INH; EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FLUTICASONE PROPIONATE

CREAM; TOPICAL							
FLUTICASONE PROPIONATE							
AB	+	PERRIGO NEW YORK	0.05%	A076793	001	May 14, 2004	Oct CRLD

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL							
FLUVASTATIN SODIUM							
AB	MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug	NEWA
	LESCOL XL						
AB	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug CFTG

FLUVOXAMINE MALEATE

TABLET; ORAL							
FLUVOXAMINE MALEATE							
AB	ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul	CAHN
	@	25MG	A075898	001	Mar 12, 2001	Jul	CAHN
AB		50MG	A075897	002	Jan 25, 2001	Jul	CAHN
	@	50MG	A075898	002	Mar 12, 2001	Jul	CAHN
AB		100MG	A075897	003	Jan 25, 2001	Jul	CAHN
	@	100MG	A075898	003	Mar 12, 2001	Jul	CAHN

FOLIC ACID

TABLET; ORAL							
FOLIC ACID							
AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug	CAHN
AA	NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL							
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE							
AB	SUN PHARM INDS LTD	10MG; 12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB		20MG; 12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDE

INJECTABLE;INJECTION
FUROSEMIDE

@ IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar CAHN
@	10MG/ML	A070096	001	Sep 09, 1985	Mar CAHN

GABAPENTIN

CAPSULE;ORAL
GABAPENTIN

AB	SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr CAHN
AB		300MG	A076606	002	Oct 07, 2005	Apr CAHN
AB		400MG	A076606	003	Oct 07, 2005	Apr CAHN

TABLET;ORAL

GABAPENTIN

>A> AB	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Dec NEWA
>A> AB		800MG	A206402	002	Dec 23, 2015	Dec NEWA
	@ HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun DISC
	@	800MG	A078782	002	Jul 21, 2011	Jun DISC

GADOVERSETAMIDE

INJECTABLE;INJECTION
OPTIMARK

+	LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb CAHN
+		3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb CAHN
+		16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb CAHN

OPTIMARK IN PLASTIC CONTAINER

+	LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb CAHN
+		4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb CAHN
+		6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb CAHN
+		9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb CAHN

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION
GALLIUM CITRATE GA 67

>D> BS	MALLINCKRODT	2mCi/ML	N018058	001		Dec CAHN
>A> BS	MALLINKRODT NUCLEAR	2mCi/ML	N018058	001		Dec CAHN

GEFITINIB

TABLET;ORAL

IRESSA

+	ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul NEWA
---	--------------------	-------	---------	-----	--------------	----------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION
GEMCITABINE HYDROCHLORIDE

>A> AP	GLAND PHARMA LTD	EQ 200MG BASE/VIAL	A204520	001	Jan 05, 2016	Dec NEWA
>A> AP		EQ 1GM BASE/VIAL	A204520	002	Jan 05, 2016	Dec NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug NEWA
----	----------------------	-------	---------	-----	--------------	----------

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	+	LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun CFTG
		GEMIFLOXACIN MESYLATE					
AB		ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun NEWA

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D> AP	+	B BRAUN	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987	Dec DISC
>A>		@	EQ 0.8MG BASE/ML	A062814	001	Aug 28, 1987	Dec DISC
>D> AP	+		EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987	Dec DISC
>A>		@	EQ 1.2MG BASE/ML	A062814	002	Aug 28, 1987	Dec DISC
>D> AP	+		EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987	Dec DISC
>A>		@	EQ 1.4MG BASE/ML	A062814	003	Aug 28, 1987	Dec DISC

INJECTABLE;INJECTION

GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

>D>	AP	+		EQ	1.6MG	BASE/ML	A062814	004	Aug 28, 1987	Dec	DISC
>A>		@		EQ	1.6MG	BASE/ML	A062814	004	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	1.8MG	BASE/ML	A062814	005	Aug 28, 1987	Dec	DISC
>A>		@		EQ	1.8MG	BASE/ML	A062814	005	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	2MG	BASE/ML	A062814	006	Aug 28, 1987	Dec	DISC
>A>		@		EQ	2MG	BASE/ML	A062814	006	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	2.4MG	BASE/ML	A062814	007	Aug 28, 1987	Dec	DISC
>A>		@		EQ	2.4MG	BASE/ML	A062814	007	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	40MG	BASE/100ML	A062814	008	Aug 28, 1987	Dec	DISC
>A>		@		EQ	40MG	BASE/100ML	A062814	008	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	60MG	BASE/100ML	A062814	009	Aug 28, 1987	Dec	DISC
>A>		@		EQ	60MG	BASE/100ML	A062814	009	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	70MG	BASE/100ML	A062814	010	Aug 28, 1987	Dec	DISC
>A>		@		EQ	70MG	BASE/100ML	A062814	010	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	80MG	BASE/100ML	A062814	011	Aug 28, 1987	Dec	DISC
>A>		@		EQ	80MG	BASE/100ML	A062814	011	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	90MG	BASE/100ML	A062814	012	Aug 28, 1987	Dec	DISC
>A>		@		EQ	90MG	BASE/100ML	A062814	012	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	100MG	BASE/100ML	A062814	013	Aug 28, 1987	Dec	DISC
>A>		@		EQ	100MG	BASE/100ML	A062814	013	Aug 28, 1987	Dec	DISC
>D>	AP	+		EQ	120MG	BASE/100ML	A062814	014	Aug 28, 1987	Dec	DISC
>A>		@		EQ	120MG	BASE/100ML	A062814	014	Aug 28, 1987	Dec	DISC
		@	BAXTER HLTHCARE	EQ	0.8MG	BASE/ML	A062373	001	Sep 07, 1982	Nov	DISC
	AP			EQ	0.8MG	BASE/ML	A062373	001	Sep 07, 1982	Nov	CTNA
	AP			EQ	1.2MG	BASE/ML	A062373	007	Sep 07, 1982	Nov	CTNA
	AP			EQ	1.6MG	BASE/ML	A062373	008	Sep 07, 1982	Nov	CTNA
>D>	AP			EQ	2MG	BASE/ML	A062373	009	Sep 07, 1982	Dec	CTEC
>A>		+		EQ	2MG	BASE/ML	A062373	009	Sep 07, 1982	Dec	CRLD
>A>				EQ	2MG	BASE/ML	A062373	009	Sep 07, 1982	Dec	CTEC
	AP			EQ	2MG	BASE/ML	A062373	009	Sep 07, 1982	Nov	CTNA
		@		EQ	2.4MG	BASE/ML	A062373	010	Sep 07, 1982	Nov	DISC
	AP			EQ	2.4MG	BASE/ML	A062373	010	Sep 07, 1982	Nov	CTNA
		@		EQ	40MG	BASE/100ML	A062373	003	Sep 07, 1982	Nov	DISC
	AP			EQ	40MG	BASE/100ML	A062373	003	Sep 07, 1982	Nov	CTNA
		@		EQ	60MG	BASE/100ML	A062373	004	Sep 07, 1982	Nov	DISC
	AP			EQ	60MG	BASE/100ML	A062373	004	Sep 07, 1982	Nov	CTNA
	AP			EQ	80MG	BASE/100ML	A062373	002	Sep 07, 1982	Nov	CTNA
	AP			EQ	100MG	BASE/100ML	A062373	005	Sep 07, 1982	Nov	CTNA
>D>	AP			EQ	120MG	BASE/100ML	A062373	006	Sep 07, 1982	Dec	CTEC
>A>		+		EQ	120MG	BASE/100ML	A062373	006	Sep 07, 1982	Dec	CRLD
>A>				EQ	120MG	BASE/100ML	A062373	006	Sep 07, 1982	Dec	CTEC
	AP			EQ	120MG	BASE/100ML	A062373	006	Sep 07, 1982	Nov	CTNA
>D>	AP		HOSPIRA	EQ	1.4MG	BASE/ML	A062414	002	Aug 15, 1983	Dec	DISC
>A>		@		EQ	1.4MG	BASE/ML	A062414	002	Aug 15, 1983	Dec	DISC
>D>	AP			EQ	1.8MG	BASE/ML	A062414	004	Aug 15, 1983	Dec	DISC
>A>		@		EQ	1.8MG	BASE/ML	A062414	004	Aug 15, 1983	Dec	DISC
>D>	AP			EQ	2MG	BASE/ML	A062414	005	Aug 15, 1983	Dec	DISC
>A>		@		EQ	2MG	BASE/ML	A062414	005	Aug 15, 1983	Dec	DISC
>D>	AP			EQ	60MG	BASE/100ML	A062414	006	Aug 15, 1983	Dec	DISC
>A>		@		EQ	60MG	BASE/100ML	A062414	006	Aug 15, 1983	Dec	DISC
>D>	AP			EQ	70MG	BASE/100ML	A062414	007	Aug 15, 1983	Dec	DISC
>A>		@		EQ	70MG	BASE/100ML	A062414	007	Aug 15, 1983	Dec	DISC
>D>	AP			EQ	90MG	BASE/100ML	A062414	009	Aug 15, 1983	Dec	DISC
>A>		@		EQ	90MG	BASE/100ML	A062414	009	Aug 15, 1983	Dec	DISC

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+	TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG
AP		GLATOPIA						
AP		SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
@		4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLIPIZIDE

TABLET; ORAL							
GLIPIZIDE							
	@ ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug	CAHN
AB		5MG	A074497	001	Aug 31, 1995	Oct	CAHN
	@	10MG	A074387	002	Mar 04, 1996	Aug	CAHN
AB		10MG	A074497	002	Aug 31, 1995	Oct	CAHN
TABLET, EXTENDED RELEASE; ORAL							
GLIPIZIDE							
AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May	NEWA
AB		5MG	A202298	002	May 19, 2015	May	NEWA
AB		10MG	A202298	003	May 19, 2015	May	NEWA

GLUCAGON HYDROCHLORIDE

POWDER; INTRAMUSCULAR, INTRAVENOUS							
GLUCAGON							
	+ FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May	NEWA

GLYBURIDE

TABLET; ORAL							
DIABETA							
AB2	SANOFI AVENTIS US	1.25MG	N017532	001	May 01, 1984	Sep	CFTG
AB2		2.5MG	N017532	002	May 01, 1984	Sep	CFTG
AB2	+	5MG	N017532	003	May 01, 1984	Sep	CFTG
GLYBURIDE							
AB1	AUROBINDO PHARMA	1.25MG	A077537	001	Oct 18, 2007	Sep	CTEC
AB1		2.5MG	A077537	002	Oct 18, 2007	Sep	CTEC
AB1		5MG	A077537	003	Oct 18, 2007	Sep	CTEC
AB1	COREPHARMA	1.25MG	A076257	001	Jun 27, 2002	Sep	CTEC
AB2		1.25MG	A206079	001	Sep 30, 2015	Sep	NEWA
AB1		2.5MG	A076257	002	Jun 27, 2002	Sep	CTEC
AB2		2.5MG	A206079	002	Sep 30, 2015	Sep	NEWA
AB1		5MG	A076257	003	Jun 27, 2002	Sep	CTEC
AB2		5MG	A206079	003	Sep 30, 2015	Sep	NEWA
AB1	HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	Sep	CTEC
AB1		2.5MG	A090937	002	Feb 28, 2011	Sep	CTEC
AB1		5MG	A090937	003	Feb 28, 2011	Sep	CTEC
AB1	TEVA	1.25MG	A074388	001	Aug 29, 1995	Sep	CTEC
AB1		2.5MG	A074388	002	Aug 29, 1995	Sep	CTEC
AB1	+	5MG	A074388	003	Aug 29, 1995	Sep	CTEC

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL							
GLUCOVANCE							
	@ BRISTOL MYERS SQUIBB	1.25MG; 250MG	N021178	001	Jul 31, 2000	Oct	DISC

GLYCEROL PHENYLBUTYRATE

LIQUID; ORAL							
RAVICTI							
	+ HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May	CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION							
ROBINUL							
AP	+ EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun	CAHN
POWDER; INHALATION							
SEEBRI							
	+ NOVARTIS PHARMS CORP	15.6MCG/INH	N207923	001	Oct 29, 2015	Oct	NEWA
TABLET; ORAL							
GLYCOPYRROLATE							
AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr	CAHN
AA		2MG	A040844	002	Aug 18, 2009	Apr	CAHN

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER; INHALATION							
UTIBRON							
	+ NOVARTIS PHARMS CORP	15.6MCG/INH; 27.5MCG/INH	N207930	001	Oct 29, 2015	Oct	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GRISEOFULVIN, MICROSIZE

TABLET; ORAL

GRIFULVIN V

	@ VALEANT LUXEMBOURG	500MG	A062279	003		Nov DISC
	GRISEOFULVIN					
AB	+ SANDOZ INC	500MG	A091592	002	Aug 07, 2013	Nov CRLD

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

FLOWTUSS

	MIKART INC	200MG/5ML; 2.5MG/5ML	N022424	001	May 14, 2015	May NEWA
	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML	N022424	001	May 14, 2015	Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MIKART INC	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	May NEWA
---	------------	--------------------------------	---------	-----	--------------	----------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Oct NEWA
AB		EQ 2MG BASE	A202238	002	Oct 20, 2015	Oct NEWA
AB		EQ 3MG BASE	A202238	003	Oct 20, 2015	Oct NEWA
AB		EQ 4MG BASE	A202238	004	Oct 20, 2015	Oct NEWA
AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOBETASOL PROPIONATE

LOTION; TOPICAL

ULTRAVATE

+	FERNDALE LABS INC	0.05%	N208183	001	Nov 06, 2015	Nov NEWA
---	-------------------	-------	---------	-----	--------------	----------

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@ CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
	@	1MG	A071129	001	Feb 17, 1987	Jun CAHN
	@	5MG	A071131	001	Feb 17, 1987	Jun CAHN
	@	10MG	A071132	001	May 12, 1987	Jun CAHN
	@	20MG	A071133	001	May 12, 1987	May CAHN
	@ ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE; ORAL

HALOPERIDOL INTENSOL

@ CYCLE PHARMS LTD

EQ 2MG BASE/ML

A072045 001 Apr 12, 1988 May CAHN

INJECTABLE; INJECTION

HALOPERIDOL

@ CLARIS PHARMASERVICE

EQ 5MG BASE/ML

A076791 001 Aug 25, 2004 Apr CAHN

@

EQ 5MG BASE/ML

A076828 001 Aug 25, 2004 May CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

@ EUROHLTH INTL SARL

1,000 UNITS/ML

N017007 001

Aug CAHN

AP

+

1,000 UNITS/ML

N017037 001

Jun CAHN

@

2,500 UNITS/ML

N017007 007

Aug CAHN

@

5,000 UNITS/ML

N017007 002

Aug CAHN

@

5,000 UNITS/0.5ML

N017007 010

Aug CAHN

AP

+

5,000 UNITS/ML

N017037 002

Jun CAHN

@

5,000 UNITS/0.5ML

N017037 013 Apr 07, 1986

Jun CAHN

@

7,500 UNITS/ML

N017007 003

Aug CAHN

@

10,000 UNITS/ML

N017007 004

Aug CAHN

AP

+

10,000 UNITS/ML

N017037 003

Jun CAHN

@

15,000 UNITS/ML

N017007 005

Aug CAHN

@

20,000 UNITS/ML

N017007 006

Aug CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDRALAZINE HYDROCHLORIDE

AP

+

AKORN

20MG/ML

A040730 001

Apr 21, 2009

Feb CRLD

AP

LUITPOLD

20MG/ML

A040136 001

Jun 30, 1997

Feb CRLD

AP

X-GEN PHARMS INC

20MG/ML

A203110 001

Jun 29, 2015

Jun NEWA

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@ HERITAGE PHARMS INC

10MG

A040858 001

Feb 26, 2010

Sep CAHN

@

25MG

A040858 002

Feb 26, 2010

Sep CAHN

@

50MG

A040858 003

Feb 26, 2010

Sep CAHN

@

100MG

A040858 004

Feb 26, 2010

Sep CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>D>

@ SUN PHARM INDS INC

12.5MG

A090651 001

Apr 07, 2014

Dec CMFD

>A> AB

12.5MG

A090651 001

Apr 07, 2014

Dec CMFD

@

12.5MG

A090651 001

Apr 07, 2014

Aug DISC

MICROZIDE

AB

+

ACTAVIS LABS UT INC

12.5MG

N020504 001

Dec 27, 1996

Feb CAHN

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB

SUN PHARM INDS LTD

12.5MG; 10MG

A076007 001

Jul 01, 2002

Apr CAHN

AB

12.5MG; 20MG

A076007 002

Jul 01, 2002

Apr CAHN

AB

25MG; 20MG

A076007 003

Jul 01, 2002

Apr CAHN

>D>

PRINZIDE

>D> AB

MERCK

12.5MG; 10MG

N019778 003

Nov 18, 1993

Dec DISC

>A>

@

12.5MG; 10MG

N019778 003

Nov 18, 1993

Dec DISC

>D> AB

12.5MG; 20MG

N019778 001

Feb 16, 1989

Dec DISC

>A>

@

12.5MG; 20MG

N019778 001

Feb 16, 1989

Dec DISC

ZESTORETIC

AB

ALVOGEN IPCO SARL

12.5MG; 10MG

N019888 003

Nov 18, 1993

Feb CAHN

AB

+

12.5MG; 20MG

N019888 001

Sep 20, 1990

Feb CAHN

AB

+

25MG; 20MG

N019888 002

Jul 20, 1989

Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

CONCORDIA PHARMS INC

12.5MG; EQ 25MG TARTRATE

N021956 001

Aug 28, 2006

Jun CAHN

12.5MG; EQ 50MG TARTRATE

N021956 002

Aug 28, 2006

Jun CAHN

+

12.5MG; EQ 100MG TARTRATE

N021956 003

Aug 28, 2006

Jun CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL					
INDERIDE-40/25					
@ WYETH PHARMS INC		25MG; 40MG	N018031	001	Oct DISC
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
@ ANI PHARMS INC		25MG; 40MG	A070704	001	Oct 01, 1986
AB		25MG; 40MG	A072042	001	Mar 14, 1988
	@	25MG; 80MG	A070705	001	Oct 01, 1986
AB		25MG; 80MG	A072043	001	Mar 14, 1988
AB	+	MYLAN	A070947	002	Mar 04, 1987
		25MG; 40MG			Oct CRLD

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL					
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
AB	SUN PHARM INDS LTD	12.5MG; EQ 10MG BASE	A078211	001	Mar 04, 2009
AB		12.5MG; EQ 20MG BASE	A078211	002	Mar 04, 2009
AB		25MG; EQ 20MG BASE	A078211	003	Mar 04, 2009
					Apr CAHN
					Apr CAHN
					Apr CAHN

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL					
TELMISARTAN AND HYDROCHLOROTHIAZIDE					
AB	MACLEODS PHARMS LTD	12.5MG; 40MG	A204169	001	Nov 02, 2015
AB		12.5MG; 80MG	A204169	002	Nov 02, 2015
AB		25MG; 80MG	A204169	003	Nov 02, 2015
					Oct NEWA
					Oct NEWA
					Oct NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL					
TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
@ ANI PHARMS INC		25MG; 37.5MG	A074970	001	Jan 06, 1998
TABLET; ORAL					
TRIAMTERENE AND HYDROCHLOROTHIAZIDE					
AB	ANI PHARMS INC	50MG; 75MG	A073467	001	Jan 31, 1996
					Aug CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE; ORAL					
ZOHYDRO ER					
+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013
		15MG	N202880	002	Oct 25, 2013
		20MG	N202880	003	Oct 25, 2013
		30MG	N202880	004	Oct 25, 2013
		40MG	N202880	005	Oct 25, 2013
		50MG	N202880	006	Oct 25, 2013
+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013
		15MG	N202880	002	Oct 25, 2013
		20MG	N202880	003	Oct 25, 2013
		30MG	N202880	004	Oct 25, 2013
		40MG	N202880	005	Oct 25, 2013
		50MG	N202880	006	Oct 25, 2013
TABLET, EXTENDED RELEASE; ORAL					
HYSINGLA					
+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014
					Mar CRLD

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL					
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE					
AA	COASTAL PHARMS	5MG/5ML; 60MG/5ML	A205658	001	Nov 17, 2015
					Nov NEWA

HYDROCORTISONE

CREAM; TOPICAL					
ALA-CORT					
>A> AT	CROWN LABS	2.5%	A080706	007	Jan 05, 2016
	HYDROCORTISONE				Dec NEWA
AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010
					Mar CAHN
POWDER; FOR RX COMPOUNDING					
HYDRO-RX					
@ X GEN PHARMS		100%	A085982	001	Apr DISC
TABLET; ORAL					
HYDROCORTISONE					
AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015
AB		10MG	A083365	003	Feb 23, 2015
AB		20MG	A083365	001	Feb CMFD

HYDROCORTISONE ACETATEPOWDER;FOR RX COMPOUNDING
HYDROCORTISONE ACETATE

@ X GEN PHARMS	100%	A085981	001		Apr	DISC
----------------	------	---------	-----	--	-----	------

HYDROCORTISONE VALERATECREAM;TOPICAL
HYDROCORTISONE VALERATE

@ G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr	CAHN
--------------------	------	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATESUSPENSION/DROPS;OTIC
CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001		Jun	CMS2
----	---	-------------------	-------------------------------------	---------	-----	--	-----	------

HYDROMORPHONE HYDROCHLORIDEINJECTABLE;INJECTION
DILAUDID-HP

@ PURDUE PHARM PRODS	250MG/VIAL	N019034	002	Aug 04, 1994	Oct	DISC
----------------------	------------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE;ORAL
HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar	NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar	NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar	NEWA

HYDROXOCOBALAMININJECTABLE;INJECTION
CYANOKIT

@ SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr	CAHN
+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	CAHN

HYDROXYCHLOROQUINE SULFATETABLET;ORAL
PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001		Jun	CAHN
----	---	----------------------	-------	---------	-----	--	-----	------

HYDROXYPROGESTERONE CAPROATEINJECTABLE;INJECTION
HYDROXYPROGESTERONE CAPROATE

@ ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar	CAHN
@	250MG/ML	N017439	002		Mar	CAHN
+	MCGUFF	A200271	001	Aug 24, 2015	Aug	NEWA

HYDROXYZINE HYDROCHLORIDETABLET;ORAL
HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun	CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun	CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun	CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar	CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar	CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar	CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar	CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar	CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar	CMFD
		@ MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul	DISC
		@	25MG	A089382	001	May 19, 1986	Jul	DISC
		@	50MG	A089383	001	May 19, 1986	Jul	DISC
>A> AB		NORTHSTAR HLTHCARE	10MG	A040840	002	Mar 31, 2008	Dec	NEWA
>A> AB			25MG	A040840	003	Mar 31, 2008	Dec	NEWA
		@ WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul	DISC
		@	25MG	A088349	001	Sep 15, 1983	Jul	DISC
		@	50MG	A088350	001	Sep 15, 1983	Jul	DISC

HYDROXYZINE PAMOATECAPSULE;ORAL
HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar	CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar	CAHN

IBANDRONATE SODIUMINJECTABLE;INTRAVENOUS
IBANDRONATE SODIUM

AP	APOTEX INC	EQ 3MG BASE/3ML	A204222	001	Oct 16, 2015	Oct NEWA
AP	AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug NEWA

IBUPROFENTABLET;ORAL
IBUPROFEN

AB	GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug NEWA
AB		600MG	A091625	002	Sep 15, 2015	Aug NEWA
AB		800MG	A091625	003	Sep 15, 2015	Aug NEWA
	@ VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul DISC
	@	400MG	A071231	001	Oct 22, 1986	Jul DISC
	@	600MG	A071232	001	Oct 22, 1986	Jul DISC
	@	800MG	A072004	001	Nov 18, 1987	Jul DISC

ILOPERIDONETABLET;ORAL
FANAPT

+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan CAHN
		2MG	N022192	002	May 06, 2009	Jan CAHN
		4MG	N022192	003	May 06, 2009	Jan CAHN
		6MG	N022192	004	May 06, 2009	Jan CAHN
		8MG	N022192	005	May 06, 2009	Jan CAHN
		10MG	N022192	006	May 06, 2009	Jan CAHN
		12MG	N022192	007	May 06, 2009	Jan CAHN

IMATINIB MESYLATETABLET;ORAL
GLEEVEC

AB	NOVARTIS	EQ 100MG BASE	N021588	001	Apr 18, 2003	Nov CFTG
AB	+	EQ 400MG BASE	N021588	002	Apr 18, 2003	Nov CFTG
	IMATINIB MESYLATE					
AB	SUN PHARMA GLOBAL	EQ 100MG BASE	A078340	001	Dec 03, 2015	Nov NEWA
AB		EQ 400MG BASE	A078340	002	Dec 03, 2015	Nov NEWA

IMIQUIMODCREAM;TOPICAL
IMIQUIMOD

AB	G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr CAHN
----	------------------	----	---------	-----	--------------	----------

INDAPAMIDETABLET;ORAL
INDAPAMIDE

AB	ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul CAHN
	@	1.25MG	A074498	002	Feb 12, 1998	Jul CAHN
AB		2.5MG	A074299	001	Jul 27, 1995	Jul CAHN
	@	2.5MG	A074498	001	Oct 31, 1996	Jul CAHN

INDOMETHACINCAPSULE, EXTENDED RELEASE;ORAL
INDOMETHACIN

AB	JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Sep NEWA
----	-------------------	------	---------	-----	--------------	----------

INGENOL MEBUTATEGEL;TOPICAL
PICATO

+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May CRLD
---	---------------	--------	---------	-----	--------------	----------

INSULIN DEGLUDECSOLUTION;SUBCUTANEOUS
TRESIBA

	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N203314	001	Sep 25, 2015	Sep NEWA
+		600 UNITS/3ML (200 UNITS/ML)	N203314	002	Sep 25, 2015	Sep NEWA

INSULIN GLARGINE

SOLUTION;SUBCUTANEOUS
BASAGLAR

>A> ELI LILLY AND CO 300 UNITS/3ML (100 UNITS/ML) N205692 001 Dec 16, 2015 Dec NEWA

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS
TOUJEO SOLOSTAR

+ SANOFI US SERVICES 300 UNITS/ML (300 UNITS/ML) N206538 001 Feb 25, 2015 Feb NEWA

INSULIN LISPRO RECOMBINANT

SOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN

+ ELI LILLY AND CO 200 UNITS/ML N205747 001 May 26, 2015 May NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION
AFREZZA

SANOFI AVENTIS 12 UNITS/INH N022472 003 Apr 17, 2015 Apr NEWA

IOHEXOL

FOR SOLUTION;ORAL
ORALTAG

INTERPHARMA PRAHA AS 9.7GM/BOT N205383 001 Mar 26, 2015 Mar NEWA

IOPAMIDOL

INJECTABLE;INJECTION
IOPAMIDOL-250

@ FRESENIUS KABI USA 51% A074679 001 Apr 02, 1997 Jan DISC

IOPAMIDOL-300

@ FRESENIUS KABI USA 61% A074679 002 Apr 02, 1997 Jan DISC

IOPAMIDOL-370

@ FRESENIUS KABI USA 76% A074679 003 Apr 02, 1997 Jan DISC

ISOVUE-200

+ BRACCO 41% N018735 006 Jul 07, 1987 Feb CTEC

ISOVUE-250

+ BRACCO 51% N018735 007 Jul 06, 1992 Feb CTEC

+ 51% N020327 002 Oct 12, 1994 Feb CTEC

ISOVUE-300

+ BRACCO 61% N020327 003 Oct 12, 1994 Feb CTEC

ISOVUE-370

+ BRACCO 76% N020327 004 Oct 12, 1994 Feb CTEC

SCANLUX-300

AP MYLAN INSTITUTIONAL 61% A090394 001 Jun 18, 2010 Aug CAHN

SCANLUX-370

AP MYLAN INSTITUTIONAL 76% A090394 002 Jun 18, 2010 Aug CAHN

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION
CONRAY

+ LIEBEL-FLARSHEIM 60% N013295 001 Feb CAHN

CONRAY 30

+ LIEBEL-FLARSHEIM 30% N016983 001 Feb CAHN

CONRAY 43

+ LIEBEL-FLARSHEIM 43% N013295 002 Feb CAHN

SOLUTION;INTRAVESICAL
CYSTO-CONRAY II

LIEBEL-FLARSHEIM 17.2% N017057 002 Feb CAHN

IOVERSOL

INJECTABLE;INJECTION
OPTIRAY 160

@ LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988 Feb CAHN

OPTIRAY 240

+ LIEBEL-FLARSHEIM 51% N019710 002 Dec 30, 1988 Feb CAHN

@ 51% N020923 001 May 28, 1998 Feb CAHN

OPTIRAY 300

+ LIEBEL-FLARSHEIM 64% N019710 004 Jan 22, 1992 Feb CAHN

+ 64% N020923 004 May 13, 1999 Feb CAHN

INJECTABLE; INJECTION

OPTIRAY 320

+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb CAHN
+		68%	N020923	002	May 29, 1998	Oct CMFD
@		68%	N020923	002	May 29, 1998	Feb CAHN
OPTIRAY 350						
+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb CAHN
+		74%	N020923	003	May 28, 1998	Feb CAHN

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM

INJECTABLE; INJECTION

HEXABRIX

@	GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985	May DISC
---	---------	-------------	---------	-----	--------------	----------

IRBESARTAN

TABLET; ORAL

IRBESARTAN

AB	AJANTA PHARMA LTD	75MG	A203685	001	Dec 10, 2015	Nov NEWA
AB		150MG	A203685	002	Dec 10, 2015	Nov NEWA
AB		300MG	A203685	003	Dec 10, 2015	Nov NEWA
AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb NEWA
AB		150MG	A203534	002	Feb 23, 2015	Feb NEWA
AB		300MG	A203534	003	Feb 23, 2015	Feb NEWA
AB	SCIEGEN PHARMS INC	75MG	A204774	001	Dec 07, 2015	Nov NEWA
AB		150MG	A204774	002	Dec 07, 2015	Nov NEWA
AB		300MG	A204774	003	Dec 07, 2015	Nov NEWA
AB	UNICHEM LABS LTD	75MG	A203020	001	Dec 07, 2015	Nov NEWA
AB		150MG	A203020	002	Dec 07, 2015	Nov NEWA
AB		300MG	A203020	003	Dec 07, 2015	Nov NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	ACTAVIS TOTOWA	500MG/25ML (20MG/ML)	A078589	003	Nov 18, 2015	Nov NEWA
INJECTABLE, LIPOSOMAL; IV (INFUSION)						
ONIVYDE						
+	MERRIMACK PHARMS	EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML)	N207793	001	Oct 22, 2015	Oct NEWA

IRON DEXTRAN

INJECTABLE; INJECTION

INFED

BP	+	ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001	Mar CAHN
----	---	---------------------	-----------------	---------	-----	----------

ISAVUCONAZONIUM SULFATE

CAPSULE; ORAL

CRESEMBA

+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

POWDER; IV (INFUSION)

CRESEMBA

+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar NEWA
---	----------	-------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

TABLET; ORAL

ISORDIL

AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb CAHN
+		40MG	N012093	001	Jul 29, 1988	Feb CAHN

ISOTRETINOIN

CAPSULE; ORAL

ABSORICA

RANBAXY

25MG

N021951 005 Aug 15, 2014 Feb NEWA

35MG

N021951 006 Aug 15, 2014 Feb NEWA

MYORISAN

AB	DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug NEWA
----	----------------	------	---------	-----	--------------	----------

SOTRET

AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr CAHN

	CAPSULE;ORAL					
	ZENATANE					
AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb NEWA

ISRADIPINE

	CAPSULE;ORAL					
	ISRADIPINE					
AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar CAHN
	TABLET, EXTENDED RELEASE;ORAL					
	ISRADIPINE					
	MYLAN PHARMS INC	5MG	A201067	001	Nov 27, 2015	Nov NEWA
		10MG	A201067	002	Nov 27, 2015	Nov NEWA

ITRACONAZOLE

	SOLUTION;ORAL					
	ITRACONAZOLE					
AA	AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Oct NEWA
	SPORANOX					
AA	+ JANSSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Oct CFTG

IVABRADINE HYDROCHLORIDE

	TABLET;ORAL					
	CORLANOR					
	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr NEWA
	+	EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr NEWA

IVACAFTOR

	GRANULE;ORAL					
	KALYDECO					
	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar NEWA
	+	75MG/PACKET	N207925	002	Mar 17, 2015	Mar NEWA

IVACAFTOR; LUMACAFTOR

	TABLET;ORAL					
	ORKAMBI					
	+ VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul NEWA

IXABEPILONE

	INJECTABLE;IV (INFUSION)					
	IXEMPRA KIT					
	+ R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun CAHN
	+	45MG/VIAL	N022065	002	Oct 16, 2007	Jun CAHN

IXAZOMIB CITRATE

	CAPSULE;ORAL					
	NINLARO					
	MILLENNIUM PHARMS	EQ 2.3MG BASE	N208462	001	Nov 20, 2015	Nov NEWA
		EQ 3MG BASE	N208462	002	Nov 20, 2015	Nov NEWA
	+	EQ 4MG BASE	N208462	003	Nov 20, 2015	Nov NEWA

KANAMYCIN SULFATE

	INJECTABLE;INJECTION					
	KANAMYCIN					
	@ EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun CAHN
	@	EQ 500MG BASE/2ML	A062324	002		Jun CAHN
	@	EQ 1GM BASE/3ML	A062324	003		Jun CAHN

KETOROLAC TROMETHAMINE

	INJECTABLE;INJECTION					
	KETOROLAC TROMETHAMINE					
>D>	@ AMPHASTAR PHARM	15MG/ML	A076209	001	Jul 21, 2004	Dec CMFD
>A> AP		15MG/ML	A076209	001	Jul 21, 2004	Dec CMFD
>D>	@	30MG/ML	A076209	002	Jul 21, 2004	Dec CMFD
>A> AP		30MG/ML	A076209	002	Jul 21, 2004	Dec CMFD
AP	BD RX	15MG/ML	A203242	001	Oct 07, 2015	Sep NEWA
AP		30MG/ML	A203242	002	Oct 07, 2015	Sep NEWA
	@ CLARIS PHARMASERVICE	15MG/ML	A075631	002	Jun 29, 2001	Apr CAHN
	@	30MG/ML	A075631	001	Jun 29, 2001	Apr CAHN
	@ EUROHLTH INTL SARL	15MG/ML	A075772	001	Jul 21, 2004	Jun CAHN
	@	30MG/ML	A075772	002	Jul 21, 2004	Jun CAHN

SPRAY, METERED;NASAL
SPRIX

+ EGALET US INC 15.75MG/SPRAY N022382 001 May 14, 2010 Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION
OMIDRIA

+ OMEROS EQ 4.24MG BASE/ML;EQ 12.4MG
BASE/ML N205388 001 May 30, 2014 Feb CPOT

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION
LABETALOL HYDROCHLORIDE
@ CLARIS PHARMASERVICE 5MG/ML

A076051 001 Jul 05, 2002 Apr CAHN

TABLET;ORAL
LABETALOL HYDROCHLORIDE

AB MUTUAL PHARM 100MG A075215 001 Jul 29, 1999 Jan CMFD
AB 200MG A075215 002 Jul 29, 1999 Jan CMFD
AB 300MG A075215 003 Jul 29, 1999 Jan CMFD

LACTULOSE

SOLUTION;ORAL, RECTAL
LACTULOSE

AA BIO-PHARM INC 10GM/15ML A203762 001 Mar 27, 2015 Mar NEWA

LAMIVUDINE; RALTEGRAVIR POTASSIUM

TABLET;ORAL
DUTREBIS

@ MERCK SHARP DOHME 150MG;EQ 300MG BASE N206510 001 Feb 06, 2015 Aug DISC
+ 150MG;EQ 300MG BASE N206510 001 Feb 06, 2015 Feb NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL
LAMIVUDINE AND ZIDOVUDINE

AB HETERO LABS LTD III 150MG;300MG A079124 001 Sep 17, 2015 Aug NEWA
AB STRIDES ARCOLAB LTD 150MG;300MG A079128 001 May 13, 2015 Apr NEWA
AB STRIDES PHARMA 150MG;300MG A079128 001 May 13, 2015 Aug CAHN

LAMOTRIGINE

TABLET;ORAL
LAMOTRIGINE

@ HIKMA PHARMS 25MG A078134 001 Apr 19, 2011 May DISC
@ 100MG A078134 002 Apr 19, 2011 May DISC
@ 150MG A078134 003 Apr 19, 2011 May DISC
@ 200MG A078134 004 Apr 19, 2011 May DISC

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB PAR PHARM 25MG A204158 001 Oct 27, 2015 Oct NEWA
AB 50MG A204158 002 Oct 27, 2015 Oct NEWA
AB 100MG A204158 003 Oct 27, 2015 Oct NEWA
AB 200MG A204158 004 Oct 27, 2015 Oct NEWA

LAPATINIB DITOSYLATE

TABLET;ORAL
TYKERB

+ NOVARTIS PHARMS CORP EQ 250MG BASE N022059 001 Mar 13, 2007 Mar CAHN

LENVATINIB MESYLATE

CAPSULE;ORAL
LENVIMA

EISAI INC EQ 4MG BASE N206947 001 Feb 13, 2015 Feb NEWA
+ EQ 10MG BASE N206947 002 Feb 13, 2015 Feb NEWA

>A> LESINURAD

>A> TABLET;ORAL
>A> ZURAMPIC

>A> + ARDEA BIOSCIENCES 200MG N207988 001 Dec 22, 2015 Dec NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul	NEWA
	SOLUTION;ORAL						
	LEVETIRACETAM						
AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA
	TABLET;ORAL						
	LEVETIRACETAM						
AB	SECAN PHARMS	250MG	A205102	001	Dec 16, 2015	Nov	NEWA
AB		750MG	A205102	002	Dec 16, 2015	Nov	NEWA
AB		1GM	A205102	003	Dec 16, 2015	Nov	NEWA
	SPRITAM						
	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul	NEWA
		500MG	N207958	002	Jul 31, 2015	Jul	NEWA
		750MG	N207958	003	Jul 31, 2015	Jul	NEWA
		1GM	N207958	004	Jul 31, 2015	Jul	NEWA
	TABLET, EXTENDED RELEASE;ORAL						
	LEVETIRACETAM						
	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug	NEWA
AB		750MG	A202167	002	Sep 04, 2015	Aug	NEWA
	MYLAN PHARMS INC	1GM	A200475	003	Dec 07, 2015	Nov	NEWA
AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug	CAHN
AB		750MG	A201464	002	May 25, 2012	Aug	CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
AB		750MG	A203468	002	May 21, 2015	May	NEWA

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

@	TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC
---	-----------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
>A> AB	MACLEODS PHARMS LTD	5MG	A205564	001	Jan 11, 2016	Dec	NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun	NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul	NEWA
	LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug	NEWA
AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug	NEWA
AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug	NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT	+ NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul	CRLD
	TABLET;ORAL						
	LEVOFLOXACIN						
AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

AP	MYLAN TEORANTA	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203576	001	Oct 20, 2015	Oct	NEWA
AP		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203576	002	Oct 20, 2015	Oct	NEWA
	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
AP	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Oct	CTEC

SOLUTION; IV (INFUSION)									
LEVOLEUCOVORIN CALCIUM									
AP	+		EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA	
			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Oct	CTEC	
			EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD	
<u>LEVONORGESTREL</u>									
INTRAUTERINE DEVICE; INTRAUTERINE									
LILETTA									
		MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb	NEWA	
<u>LEVORPHANOL TARTRATE</u>									
TABLET; ORAL									
LEVORPHANOL TARTRATE									
	+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr	CAHN	
<u>LEVOTHYROXINE SODIUM</u>									
POWDER; INTRAVENOUS									
LEVOTHYROXINE SODIUM									
AP	+	FRESENIUS KABI USA	200MCG/VIAL	N202231	002	Jun 24, 2011	Nov	CFTG	
AP		PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	Nov	NEWA	
<u>LIDOCAINE</u>									
OINTMENT; TOPICAL									
LIDOCAINE									
AT		AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul	NEWA	
	@	BELMORA LLC	5%	A080210	001		Sep	CAHN	
PATCH; TOPICAL									
LIDOCAINE									
AB		ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN	
AB		MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul	NEWA	
<u>LIDOCAINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LIDOCAINE HYDROCHLORIDE									
AP	@	EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN	
	@		2%	A080407	002		Mar	CAHN	
		LUITPOLD	1%	A091564	001	Aug 14, 2015	Aug	NEWA	
		LIDOCAINE HYDROCHLORIDE	PRESERVATIVE FREE						
	@	EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN	
	@		2%	A084625	002		Feb	CAHN	
JELLY; TOPICAL									
ANESTACON									
	@	BANNER LIFE SCIENCES	2%	A080429	001		Jan	CAHN	
LIDOCAINE HYDROCHLORIDE									
	@	G AND W LABS INC	2%	A081318	001	Apr 29, 1993	Apr	CAHN	
<u>LIDOCAINE; PRILOCAINE</u>									
CREAM; TOPICAL									
EMLA									
AB	+	ACTAVIS LABS UT INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	Feb	CAHN	
<u>LINACLOTIDE</u>									
CAPSULE; ORAL									
LINZESS									
		FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012	Mar	CAHN	
	+		290MCG	N202811	002	Aug 30, 2012	Mar	CAHN	
<u>LINCOMYCIN HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
LINCOCIN									
AP	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		May	CFTG	
LINCOMYCIN									
AP		X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	May	NEWA	

LINEZOLIDFOR SUSPENSION; ORAL
LINEZOLID

AB	ROXANE	100MG/5ML	A200068	001	Jun 03, 2015	May NEWA
	ZYVOX					

AB	+ PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000	May CFTG
	SOLUTION; IV (INFUSION)					

LINEZOLID

AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	Jun NEWA
----	-------------	----------------------	---------	-----	--------------	----------

AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	Jul NEWA
----	------------	----------------------	---------	-----	--------------	----------

AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	Jul NEWA
----	--	----------------------	---------	-----	--------------	----------

AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May CDFR
----	-------------	----------------------	---------	-----	--------------	----------

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+ HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	Jun NEWA
	ZYVOX					

AP	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	Jul CTEC
----	----------------------	----------------------	---------	-----	--------------	----------

		200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May CDFR
--	--	----------------------	---------	-----	--------------	----------

		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May NEWA
--	--	----------------------	---------	-----	--------------	----------

AP	+	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May NEWA
----	---	----------------------	---------	-----	--------------	----------

TABLET; ORAL

LINEZOLID

>A>	AB	ALEMBIC PHARMS LTD	600MG	A205233	001	Dec 21, 2015	Dec NEWA
-----	----	--------------------	-------	---------	-----	--------------	----------

>A>	AB	ALKEM LABS LTD	600MG	A205517	001	Dec 21, 2015	Dec NEWA
-----	----	----------------	-------	---------	-----	--------------	----------

>A>	AB	AMNEAL PHARMS	600MG	A204536	001	Dec 21, 2015	Dec NEWA
-----	----	---------------	-------	---------	-----	--------------	----------

>A>	AB	GLENMARK PHARMS LTD	600MG	A078987	001	Dec 21, 2015	Dec NEWA
-----	----	---------------------	-------	---------	-----	--------------	----------

>A>	AB	HETERO LABS LTD V	600MG	A204239	001	Dec 21, 2015	Dec NEWA
-----	----	-------------------	-------	---------	-----	--------------	----------

>A>	AB	MYLAN PHARMS INC	600MG	A078845	001	Dec 21, 2015	Dec NEWA
-----	----	------------------	-------	---------	-----	--------------	----------

	AB	TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May NEWA
--	----	-----------------	-------	---------	-----	--------------	----------

ZYVOX

AB	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000	May CFTG
----	------------------------	-------	---------	-----	--------------	----------

LISINOPRIL

TABLET; ORAL

LISINOPRIL

AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002	Apr CAHN
----	--------------------	-------	---------	-----	--------------	----------

AB		5MG	A075944	002	Jul 01, 2002	Apr CAHN
----	--	-----	---------	-----	--------------	----------

AB		10MG	A075944	003	Jul 01, 2002	Apr CAHN
----	--	------	---------	-----	--------------	----------

AB		20MG	A075944	004	Jul 01, 2002	Apr CAHN
----	--	------	---------	-----	--------------	----------

AB		30MG	A075944	006	Feb 11, 2003	Apr CAHN
----	--	------	---------	-----	--------------	----------

AB		40MG	A075944	005	Jul 01, 2002	Apr CAHN
----	--	------	---------	-----	--------------	----------

ZESTRIL

AB	ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb CAHN
----	-------------------	-------	---------	-----	--------------	----------

AB		5MG	N019777	001	May 19, 1988	Feb CAHN
----	--	-----	---------	-----	--------------	----------

AB		10MG	N019777	002	May 19, 1988	Feb CAHN
----	--	------	---------	-----	--------------	----------

AB		20MG	N019777	003	May 19, 1988	Feb CAHN
----	--	------	---------	-----	--------------	----------

AB		30MG	N019777	006	Jan 20, 1999	Feb CAHN
----	--	------	---------	-----	--------------	----------

AB	+	40MG	N019777	004	May 19, 1988	Feb CAHN
----	---	------	---------	-----	--------------	----------

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May NEWA
----	--------------------	-------	---------	-----	--------------	----------

>D>	AB	GLENMARK GENERICS	300MG	A091544	001	Dec 27, 2010	Dec CAHN
-----	----	-------------------	-------	---------	-----	--------------	----------

>A>	AB	GLENMARK PHARMS INC	300MG	A091544	001	Dec 27, 2010	Dec CAHN
-----	----	---------------------	-------	---------	-----	--------------	----------

	@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb DISC
--	---------------------	-------	---------	-----	--------------	----------

AB	UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul NEWA
----	-------------------	-------	---------	-----	--------------	----------

LOMITAPIDE MESYLATE

CAPSULE; ORAL

JUXTAPID

	AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr NEWA
--	----------	--------------	---------	-----	--------------	----------

		EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr NEWA
--	--	--------------	---------	-----	--------------	----------

		EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr NEWA
--	--	--------------	---------	-----	--------------	----------

LOMUSTINE

CAPSULE; ORAL

GLEOSTINE

	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan NEWA
--	---------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE; ORAL					
IMODIUM					
	@ J AND J CONSUMER INC	2MG	N017690	001	Jul CAHN
AB	+	2MG	N017694	001	Jul CAHN

LOPINAVIR; RITONAVIR

CAPSULE; ORAL					
KALETRA					
	@ ABBVIE	133.3MG; 33.3MG	N021226	001	Sep 15, 2000 Jun DISC

LORAZEPAM

INJECTABLE; INJECTION					
ATIVAN					
AP	+	EUROHLTH INTL SARL	2MG/ML	N018140	001 Jun CAHN
AP	+		4MG/ML	N018140	002 Jun CAHN
TABLET; ORAL					
LORAZEPAM					
AB		ANI PHARMS INC	0.5MG	A077396	001 Dec 13, 2006 Oct CAHN
AB			1MG	A077396	002 Dec 13, 2006 Oct CAHN
AB			2MG	A077396	003 Dec 13, 2006 Oct CAHN
AB		SUN PHARM INDS LTD	0.5MG	A076045	001 Aug 29, 2001 Apr CAHN
AB			1MG	A076045	002 Aug 29, 2001 Apr CAHN
AB			2MG	A076045	003 Aug 29, 2001 Apr CAHN

LOSARTAN POTASSIUM

TABLET; ORAL					
LOSARTAN POTASSIUM					
AB		HETERO LABS LTD V	25MG	A203835	001 Aug 12, 2015 Jul NEWA
AB			50MG	A203835	002 Aug 12, 2015 Jul NEWA
AB			100MG	A203835	003 Aug 12, 2015 Jul NEWA
AB		UNICHEM LABS LTD	25MG	A203030	001 Oct 14, 2015 Oct NEWA
AB			50MG	A203030	002 Oct 14, 2015 Oct NEWA
AB			100MG	A203030	003 Oct 14, 2015 Oct NEWA
AB		WATSON LABS	25MG	A091129	001 Oct 06, 2010 Feb CMFD
AB			50MG	A091129	002 Oct 06, 2010 Feb CMFD
AB			100MG	A091129	003 Oct 06, 2010 Feb CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE; ORAL					
ALTOPREV					
	@ COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002 May CAHN
		20MG	N021316	002	Jun 26, 2002 May CAHN
		40MG	N021316	003	Jun 26, 2002 May CAHN
	+	60MG	N021316	004	Jun 26, 2002 May CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE; ORAL					
LOXITANE C					
	@ ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001	Mar CAHN
INJECTABLE; INJECTION					
LOXITANE IM					
	@ ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001	Mar CAHN

LOXAPINE SUCCINATE

CAPSULE; ORAL					
LOXAPINE SUCCINATE					
AB		ELITE LABS INC	EQ 5MG BASE	A076868	001 Aug 04, 2005 May CAHN
AB			EQ 10MG BASE	A076868	002 Aug 04, 2005 May CAHN
AB			EQ 25MG BASE	A076868	003 Aug 04, 2005 May CAHN
AB			EQ 50MG BASE	A076868	004 Aug 04, 2005 May CAHN
LOXITANE					
	@ ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001	Mar CAHN
	@	EQ 10MG BASE	N017525	002	Mar CAHN
	@	EQ 25MG BASE	N017525	003	Mar CAHN
	@	EQ 50MG BASE	N017525	004	Mar CAHN
TABLET; ORAL					
LOXITANE					
	@ ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006	Mar CAHN
	@	EQ 25MG BASE	N017525	007	Mar CAHN
	@	EQ 50MG BASE	N017525	008	Mar CAHN

LUCINACTANTSUSPENSION;INTRATRACHEAL
SURFAXIN

@ DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May DISC
------------------	-------	---------	-----	--------------	----------

MAGNESIUM SULFATESOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr CDFR
AP	+ FRESINIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr CPOT
AP	+ HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr NEWA

MAGNESIUM SULFATESOLUTION;INTRAMUSCULAR, INTRAVENOUS
MAGNESIUM SULFATE

+ FRESINIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr NEWA
----------------------	--------------------	---------	-----	--------------	----------

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATESOLUTION;ORAL
SUCLEAR

@ BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A,N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013	Aug DISC
------------------	---	---------	-----	--------------	----------

MANNITOL

INJECTABLE;INJECTION

>D>	MANNITOL 10%				
>D> AP	B BRAUN	10GM/100ML	N016080	002	Dec DISC
>A>	@	10GM/100ML	N016080	002	Dec DISC
>D>	MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER				
>D> AP	B BRAUN	10GM/100ML	N016080	006	Dec DISC
>A>	@	10GM/100ML	N016080	006	Dec DISC
>D>	MANNITOL 15%				
>D> AP	B BRAUN	15GM/100ML	N016080	003	Dec DISC
>A>	@	15GM/100ML	N016080	003	Dec DISC
>D>	MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%				
>D> AP	B BRAUN	15GM/100ML	N016080	005	Dec DISC
>A>	@	15GM/100ML	N016080	005	Dec DISC
>D>	MANNITOL 20%				
>D> AP	B BRAUN	20GM/100ML	N016080	004	Dec DISC
>A>	@	20GM/100ML	N016080	004	Dec DISC
	MANNITOL 25%				
	@ IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987
	@	12.5GM/50ML	A089240	001	May 06, 1987
>D>	MANNITOL 5%				
>D> AP	B BRAUN	5GM/100ML	N016080	001	Dec DISC
>A>	@	5GM/100ML	N016080	001	Dec DISC
>D>	MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%				
>D> AP	B BRAUN	5GM/100ML	N016080	007	Dec DISC
>A>	@	5GM/100ML	N016080	007	Dec DISC

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

@ ANI PHARMS INC	12.5MG	A084975	001		Aug CAHN
@	25MG	A084657	001		Aug CAHN
@ VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun DISC
@	25MG	A040179	002	Jan 30, 1997	Jun DISC

MELOXICAM

CAPSULE;ORAL

VIVLODEX

IROKO PHARMS LLC	5MG	N207233	001	Oct 22, 2015	Oct NEWA
+	10MG	N207233	002	Oct 22, 2015	Oct NEWA

MEMANTINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR

FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN
	14MG	N022525	002	Jun 21, 2010	Mar CAHN
	21MG	N022525	003	Jun 21, 2010	Mar CAHN
+	28MG	N022525	004	Jun 21, 2010	Mar CAHN

SOLUTION;ORAL

MEMANTINE HYDROCHLORIDE

AA	BIO-PHARM INC	2MG/ML	A205446	001	Dec 07, 2015	Nov NEWA
AA	MACLEODS PHARMS LTD	2MG/ML	A202790	001	Oct 13, 2015	Sep NEWA
AA	SILARX PHARMS INC	2MG/ML	A204033	001	Oct 13, 2015	Sep NEWA
NAMENDA						
AA	+ FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Sep CFTG
	+	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN

TABLET;ORAL

MEMANTINE HYDROCHLORIDE

AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD
AB		10MG	A090058	002	May 05, 2010	Mar CMFD
MEMANTINE HYDROCHLORIDE						
AB	AJANTA PHARMA LTD	5MG	A206528	001	Nov 30, 2015	Nov NEWA
AB		10MG	A206528	002	Nov 30, 2015	Nov NEWA
AB	ALEMBIC PHARMS LTD	5MG	A200891	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200891	002	Oct 13, 2015	Sep NEWA
AB	AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090041	002	Apr 10, 2015	Mar NEWA
AB	AUROBINDO PHARMA LTD	5MG	A203175	001	Oct 13, 2015	Sep NEWA
AB		10MG	A203175	002	Oct 13, 2015	Sep NEWA
AB	DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD
AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
AB	JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Sep NEWA
AB		10MG	A091585	002	Oct 13, 2015	Sep NEWA
AB	LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA
AB		10MG	A090051	002	Apr 10, 2015	Mar NEWA
AB	MACLEODS PHARMS LTD	5MG	A202840	001	Oct 13, 2015	Sep NEWA
AB		10MG	A202840	002	Oct 13, 2015	Sep NEWA
AB	MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD
	@	5MG	A079225	001	Jan 30, 2015	Mar DISC
AB		5MG	A079225	001	Jan 30, 2015	Jan NEWA
AB		10MG	A079225	002	Jan 30, 2015	Jun CMFD
	@	10MG	A079225	002	Jan 30, 2015	Mar DISC
AB		10MG	A079225	002	Jan 30, 2015	Jan NEWA
AB	PURACAP PHARM LLC	5MG	A206855	001	Nov 17, 2015	Nov NEWA
AB		10MG	A206855	002	Nov 17, 2015	Nov NEWA
AB	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Oct CTNA
AB		10MG	A090058	002	May 05, 2010	Oct CTNA
AB	TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD
AB		10MG	A090052	002	Oct 25, 2011	May CMFD
AB	TORRENT PHARMS LTD	5MG	A200155	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200155	002	Oct 13, 2015	Sep NEWA
AB	UNICHEM LABS LTD	5MG	A200022	001	Oct 13, 2015	Sep NEWA
AB		10MG	A200022	002	Oct 13, 2015	Sep NEWA
AB	UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul NEWA
AB		10MG	A090043	002	Jul 31, 2015	Jul NEWA
AB	WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug NEWA
AB		10MG	A090073	002	Sep 04, 2015	Aug NEWA
NAMENDA						
AB	FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN
AB	+	10MG	N021487	002	Oct 16, 2003	Mar CAHN

MENOTROPINS (FSH;LH)INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
REPRONEX

@ FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC
-----------	-----------------------	---------	-----	--------------	----------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001		Feb CAHN
AP		50MG/ML	A080445	002		Feb CAHN
AP		75MG/ML	A080445	003		Feb CAHN
AP		100MG/ML	A080445	004		Feb CAHN

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

@	IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989	May CAHN
@		50MG/ML	A089782	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089783	001	Mar 31, 1989	Mar CAHN
@		50MG/ML	A089784	001	Mar 31, 1989	Mar CAHN
@		75MG/ML	A089785	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089786	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089787	001	Mar 31, 1989	Mar CAHN
@		100MG/ML	A089788	001	Mar 31, 1989	Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERGAN

@	EUROHLTH INTL SARL	25MG/ML; 25MG/ML	N011730	001		Jun CAHN
---	--------------------	------------------	---------	-----	--	----------

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>A>	AP	DAEWOONG PHARM CO	500MG/VIAL	A204854	001	Dec 18, 2015	Dec NEWA
>A>	AP		1GM/VIAL	A204854	002	Dec 18, 2015	Dec NEWA

POWDER; IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

B	BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015	Apr NEWA
		1GM/VIAL	N202106	002	Apr 30, 2015	Apr NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

APRISO

+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008	Jul CAHN
---	---------------------	-------	---------	-----	--------------	----------

ENEMA; RECTAL

MESALAMINE

AB		G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004	Aug CAHN
----	--	------------------	----------	---------	-----	--------------	----------

SUPPOSITORY; RECTAL

CANASA

	@	FOREST LABS LLC	500MG	N021252	001	Jan 05, 2001	Aug CAHN
AB	+		1GM	N021252	002	Nov 05, 2004	Nov CFTG
	+		1GM	N021252	002	Nov 05, 2004	Aug CAHN

MESALAMINE

AB		MYLAN PHARMS INC	1GM	A204354	001	Nov 24, 2015	Nov NEWA
----	--	------------------	-----	---------	-----	--------------	----------

TABLET, DELAYED RELEASE; ORAL

ASACOL

@	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Oct DISC
---	---------------------	-------	---------	-----	--------------	----------

MESTRANOL; NORETHINDRONE

TABLET; ORAL-20

NORINYL

@	ACTAVIS LABS UT INC	0.1MG; 2MG	N013625	004		Mar CAHN
---	---------------------	------------	---------	-----	--	----------

TABLET; ORAL-21

NORINYL 1+50 21-DAY

@	ACTAVIS LABS UT INC	0.05MG; 1MG	N013625	002		Mar CAHN
---	---------------------	-------------	---------	-----	--	----------

TABLET; ORAL-28

NORINYL 1+50 28-DAY

+	ACTAVIS LABS UT INC	0.05MG; 1MG	N016659	001		Mar CAHN
---	---------------------	-------------	---------	-----	--	----------

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

@	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	Apr DISC
@		0.6%	A070804	001	Aug 17, 1987	Apr DISC
@	WOCKHARDT	0.4%	A075586	001	May 30, 2002	Apr DISC
@		0.6%	A075586	002	May 30, 2002	Apr DISC

SYRUP; ORAL

METAPROTERENOL SULFATE

@	G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992	Apr CAHN
@		10MG/5ML	A073034	001	Aug 30, 1991	Apr CAHN

METAXALONETABLET; ORAL
METAXALONE

COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
@	640MG	N022503	001	Jun 01, 2015	Nov DISC
	640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDESOLUTION; ORAL
RIOMET

+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN
---	--------------------	-----------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	500MG;EQ 15MG BASE	A204802	001	Nov 05, 2015	Oct NEWA
AB		850MG;EQ 15MG BASE	A204802	002	Nov 05, 2015	Oct NEWA

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET; ORAL

PRANDIMET

AB	NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
AB	+	500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB	LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun NEWA
AB		500MG;2MG	A200624	002	Jul 15, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

@ SB PHARMCO 500MG;EQ 2MG BASE

N021410 002 Oct 10, 2002 May DISC

@ 500MG;EQ 4MG BASE

N021410 003 Oct 10, 2002 May DISC

@ 1GM;EQ 2MG BASE

N021410 004 Aug 25, 2003 May DISC

@ 1GM;EQ 4MG BASE

N021410 005 Aug 25, 2003 May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

TEVA 500MG;EQ 2MG BASE

A077337 001 May 07, 2014 May CTEC

500MG;EQ 4MG BASE

A077337 002 May 07, 2014 May CTEC

+ 1GM;EQ 4MG BASE

A077337 004 May 07, 2014 May CRLD

1GM;EQ 2MG BASE

A077337 003 May 07, 2014 May CTEC

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
AA		10MG	A203502	002	Aug 31, 2015	Aug NEWA
AA	COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
AA		10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

METHAMPHETAMINE HYDROCHLORIDE

AA	ROXANE	5MG	A203846	001	Nov 17, 2015	Nov NEWA
----	--------	-----	---------	-----	--------------	----------

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB		10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION; IM-IV

ROBAXIN

AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001	Jun CAHN
----	---	--------------------	---------------------	---------	-----	----------

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD
----	--------------------	-----------------	---------	-----	--------------	----------

METHOXSALLENCAPSULE;ORAL
METHOXSALLEN

AB	ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA
----	-------------	------	---------	-----	--------------	----------

METHSCOPOLAMINE BROMIDETABLET;ORAL
METHSCOPOLAMINE BROMIDE

>D> AA	VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Dec CRLD
>A> AA	+	2.5MG	A040624	001	Dec 28, 2006	Dec CRLD
>D> AA		5MG	A040624	002	Dec 28, 2006	Dec CRLD
>A> AA	+	5MG	A040624	002	Dec 28, 2006	Dec CRLD
>D>	PAMINE					
>D> AA	+	FOUGERA PHARMS	2.5MG	N008848	001	Dec DISC
>A>	@	2.5MG	N008848	001		Dec DISC
>D>	PAMINE FORTE					
>D> AA	+	FOUGERA PHARMS	5MG	N008848	002	Mar 25, 2003
>A>	@	5MG	N008848	002	Mar 25, 2003	Dec DISC

METHYLNALTREXONE BROMIDESOLUTION;SUBCUTANEOUS
RELISTOR

	SALIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Nov CDFR
+		12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Nov CDFR

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL
APTENSIO XR

	RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr NEWA
		15MG	N205831	002	Apr 17, 2015	Apr NEWA
		20MG	N205831	003	Apr 17, 2015	Apr NEWA
		30MG	N205831	004	Apr 17, 2015	Apr NEWA
		40MG	N205831	005	Apr 17, 2015	Apr NEWA
		50MG	N205831	006	Apr 17, 2015	Apr NEWA
+		60MG	N205831	007	Apr 17, 2015	Apr NEWA
	METHYLPHENIDATE HYDROCHLORIDE					
AB2	MALLINCKRODT INC	10MG	A203583	001	Sep 29, 2015	Sep NEWA
AB2		20MG	A203583	002	Sep 29, 2015	Sep NEWA
AB2		30MG	A203583	003	Sep 29, 2015	Sep NEWA
AB2		40MG	A203583	004	Sep 29, 2015	Sep NEWA
AB2		50MG	A203583	005	Sep 29, 2015	Sep NEWA
AB2		60MG	A203583	006	Sep 29, 2015	Sep NEWA
	RITALIN LA					
AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb CRLD
+		60MG	N021284	005	Oct 27, 2014	Feb CRLD

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug NEWA
AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug NEWA

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	ASCENT PHARMS INC	5MG	A207416	001	Sep 22, 2015	Sep NEWA
AB		10MG	A207416	002	Sep 22, 2015	Sep NEWA
AB		20MG	A207416	003	Sep 22, 2015	Sep NEWA
AB	NOVEL LABS INC	5MG	A207884	001	Nov 13, 2015	Nov NEWA
AB		10MG	A207884	002	Nov 13, 2015	Nov NEWA
AB		20MG	A207884	003	Nov 13, 2015	Nov NEWA

TABLET, CHEWABLE;ORAL

METHYLIN

	@ MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Nov DISC
AB		2.5MG	N021475	001	Apr 15, 2003	Feb CFTG
	@	5MG	N021475	002	Apr 15, 2003	Nov DISC
AB		5MG	N021475	002	Apr 15, 2003	Feb CFTG
	@	10MG	N021475	003	Apr 15, 2003	Nov DISC
AB	+	10MG	N021475	003	Apr 15, 2003	Feb CFTG
	METHYLPHENIDATE HYDROCHLORIDE					
	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Nov CTEC
AB		2.5MG	A204115	001	Feb 25, 2015	Feb NEWA
		5MG	A204115	002	Feb 25, 2015	Nov CTEC
AB		5MG	A204115	002	Feb 25, 2015	Feb NEWA
+		10MG	A204115	003	Feb 25, 2015	Nov CRLD

TABLET, CHEWABLE;ORAL					
METHYLPHENIDATE HYDROCHLORIDE					
AB		10MG	A204115	003	Feb 25, 2015 Feb NEWA
TABLET, EXTENDED RELEASE;ORAL					
METHYLIN ER					
AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000 May CTEC
METHYLPHENIDATE HYDROCHLORIDE					
AB	ABHAI	10MG	A207488	001	Jun 09, 2015 May NEWA
AB		20MG	A207488	002	Jun 09, 2015 May NEWA
>A> BX	KREMERS URBAN PHARMS	18MG	A091695	001	Jul 09, 2013 Dec CAHN
>A> BX		27MG	A091695	002	Jul 09, 2013 Dec CAHN
>A> BX		36MG	A091695	003	Sep 23, 2013 Dec CAHN
>A> BX		54MG	A091695	004	Sep 23, 2013 Dec CAHN
>D> BX	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013 Dec CAHN
>D> BX		27MG	A091695	002	Jul 09, 2013 Dec CAHN
>D> BX		36MG	A091695	003	Sep 23, 2013 Dec CAHN
>D> BX		54MG	A091695	004	Sep 23, 2013 Dec CAHN
TABLET, EXTENDED RELEASE, CHEWABLE;ORAL					
QUILLICHEW ER					
>A>	PFIZER INC	20MG	N207960	001	Dec 04, 2015 Dec NEWA
>A>		30MG	N207960	002	Dec 04, 2015 Dec NEWA
>A>	+	40MG	N207960	003	Dec 04, 2015 Dec NEWA
<u>METHYLPREDNISOLONE SODIUM SUCCINATE</u>					
INJECTABLE;INJECTION					
METHYLPREDNISOLONE SODIUM SUCCINATE					
AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A207667	001	Dec 15, 2015 Nov NEWA
AP		EQ 125MG BASE/VIAL	A207667	002	Dec 15, 2015 Nov NEWA
AP		EQ 500MG BASE/VIAL	A207667	003	Dec 15, 2015 Nov NEWA
AP		EQ 2GM BASE/VIAL	A207667	004	Dec 15, 2015 Nov NEWA
<u>METHYLTESTOSTERONE</u>					
CAPSULE;ORAL					
METHYLTESTOSTERONE					
AB	IMPAX LABS INC	10MG	A204851	001	Sep 21, 2015 Sep NEWA
TESTRED					
AB	+ VALEANT PHARM INTL	10MG	A083976	001	Sep CTEC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>					
INJECTABLE;INJECTION					
METOCLOPRAMIDE HYDROCHLORIDE					
AP	+ HOSPIRA	EQ 5MG BASE/ML	A073118	001	Jan 17, 1991 Nov CRLD
REGLAN					
	@ EUROHLTH INTL SARL	EQ 5MG BASE/ML	N017862	001	Nov DISC
AP	+	EQ 5MG BASE/ML	N017862	001	Nov CAHN
	@	EQ 10MG BASE/ML	N017862	004	May 28, 1987 Nov CAHN
<u>METOPROLOL TARTRATE</u>					
INJECTABLE;INJECTION					
METOPROLOL TARTRATE					
AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013 Apr CAHN
TABLET;ORAL					
METOPROLOL TARTRATE					
	MYLAN	37.5MG	A076704	004	Mar 18, 2015 Mar NEWA
		75MG	A076704	005	Mar 18, 2015 Mar NEWA
<u>METRONIDAZOLE</u>					
CREAM;TOPICAL					
NORITATE					
+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997 Feb CAHN
GEL;VAGINAL					
METRONIDAZOLE					
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014 Feb CAHN
NUVESSA					
+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014 Feb CTNA
INJECTABLE;INJECTION					
FLAGYL I.V. RTU IN PLASTIC CONTAINER					
	@ PFIZER	500MG/100ML	N018353	002	Nov DISC
METRONIDAZOLE					
	@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984 Aug CAHN

INJECTABLE;INJECTION							
METRONIDAZOLE IN PLASTIC CONTAINER							
AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
TABLET;ORAL							
METRONIDAZOLE							
AB	APPCO PHARMA LLC	250MG	A205245	001	Sep 23, 2015	Sep	NEWA
AB		500MG	A205245	002	Sep 23, 2015	Sep	NEWA
AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
AB		500MG	A203974	002	May 29, 2015	May	NEWA
<u>MEXILETINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
MEXILETINE HYDROCHLORIDE							
	@ IDT AUSTRALIA LTD	150MG	A074450	001	May 16, 1996	Oct	CAHN
	@	200MG	A074450	002	May 16, 1996	Oct	CAHN
	@	250MG	A074450	003	May 16, 1996	Oct	CAHN
<u>MICONAZOLE</u>							
TABLET;BUCCAL							
ORAVIG							
+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
<u>MIDAZOLAM HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
MIDAZOLAM HYDROCHLORIDE							
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A075637	001	Oct 31, 2000	Apr	CAHN
	@	EQ 5MG BASE/ML	A075637	002	Oct 31, 2000	Apr	CAHN
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075243	001	Jun 20, 2000	Jun	CAHN
AP		EQ 5MG BASE/ML	A075243	002	Jun 20, 2000	Jun	CAHN
	@ IGI LABS INC	EQ 5MG BASE/ML	A075263	001	Jun 26, 2000	Apr	CAHN
	@ WOCKHARDT	EQ 1MG BASE/ML	A078141	001	May 30, 2008	Mar	DISC
	@	EQ 1MG BASE/ML	A078511	001	Nov 10, 2008	Mar	DISC
	@	EQ 5MG BASE/ML	A078141	002	May 30, 2008	Mar	DISC
	@	EQ 5MG BASE/ML	A078511	002	Nov 10, 2008	Mar	DISC
SYRUP;ORAL							
MIDAZOLAM HYDROCHLORIDE							
AA	SUN PHARM INDS LTD	EQ 2MG BASE/ML	A076058	001	Mar 15, 2002	Apr	CAHN
<u>MIGLITOL</u>							
TABLET;ORAL							
GLYSET							
AB	PHARMACIA AND UPJOHN	25MG	N020682	001	Dec 18, 1996	Mar	CTEC
AA		25MG	N020682	001	Dec 18, 1996	Feb	CFTG
AB		50MG	N020682	002	Dec 18, 1996	Mar	CTEC
AA		50MG	N020682	002	Dec 18, 1996	Feb	CFTG
AB	+	100MG	N020682	003	Dec 18, 1996	Mar	CTEC
AA	+	100MG	N020682	003	Dec 18, 1996	Feb	CFTG
MIGLITOL							
AB	ORIENT PHARMA CO LTD	25MG	A203965	001	Feb 24, 2015	Mar	CTEC
AA		25MG	A203965	001	Feb 24, 2015	Feb	NEWA
AB		50MG	A203965	002	Feb 24, 2015	Mar	CTEC
AA		50MG	A203965	002	Feb 24, 2015	Feb	NEWA
AB		100MG	A203965	003	Feb 24, 2015	Mar	CTEC
AA		100MG	A203965	003	Feb 24, 2015	Feb	NEWA
<u>MILRINONE LACTATE</u>							
INJECTABLE;INJECTION							
MILRINONE LACTATE							
AP	BEDFORD	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Jan	CRLD
AP	EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075530	001	May 28, 2002	Jun	CAHN
	@	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep	CAHN
AP	+	HIKMA FARMACEUTICA	A077966	001	Dec 03, 2010	Jan	CRLD
<u>MINOCYCLINE HYDROCHLORIDE</u>							
CAPSULE;ORAL							
MINOCYCLINE HYDROCHLORIDE							
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065062	001	Nov 30, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Apr	CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Apr	CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065062	001	Nov 30, 2000	Jun	CAHN
AB		EQ 75MG BASE	A065062	002	Nov 30, 2000	Jun	CAHN
AB		EQ 100MG BASE	A065062	003	Nov 30, 2000	Jun	CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

@	SUN PHARM INDS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Apr CAHN
@		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Apr CAHN
@		EQ 90MG BASE	N201922	003	Jul 11, 2012	Apr CAHN
@		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Apr CAHN
@		EQ 135MG BASE	N201922	005	Jul 11, 2012	Apr CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065156	001	Jan 06, 2004	Apr CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Apr CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Apr CAHN
AB	TORRENT PHARMA INC	EQ 50MG BASE	A065156	001	Jan 06, 2004	Jun CAHN
AB		EQ 75MG BASE	A065156	002	Jan 06, 2004	Jun CAHN
AB		EQ 100MG BASE	A065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB	+	SANDOZ	EQ 135MG BASE	A090422	003	Aug 13, 2009	Sep CRLD
>A>	AB	SIDMAK LABS INDIA	EQ 45MG BASE	A204394	001	Dec 30, 2015	Dec NEWA
>A>	AB		EQ 80MG BASE	A204394	004	Dec 30, 2015	Dec NEWA
>A>	AB		EQ 105MG BASE	A204394	005	Dec 30, 2015	Dec NEWA
>A>	AB		EQ 135MG BASE	A204394	007	Dec 30, 2015	Dec NEWA
AB		SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Apr CAHN
AB			EQ 80MG BASE	A091118	004	Sep 25, 2014	Apr CAHN
AB			EQ 90MG BASE	A091118	005	Sep 25, 2014	Apr CAHN
AB			EQ 105MG BASE	A091118	006	Sep 25, 2014	Apr CAHN
AB			EQ 135MG BASE	A091118	008	Sep 25, 2014	Apr CAHN
		SOLODYN					
		MEDICIS	EQ 55MG BASE	N050808	008	Aug 27, 2010	Sep CRLD
AB			EQ 80MG BASE	N050808	007	Aug 27, 2010	Sep CRLD
AB	+		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep CRLD

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS

MIVACRON

		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
	+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
			10MG	A090453	002	Mar 20, 2015	Mar NEWA
	+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA
----	--	-------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
AB		AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
>A>	AB	ANBISON LAB CO LTD	EQ 10MG BASE	A205683	001	Jan 12, 2016	Dec NEWA
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN
AB		UNICHEM LABS LTD	EQ 10MG BASE	A204290	001	Oct 08, 2015	Sep NEWA

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
AB			EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
AB		ANBISON LAB CO LTD	EQ 4MG BASE	A205695	001	Nov 05, 2015	Oct NEWA
AB			EQ 5MG BASE	A205695	002	Nov 05, 2015	Oct NEWA
AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
AB			EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL									
KADIAN									
AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar	CAHN	
AB1			20MG	N020616	001	Jul 03, 1996	Mar	CAHN	
AB1			30MG	N020616	004	Mar 09, 2001	Mar	CAHN	
AB1			40MG	N020616	009	Jul 09, 2012	May	CTEC	
			40MG	N020616	009	Jul 09, 2012	Mar	CAHN	
AB1			50MG	N020616	002	Jul 03, 1996	Mar	CAHN	
AB1			60MG	N020616	005	Mar 09, 2001	Mar	CAHN	
AB1			70MG	N020616	010	Jul 09, 2012	May	CTEC	
			70MG	N020616	010	Jul 09, 2012	Mar	CAHN	
AB1			80MG	N020616	006	Oct 27, 2006	Mar	CAHN	
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar	CAHN	
			130MG	N020616	011	Jul 09, 2012	Mar	CAHN	
			150MG	N020616	012	Jul 09, 2012	Mar	CAHN	
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar	CAHN	
MORPHINE SULFATE									
ACTAVIS ELIZABETH									
			30MG	A079040	001	Jan 16, 2013	Sep	CTEC	
			45MG	A079040	002	Jan 16, 2013	Sep	CTEC	
			60MG	A079040	003	Jan 16, 2013	Sep	CTEC	
			75MG	A079040	004	Jan 16, 2013	Sep	CTEC	
			90MG	A079040	005	Jan 16, 2013	Sep	CTEC	
	+		120MG	A079040	006	Jan 16, 2013	Sep	CTEC	
AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May	NEWA	
AB1			70MG	A202718	008	Jun 03, 2015	May	NEWA	
INJECTABLE;INJECTION									
DURAMORPH PF									
AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun	CAHN	
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun	CAHN	
INFUMORPH									
	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun	CAHN	
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun	CAHN	
MORPHINE SULFATE									
AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May	NEWA	
AP			8MG/ML	A205758	002	May 21, 2015	May	NEWA	
AP			10MG/ML	A205758	003	May 21, 2015	May	NEWA	
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May	CFTG	
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May	CFTG	
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May	CFTG	
SOLUTION;ORAL									
MORPHINE SULFATE									
AA		TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May	NEWA	
AA			100MG/5ML	A203518	002	May 12, 2015	May	NEWA	
AA		VINTAGE PHARMS LLC	10MG/5ML	A202309	001	Nov 25, 2015	Nov	NEWA	
AA			20MG/5ML	A202310	001	Oct 30, 2015	Oct	NEWA	
TABLET, EXTENDED RELEASE;ORAL									
MORPHABOND									
IDT									
			15MG	N206544	001	Oct 02, 2015	Oct	NEWA	
			30MG	N206544	002	Oct 02, 2015	Oct	NEWA	
			60MG	N206544	003	Oct 02, 2015	Oct	NEWA	
	+		100MG	N206544	004	Oct 02, 2015	Oct	NEWA	
MORPHINE SULFATE									
AB		ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar	NEWA	
AB			30MG	A203849	002	Apr 06, 2015	Mar	NEWA	
AB			60MG	A203849	003	Apr 06, 2015	Mar	NEWA	
AB			100MG	A203849	004	Apr 06, 2015	Mar	NEWA	
AB			200MG	A203849	005	Apr 06, 2015	Mar	NEWA	
AB		NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Nov	NEWA	
AB			30MG	A203602	002	Dec 16, 2015	Nov	NEWA	
AB			60MG	A203602	003	Dec 16, 2015	Nov	NEWA	
AB			100MG	A203602	004	Dec 16, 2015	Nov	NEWA	
AB			200MG	A203602	005	Dec 16, 2015	Nov	NEWA	
AB		SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN	
AB			30MG	A078761	002	May 11, 2012	Apr	CAHN	
AB			60MG	A078761	003	May 11, 2012	Apr	CAHN	
AB			100MG	A078761	004	May 11, 2012	Apr	CAHN	
AB			200MG	A078761	005	May 11, 2012	Apr	CAHN	

MOXIFLOXACIN HYDROCHLORIDE

>D>	INJECTABLE;IV (INFUSION)						
>D>	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
>D>	+ BAYER HLTHCARE	160MG/100ML	N021277	001	Nov 30, 2001	Dec	CDFR
>A>	SOLUTION;IV (INFUSION)						
>A>	AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER						
>A>	+ BAYER HLTHCARE	400MG/250ML (1.6MG/ML)	N021277	001	Nov 30, 2001	Dec	CDFR
	MOXIFLOXACIN HYDROCHLORIDE						
	+ FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
	SOLUTION/DROPS;OPHTHALMIC						
	MOXEZA						
AT2	+ ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
	MOXIFLOXACIN HYDROCHLORIDE						
AT1	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
AT1	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
AT		EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
	VIGAMOX						
AT1	+ ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC
	TABLET;ORAL						
	MOXIFLOXACIN HYDROCHLORIDE						
AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug	NEWA

MYCOPHENOLATE MOFETIL

	CAPSULE;ORAL						
	MYCOPHENOLATE MOFETIL						
	@ DR REDDYS LABS LTD	250MG	A091315	001	Oct 27, 2011	Oct	DISC

NADOLOL

	TABLET;ORAL						
	CORGARD						
AB	US WORLD MEDS LLC	20MG	N018063	005	Oct 28, 1986	Oct	CAHN
AB		40MG	N018063	001		Oct	CAHN
AB	+	80MG	N018063	002		Oct	CAHN
	@	120MG	N018063	003		Oct	CAHN
	@	160MG	N018063	004		Oct	CAHN
	NADOLOL						
>A> AB	INVAGEN PHARMS	20MG	A203455	001	Dec 18, 2015	Dec	NEWA
>A> AB		40MG	A203455	002	Dec 18, 2015	Dec	NEWA
>A> AB		80MG	A203455	003	Dec 18, 2015	Dec	NEWA
AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug	NEWA
AB		80MG	A201893	002	Sep 16, 2015	Aug	NEWA

NAFTIFINE HYDROCHLORIDE

	CREAM;TOPICAL						
>A>	NAFTIFINE HYDROCHLORIDE						
>A> AB	TARO	2%	A206901	001	Jan 06, 2016	Dec	NEWA
	NAFTIN						
>D>	+ MERZ PHARMS	2%	N019599	002	Jan 13, 2012	Dec	CFTG
>A> AB	+	2%	N019599	002	Jan 13, 2012	Dec	CFTG

NALBUPHINE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	NALBUPHINE HYDROCHLORIDE						
	@ IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
	@	10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
	@	10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
	@	20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN

NALMEFENE HYDROCHLORIDE

	INJECTABLE;INJECTION						
	REVEX						
	@ EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
	@	EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE

>D>	@ EUROHLTH INTL SARL	0.4MG/ML	A 070299	001	Sep 24, 1986	Dec CMFD
>A> AP		0.4MG/ML	A 070299	001	Sep 24, 1986	Dec CMFD
	@	0.4MG/ML	A 070299	001	Sep 24, 1986	Mar CAHN
	NALOXONE HYDROCHLORIDE					
	@ IGI LABS INC	0.02MG/ML	A 072082	001	Apr 11, 1989	Mar CAHN
	@	0.02MG/ML	A 072083	001	Apr 11, 1989	Mar CAHN
	@	0.02MG/ML	A 072084	001	Apr 11, 1989	Mar CAHN
	@	0.02MG/ML	A 072085	001	Apr 11, 1989	Mar CAHN
	@	0.4MG/ML	A 072086	001	Apr 11, 1989	Mar CAHN
	@	0.4MG/ML	A 072087	001	Apr 11, 1989	Mar CAHN
	@	0.4MG/ML	A 072088	001	Apr 11, 1989	Mar CAHN
	@	0.4MG/ML	A 072089	001	Apr 11, 1989	Mar CAHN
	@	0.4MG/ML	A 072090	001	Apr 11, 1989	Mar CAHN
	@	1MG/ML	A 072091	001	Apr 11, 1989	Mar CAHN
	@	1MG/ML	A 072092	001	Apr 11, 1989	Mar CAHN
	@	1MG/ML	A 072093	001	Apr 11, 1989	Mar CAHN
	NARCAN					
	@ ADAPT	0.02MG/ML	N 016636	002		Aug CAHN
	@	0.4MG/ML	N 016636	001		Aug CAHN
	@	1MG/ML	N 016636	003	Jun 14, 1982	Aug CAHN
	SPRAY, METERED;NASAL					
	NARCAN					
	+ ADAPT PHARMA	4MG/SPRAY	N 208411	001	Nov 18, 2015	Nov NEWA

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE

AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A 075523	001	Mar 17, 2000	Apr CAHN
----	--------------------	----------------------------	----------	-----	--------------	----------

NAPROXEN

SUSPENSION;ORAL

NAPROSYN

AB	+ PEDIAPHARM INC	25MG/ML	N 018965	001	Mar 23, 1987	Apr CAHN
----	------------------	---------	----------	-----	--------------	----------

NAPROXEN SODIUM

TABLET, EXTENDED RELEASE;ORAL

NAPRELAN

AB	ALVOGEN MALTA	EQ 375MG BASE	N 020353	001	Jan 05, 1996	Oct CAHN
AB		EQ 500MG BASE	N 020353	002	Jan 05, 1996	Oct CAHN
	+	EQ 750MG BASE	N 020353	003	Jan 05, 1996	Oct CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N 021926	002	May 14, 2015	Jun NEWA
--	--------------------	-------------------	----------	-----	--------------	----------

NATEGLINIDE

TABLET;ORAL

NATEGLINIDE

AB	ALVOGEN MALTA	60MG	A 205055	001	Dec 11, 2015	Nov NEWA
AB		120MG	A 205055	002	Dec 11, 2015	Nov NEWA

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

	@ ALKEM LABS LTD	EQ 2.5MG BASE	A 203741	001	Jun 24, 2015	Jun DISC
		EQ 2.5MG BASE	A 203741	001	Jun 24, 2015	Jun NEWA
	@	EQ 5MG BASE	A 203741	002	Jun 24, 2015	Jun DISC
		EQ 5MG BASE	A 203741	002	Jun 24, 2015	Jun NEWA
	@	EQ 10MG BASE	A 203741	003	Jun 24, 2015	Jun DISC
		EQ 10MG BASE	A 203741	003	Jun 24, 2015	Jun NEWA
	@	EQ 20MG BASE	A 203741	004	Jun 24, 2015	Jun DISC
		EQ 20MG BASE	A 203741	004	Jun 24, 2015	Jun NEWA
	@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A 203659	001	Apr 16, 2015	Apr DISC
AB		EQ 2.5MG BASE	A 203659	001	Apr 16, 2015	Mar NEWA
	@	EQ 5MG BASE	A 203659	002	Apr 16, 2015	Apr DISC
AB		EQ 5MG BASE	A 203659	002	Apr 16, 2015	Mar NEWA
	@	EQ 10MG BASE	A 203659	003	Apr 16, 2015	Apr DISC

TABLET;ORAL

NEBIVOLOL HYDROCHLORIDE

AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Mar NEWA
	@	EQ 20MG BASE	A203659	004	Apr 16, 2015	Apr DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Mar NEWA
	@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul DISC
		EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul NEWA
	@	EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul DISC
		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul NEWA
	@	EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul DISC
		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul NEWA
	@	EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul DISC
		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul NEWA
	@ WATSON LABS INC	EQ 2.5MG BASE	A203683	001	Nov 27, 2015	Nov DISC
		EQ 2.5MG BASE	A203683	001	Nov 27, 2015	Nov NEWA
	@	EQ 5MG BASE	A203683	002	Nov 27, 2015	Nov DISC
		EQ 5MG BASE	A203683	002	Nov 27, 2015	Nov NEWA
	@	EQ 10MG BASE	A203683	003	Nov 27, 2015	Nov DISC
		EQ 10MG BASE	A203683	003	Nov 27, 2015	Nov NEWA
	@	EQ 20MG BASE	A203683	004	Nov 27, 2015	Nov DISC
		EQ 20MG BASE	A203683	004	Nov 27, 2015	Nov NEWA

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003	Apr CAHN
	@	100MG	A076072	002	Sep 16, 2003	Apr CAHN
	@	150MG	A076072	003	Sep 16, 2003	Apr CAHN
	@	200MG	A076072	004	Sep 16, 2003	Apr CAHN
	@	250MG	A076072	005	Sep 16, 2003	Apr CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003	Apr CAHN
AB		100MG	A076409	002	Sep 16, 2003	Apr CAHN
AB		150MG	A076409	003	Sep 16, 2003	Apr CAHN
AB		200MG	A076409	004	Sep 16, 2003	Apr CAHN
AB		250MG	A076409	005	Sep 16, 2003	Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar CAHN
---	----------------------	---------------------	---------	-----	--------------	----------

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

BLOXIVERZ

>D>	+	ECLAT PHARMS LLC	5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Dec CFTG
>A> AP	+		5MG/10ML (0.5MG/ML)	N204078	001	May 31, 2013	Dec CFTG
>D>	+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Dec CFTG
>A> AP	+		10MG/10ML (1MG/ML)	N204078	002	May 31, 2013	Dec CFTG

NEOSTIGMINE METHYLSULFATE

>A> AP		EUROHLTH INTL SARL	5MG/10ML (0.5MG/ML)	A207042	001	Dec 28, 2015	Dec NEWA
>A> AP			10MG/10ML (1MG/ML)	A207042	002	Dec 28, 2015	Dec NEWA
		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan NEWA
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB	ALVOGEN MALTA	100MG	A204621	002	Nov 09, 2015	Oct NEWA
AB		100MG	A204621	002	Nov 09, 2015	Oct CAHN
AB		400MG	A204621	001	Jul 10, 2015	Oct CAHN
AB	ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun NEWA
AB	CIPLA LTD	400MG	A206448	001	Oct 15, 2015	Oct NEWA
AB	MYLAN PHARMS INC	100MG	A206271	001	Nov 09, 2015	Oct NEWA
	VIRAMUNE XR					
AB	BOEHRINGER INGELHEIM	100MG	N201152	002	Nov 08, 2012	Oct CFTG

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB	AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul NEWA
AB		750MG	A204178	001	Dec 11, 2015	Nov NEWA
AB		1GM	A203578	002	Jul 24, 2015	Jul NEWA

NIFEDIPINE

CAPSULE;ORAL					
NIFEDIPINE					
AB	HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013 Mar CAHN
AB		20MG	A202644	002	Apr 25, 2013 Mar CAHN
TABLET, EXTENDED RELEASE;ORAL					
NIFEDIPINE					
AB2	VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001 Aug CAHN
AB2		60MG	A075289	001	Sep 27, 2000 Aug CAHN

NILUTAMIDE

TABLET;ORAL					
NILANDRON					
	@ CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996 Apr CAHN
	+	150MG	N020169	002	Apr 30, 1999 Apr CAHN

NIMODIPINE

CAPSULE;ORAL					
NIMODIPINE					
AB	+ BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008 Jan CAHN
AB	SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015 Jul NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL					
OFEV					
	BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014 Mar CAIN
	+	EQ 150MG BASE	N205832	002	Oct 15, 2014 Mar CAIN

NITRIC OXIDE

GAS;INHALATION					
INOMAX					
	@ INO	100PPM	N020845	002	Dec 23, 1999 Jun DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL					
MACRODANTIN					
AB	ALVOGEN INC	25MG	N016620	003	Jun CTEC
AB	ALVOGEN MALTA	25MG	N016620	003	Oct CAHN
AB		50MG	N016620	001	Oct CAHN
AB	+	100MG	N016620	002	Oct CAHN
NITROFURANTOIN					
AB	ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015 Jun NEWA
AB		50MG	A091095	002	Jun 18, 2015 Jun NEWA
AB		100MG	A091095	003	Jun 18, 2015 Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL					
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)					
AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015 Jun NEWA

NORETHINDRONE

TABLET;ORAL-28					
NOR-QD					
AB1	+ ACTAVIS LABS UT INC	0.35MG	N017060	001	Mar CAHN

NORETHINDRONE ACETATE

TABLET;ORAL					
NORETHINDRONE ACETATE					
>A> AB	AUROBINDO PHARMA LTD	5MG	A204236	001	Jan 08, 2016 Dec NEWA

NORGESTREL

TABLET;ORAL					
OVRETTE					
	@ LABORATOIRE HRA	0.075MG	N017031	001	Jun CAHN

NYSTATINCREAM; TOPICAL
NYSTATIN

AT	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun	CMFD
----	------------------	------------------	---------	-----	--	-----	------

SUSPENSION; ORAL
NYSTATIN

AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr	CAHN
----	------------------	------------------	---------	-----	--------------	-----	------

	@	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr	CAHN
--	---	------------------	---------	-----	--------------	-----	------

>A>	AA	PHARM ASSOC	100,000 UNITS/ML	A203621	001	Jan 07, 2016	Dec	NEWA
-----	----	-------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Mar	CMFD
----	------------------	------------------------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM; 0.1%	A062733	001	Mar 09, 1987	Mar	CMFD
----	------------------	------------------------	---------	-----	--------------	-----	------

OFLOXACINTABLET; ORAL
OFLOXACIN

AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

OLANZAPINETABLET; ORAL
OLANZAPINE

AB	ALKEM LABS LTD	2.5MG	A202295	001	Oct 20, 2015	Oct	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

AB		5MG	A202295	002	Oct 20, 2015	Oct	NEWA
----	--	-----	---------	-----	--------------	-----	------

AB		7.5MG	A202295	003	Oct 20, 2015	Oct	NEWA
----	--	-------	---------	-----	--------------	-----	------

AB		10MG	A202295	004	Oct 20, 2015	Oct	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A202295	005	Oct 20, 2015	Oct	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A202295	006	Oct 20, 2015	Oct	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr	NEWA
----	-----------------	------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
----	---------------------	-----	---------	-----	--------------	-----	------

AB		10MG	A203044	002	Feb 20, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A203044	003	Feb 20, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A203044	004	Feb 20, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
----	-----------------	-----	---------	-----	--------------	-----	------

AB		10MG	A202937	002	Mar 02, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		15MG	A202937	003	Mar 02, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		20MG	A202937	004	Mar 02, 2015	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

OLAPARIBCAPSULE; ORAL
LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA
--	--------------------	------	---------	-----	--------------	-----	------

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDESPRAY, METERED; INHALATION
STIOLTO RESPIMAT

+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH; EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA
---	----------------------	--	---------	-----	--------------	-----	------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

AT	APOTEX INC	EQ 0.1% BASE	A078350	001	Dec 07, 2015	Nov	NEWA
----	------------	--------------	---------	-----	--------------	-----	------

>A>	AT	AUROBINDO PHARMA LTD	EQ 0.1% BASE	A204812	001	Dec 18, 2015	Dec	NEWA
-----	----	----------------------	--------------	---------	-----	--------------	-----	------

AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

AT	NOVEL LABS INC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Nov	NEWA
----	----------------	--------------	---------	-----	--------------	-----	------

AT	USV NORTH AMERICA	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Nov	NEWA
----	-------------------	--------------	---------	-----	--------------	-----	------

AT	ZACH SYSTEM SPA	EQ 0.1% BASE	A204706	001	Dec 07, 2015	Nov	NEWA
----	-----------------	--------------	---------	-----	--------------	-----	------

PATADAY

AT	+	ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG
----	---	------------------	--------------	---------	-----	--------------	-----	------

PATANOL

AT	+	ALCON	EQ 0.1% BASE	N020688	001	Dec 18, 1996	Nov	CFTG
----	---	-------	--------------	---------	-----	--------------	-----	------

PAZEO

+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan	NEWA
---	---------------	--------------	---------	-----	--------------	-----	------

OMBITASVIR; PARITAPREVIR; RITONAVIRTABLET; ORAL
TECHNIVIE

+	ABBVIE INC	12.5MG; 75MG; 50MG	N207931	001	Jul 24, 2015	Aug CMS1
+		12.5MG; 75MG; 50MG	N207931	001	Jul 25, 2015	Jul NEWA

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1 GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Nov NEWA
----	---------------	---	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Aug NEWA
AB		20MG	A203270	002	Aug 19, 2015	Aug NEWA
AB		40MG	A203270	003	Aug 19, 2015	Aug NEWA
AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Aug NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN
AB		8MG	A078602	002	Feb 24, 2011	Apr CAHN
	ZOFTRAN ODT					
AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN
AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA	
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN	
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN	
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN	
AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN	
	@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC	
	ZOFTRAN						
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN
	ZOFTRAN PRESERVATIVE FREE						
AP	+	NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN
	SOLUTION; ORAL						
	ZOFTRAN						
AA	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN
	TABLET; ORAL						
	ZOFTRAN						
AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN	
AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN	
AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN	

ORPHENADRINE CITRATE

INJECTABLE; INJECTION

NORFLEX

@	IGI LABS INC	30MG/ML	N013055	001		Apr CAHN
@	MEDICIS	30MG/ML	N013055	001		Mar DISC

ORPHENADRINE CITRATE

AP	+	AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD
----	---	-------	---------	---------	-----	--------------	----------

OSIMERTINIB MESYLATE

TABLET; ORAL

TAGRISSO

	ASTRAZENECA PHARMS	EQ 40MG BASE	N208065	001	Nov 13, 2015	Nov NEWA
+		EQ 80MG BASE	N208065	002	Nov 13, 2015	Nov NEWA

OXACILLIN SODIUM

CAPSULE;ORAL

OXACILLIN SODIUM

@ ANI PHARMS INC

EQ 250MG BASE

A062222 001

Aug CAHN

@

EQ 500MG BASE

A062222 002

Aug CAHN

INJECTABLE;INJECTION

OXACILLIN SODIUM

AP HOSPIRA INC

EQ 1GM BASE/VIAL

A203950 001 Dec 11, 2015

Nov NEWA

AP

EQ 2GM BASE/VIAL

A203950 002 Dec 11, 2015

Nov NEWA

OXANDROLONE

TABLET;ORAL

OXANDRIN

AB GEMINI LABS LLC

2.5MG

N013718 001

Aug CAHN

AB +

10MG

N013718 002 Nov 05, 2001

Aug CAHN

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB SUN PHARM INDS LTD

300MG/5ML

A078734 001 Jun 26, 2009

Apr CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

AB + ACTAVIS LABS UT INC 3.9MG/24HR

N021351 002 Feb 26, 2003

Mar CAHN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

+ ACTAVIS LABS UT INC 3%

N202513 001 Dec 07, 2011

Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

+ ACTAVIS LABS UT INC 10%(100MG/PACKET)

N022204 001 Jan 27, 2009

Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

OXYBUTYNIN CHLORIDE

AB AMNEAL PHARMS

5MG

A204010 001 Nov 23, 2015

Nov NEWA

AB

10MG

A204010 002 Nov 23, 2015

Nov NEWA

AB

15MG

A204010 003 Nov 23, 2015

Nov NEWA

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB AVANTHI INC

5MG

A202773 001 Aug 17, 2015

Aug NEWA

AB NOVEL LABS INC

5MG

A204752 001 Aug 24, 2015

Aug NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA ANI PHARMS INC

5MG/5ML

A204979 001 Jun 01, 2015

May NEWA

AA NOVEL LABS INC

100MG/5ML

A204603 001 Apr 29, 2015

Apr NEWA

AA WOCKHARDT BIO AG

5MG/5ML

A206456 001 Jun 16, 2015

Jun NEWA

TABLET;ORAL

OXAYDO

ACURA PHARMS INC

5MG

N202080 001 Jun 17, 2011

Mar CTNA

7.5MG

N202080 002 Jun 17, 2011

Mar CTNA

EGALET LTD

5MG

N202080 001 Jun 17, 2011

May CAHN

7.5MG

N202080 002 Jun 17, 2011

May CAHN

EGALET US INC

5MG

N202080 001 Jun 17, 2011

Jul CAHN

7.5MG

N202080 002 Jun 17, 2011

Jul CAHN

OXYCODONE HYDROCHLORIDE

AB ACTAVIS ELIZABETH

5MG

A076636 003 Apr 07, 2015

Mar NEWA

AB EPIC PHARMA LLC

5MG

A202662 001 Sep 22, 2015

Sep NEWA

AB

10MG

A202662 002 Sep 22, 2015

Sep NEWA

AB

15MG

A202662 003 Sep 22, 2015

Sep NEWA

AB

30MG

A202662 004 Sep 22, 2015

Sep NEWA

AB VINTAGE PHARMS

10MG

A077712 004 Apr 13, 2015

Mar NEWA

AB

20MG

A077712 005 Apr 13, 2015

Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
OXYMORPHONE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	5MG		A203506	001	Apr 24, 2015	Apr	NEWA
AB			7.5MG		A203506	002	Apr 24, 2015	Apr	NEWA
AB			10MG		A203506	003	Apr 24, 2015	Apr	NEWA
AB			15MG		A203506	004	Apr 24, 2015	Apr	NEWA
AB			20MG		A203506	005	Apr 24, 2015	Apr	NEWA
AB			30MG		A203506	006	Apr 24, 2015	Apr	NEWA
AB			40MG		A203506	007	Apr 24, 2015	Apr	NEWA

OXYTOCIN

INJECTABLE;INJECTION
OXYTOCIN

AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001			Feb	CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007		Feb	CAHN

PALBOCICLIB

CAPSULE;ORAL
IBRANCE

		PFIZER INC	75MG	N207103	001	Feb 03, 2015		Feb	NEWA
			100MG	N207103	002	Feb 03, 2015		Feb	NEWA
	+		125MG	N207103	003	Feb 03, 2015		Feb	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL
INVEGA

AB		JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008		Jul	CFTG
AB			3MG	N021999	001	Dec 19, 2006		Jul	CFTG
AB	+		6MG	N021999	002	Dec 19, 2006		Jul	CFTG
AB			9MG	N021999	003	Dec 19, 2006		Jul	CFTG
		PALIPERIDONE							
AB		ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015		Jul	NEWA
AB			3MG	A202645	002	Aug 03, 2015		Jul	NEWA
AB			6MG	A202645	003	Aug 03, 2015		Jul	NEWA
AB			9MG	A202645	004	Aug 03, 2015		Jul	NEWA
AB		MYLAN PHARMS INC	1.5MG	A203802	001	Sep 24, 2015		Sep	NEWA
AB			3MG	A203802	002	Sep 24, 2015		Sep	NEWA
AB			6MG	A203802	003	Sep 24, 2015		Sep	NEWA
AB			9MG	A203802	004	Sep 24, 2015		Sep	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA

		JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015		May	NEWA
			410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015		May	NEWA
			546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015		May	NEWA
	+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015		May	NEWA

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS
ALOXI

AP	+	HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008		Sep	CFTG
AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003		Sep	CFTG
		PALONOSETRON HYDROCHLORIDE							
AP		SANDOZ INC	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202521	001	Oct 13, 2015		Sep	NEWA
AP		TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Oct 13, 2015		Sep	NEWA
AP			EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A090713	001	Oct 13, 2015		Sep	NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION
PANCURONIUM BROMIDE

	@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988		Mar	CAHN
	@		2MG/ML	A072211	001	Mar 31, 1988		Mar	CAHN
	@		2MG/ML	A072212	001	Mar 31, 1988		Mar	CAHN
	@		2MG/ML	A072213	001	Mar 31, 1988		Mar	CAHN

PANOBINOSTATCAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb NEWA
	15MG	N205353	002	Feb 23, 2015	Feb NEWA
+	20MG	N205353	003	Feb 23, 2015	Feb NEWA

PANOBINOSTAT LACTATECAPSULE; ORAL
FARYDAK

NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CAHN
	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar CPOT
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CAHN
	EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar CPOT
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CAHN
+	EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar CPOT

PANTOPRAZOLE SODIUMINJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun NEWA
	TABLET, DELAYED RELEASE; ORAL					
	PANTOPRAZOLE SODIUM					
AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr CAHN

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

>A>	AB	AMNEAL PHARMS	1MCG	A204327	001	Jan 13, 2016	Dec NEWA
>A>	AB		2MCG	A204327	002	Jan 13, 2016	Dec NEWA
>A>	AB		4MCG	A204327	003	Jan 13, 2016	Dec NEWA
>A>	AB	AUROBINDO PHARMA LTD	1MCG	A207672	001	Jan 14, 2016	Dec NEWA
>A>	AB		2MCG	A207672	002	Jan 14, 2016	Dec NEWA
>A>	AB		4MCG	A207672	003	Jan 14, 2016	Dec NEWA
	AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan CAHN
	AB		2MCG	A202539	002	Mar 27, 2014	Jan CAHN
	AB		4MCG	A202539	003	Mar 27, 2014	Jan CAHN

PAROXETINE HYDROCHLORIDETABLET; ORAL
PAROXETINE HYDROCHLORIDE

AB	JUBILANT GENERICS	EQ 10MG BASE	A205528	001	Nov 27, 2015	Nov NEWA
AB		EQ 20MG BASE	A205528	002	Nov 27, 2015	Nov NEWA
AB		EQ 30MG BASE	A205528	003	Nov 27, 2015	Nov NEWA
AB		EQ 40MG BASE	A205528	004	Nov 27, 2015	Nov NEWA

PATROMER SORBITEX CALCIUMPOWDER; ORAL
VELTASSA

RELYPSA INC	EQ 8.4GM BASE/PACKET	N205739	001	Oct 21, 2015	Oct NEWA
	EQ 16.8GM BASE/PACKET	N205739	002	Oct 21, 2015	Oct NEWA
+	EQ 25.2GM BASE/PACKET	N205739	003	Oct 21, 2015	Oct NEWA

PAZOPANIB HYDROCHLORIDETABLET; ORAL
VOTRIENT

+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar CAHN
@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug DISC
		EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar CAHN

PENTOXIFYLLINETABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

AB	VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb CAHN
----	----------------	-------	---------	-----	--------------	----------

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

AB	INDICUS PHARMA	2MG	A205973	001	Dec 17, 2015	Nov NEWA
AB		4MG	A205973	002	Dec 17, 2015	Nov NEWA
AB		8MG	A205973	003	Dec 17, 2015	Nov NEWA
AB		16MG	A205973	004	Dec 17, 2015	Nov NEWA

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

BONTRIL

@ VALEANT 105MG

PHENDIMETRAZINE TARTRATE

+ SANDOZ 105MG

A088021 001 Sep 21, 1982 Jan DISC

N018074 001 Jan CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB + CONCORDIA PHARMS INC 10MG

N008708 001 Jun CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA MIKAH PHARMA LLC 37.5MG

A040228 001 Jun 19, 1997 Jun CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

+ AKORN INC 2.5%

N207926 001 Jan 15, 2015 Sep CRLD

+ 2.5%

N207926 001 Jan 15, 2015 Jan NEWA

+ 10%

N207926 002 Jan 15, 2015 Sep CRLD

+ 10%

N207926 002 Jan 15, 2015 Jan NEWA

+ PARAGON BIOTECK 2.5%

N203510 001 Mar 21, 2013 Sep CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

AA + G AND W LABS INC 5MG/5ML; 6.25MG/5ML

A088761 001 Nov 08, 1984 Jul CAHN

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

@ WOCKHARDT 30MG EXTENDED

A040759 001 Dec 18, 2007 Jun DISC

@ WOCKHARDT USA 100MG EXTENDED

A040732 001 Jan 30, 2008 Jun DISC

PHENYTOIN SODIUM

AB AUROBINDO PHARMA LTD 100MG EXTENDED

A204309 001 Jun 10, 2015 May NEWA

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP + EUROHLTH INTL SARL 50MG/ML

A084307 001 Feb CAHN

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@ IGI LABS INC 1MG/0.5ML

N012223 002 Apr CAHN

@ 10MG/ML

N012223 001 Apr CAHN

PILOCARPINE HYDROCHLORIDE

GEL; OPHTHALMIC

PILOPINE HS

@ ALCON 4%

N018796 001 Oct 01, 1984 Aug DISC

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB ELAN PHARMA INTL LTD 5MG

A076746 001 Nov 16, 2004 Mar CAHN

PIMOZIDE

TABLET; ORAL

ORAP

AB TEVA 1MG

N017473 003 Aug 27, 1997 Sep CFTG

AB + 2MG

N017473 001 Jul 31, 1984 Sep CFTG

TABLET;ORAL							
PIMOZIDE							
AB	PAR PHARM	1MG	A204521	001	Sep 28, 2015	Sep	NEWA
AB		2MG	A204521	002	Sep 28, 2015	Sep	NEWA
<u>PINDOLOL</u>							
TABLET;ORAL							
PINDOLOL							
	@ G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
	@	5MG	A073687	001	Feb 26, 1993	Apr	CAHN
	@	5MG	A074123	001	Apr 17, 1997	Apr	CAHN
	@	10MG	A073661	002	Oct 31, 1993	Apr	CAHN
	@	10MG	A073687	002	Feb 26, 1993	Apr	CAHN
	@	10MG	A074123	002	Apr 17, 1997	Apr	CAHN
>A>	AB	NOSTRUM LABS INC	5MG	A205415	001	Jan 13, 2016	Dec NEWA
>A>	AB		10MG	A205415	002	Jan 13, 2016	Dec NEWA
<u>PIRBUTEROL ACETATE</u>							
AEROSOL, METERED;INHALATION							
MAXAIR							
	@ MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan	DISC
<u>PIRFENIDONE</u>							
CAPSULE;ORAL							
ESBRIET							
+	GENENTECH INC	267MG	N022535	001	Oct 15, 2014	Feb	CAHN
<u>PIROXICAM</u>							
CAPSULE;ORAL							
PIROXICAM							
AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993	May	CAHN
AB		20MG	A074118	001	Jun 15, 1993	May	CAHN
<u>PODOFILOX</u>							
GEL;TOPICAL							
CONDYLOX							
+	ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Feb	CAHN
SOLUTION;TOPICAL							
CONDYLOX							
AT	+	ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Jan CAHN
PODOFILOX							
AT	BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	May	CAHN
<u>POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE</u>							
SOLUTION/DROPS;OPHTHALMIC							
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE							
AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Jan	CAHN
<u>PONATINIB HYDROCHLORIDE</u>							
TABLET;ORAL							
ICLUSIG							
	ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015	Apr	NEWA
<u>POTASSIUM ACETATE</u>							
INJECTABLE;INJECTION							
POTASSIUM ACETATE							
>A>							
>A>	AP	EXELA PHARMA SCS LLC	2MEQ/ML	A206203	001	Dec 29, 2015	Dec NEWA
>A>	AP	+	HOSPIRA	2MEQ/ML	N018896	001	Jul 20, 1984 Dec CTNA
>D>		POTASSIUM ACETATE IN PLASTIC CONTAINER					
>D>	+	HOSPIRA	2MEQ/ML	N018896	001	Jul 20, 1984	Dec CTNA
<u>POTASSIUM CHLORIDE</u>							
CAPSULE, EXTENDED RELEASE;ORAL							
KLOR-CON							
AB	UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015	Jun	NEWA
AB		10MEQ	A203106	002	Jul 10, 2015	Jun	NEWA
POTASSIUM CHLORIDE							
>A>	AB	LUPIN LTD	8MEQ	A203002	001	Dec 18, 2015	Dec NEWA
>A>	AB		10MEQ	A203002	002	Dec 18, 2015	Dec NEWA
AB	PHARMACEUTICS INTL	8MEQ	A205549	001	Dec 08, 2015	Nov	NEWA
AB		10MEQ	A205549	002	Dec 08, 2015	Nov	NEWA

FOR SOLUTION;ORAL						
POTASSIUM CHLORIDE						
PHARMA RES SOFTWARE 20MEQ			N208019	001	Aug 19, 2015	Aug NEWA
TABLET, EXTENDED RELEASE;ORAL						
POTASSIUM CHLORIDE						
AB1	ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004	Jul CAHN
AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb CPOT
AB2		10MEQ	A204662	002	Aug 21, 2014	Feb CPOT
AB2	PADDOCK LLC	8MEQ	A205993	001	Nov 05, 2015	Oct NEWA
AB2		10MEQ	A205993	002	Nov 05, 2015	Oct NEWA
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>						
TABLET;ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	GLENMARK GENERICS	0.75MG	A090781	006	Sep 11, 2015	Aug NEWA
TABLET, EXTENDED RELEASE;ORAL						
PRAMIPEXOLE DIHYDROCHLORIDE						
AB	DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015	Jul NEWA
AB		0.75MG	A203354	002	Aug 07, 2015	Jul NEWA
AB		1.5MG	A203354	003	Aug 07, 2015	Jul NEWA
AB		3MG	A203354	004	Aug 07, 2015	Jul NEWA
AB		4.5MG	A203354	005	Aug 07, 2015	Jul NEWA
<u>PREDNICARBATE</u>						
OINTMENT;TOPICAL						
DERMATOP						
AB	+ VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr CAHN
<u>PREDNISOLONE ACETATE</u>						
SUSPENSION;ORAL						
FLO-PRED						
@ TARO EQ 15MG BASE/5ML			N022067	002	Jan 17, 2008	Nov DISC
<u>PREDNISONE</u>						
TABLET;ORAL						
PREDNISONE						
@ HIKMA PHARMS 1MG			A040890	001	Nov 01, 2010	Aug DISC
<u>PREGABALIN</u>						
CAPSULE;ORAL						
LYRICA						
PF PRISM CV 25MG			N021446	001	Dec 30, 2004	Apr CTEC
50MG			N021446	002	Dec 30, 2004	Apr CTEC
75MG			N021446	003	Dec 30, 2004	Apr CTEC
100MG			N021446	004	Dec 30, 2004	Apr CTEC
150MG			N021446	005	Dec 30, 2004	Apr CTEC
200MG			N021446	006	Dec 30, 2004	Apr CTEC
225MG			N021446	007	Dec 30, 2004	Apr CTEC
+ 300MG			N021446	008	Dec 30, 2004	Apr CTEC
<u>PROCAINAMIDE HYDROCHLORIDE</u>						
CAPSULE;ORAL						
PROCAINAMIDE HYDROCHLORIDE						
@ IDT AUSTRALIA LTD 250MG			A089219	001	Jul 01, 1986	Jun CAHN
@ 500MG			A089221	001	Jul 01, 1986	Jun CAHN
TABLET, EXTENDED RELEASE;ORAL						
PROCAINAMIDE HYDROCHLORIDE						
@ IDT AUSTRALIA LTD 250MG			A089369	001	Aug 14, 1987	Jun CAHN
@ 500MG			A089370	001	Jan 09, 1987	Jun CAHN
@ 750MG			A089371	001	Aug 14, 1987	Jun CAHN
<u>PROCHLORPERAZINE EDISYLATE</u>						
INJECTABLE;INJECTION						
PROCHLORPERAZINE EDISYLATE						
AP	+ EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb CAHN

PROGESTERONE

CAPSULE; ORAL					
PROGESTERONE					
AB	BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013 Jan CAHN
AB		200MG	A200900	002	Aug 16, 2013 Jan CAHN
GEL; VAGINAL					
CRINONE					
+	ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997 Nov CRLD
		4%	N020701	001	Jul 31, 1997 Feb CAHN
+		8%	N020701	002	Jul 31, 1997 Feb CAHN
INJECTABLE; INJECTION					
PROGESTERONE					
AO	+ ACTAVIS LABS UT INC	50MG/ML	N017362	002	Mar CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION					
PROMETHAZINE HYDROCHLORIDE					
AP	+ EUROHLTH INTL SARL	25MG/ML	A083312	001	Jun CAHN
AP	+	50MG/ML	A083312	002	Jun CAHN
SUPPOSITORY; RECTAL					
PHENERGAN					
	@ DELCOR ASSET CORP	12.5MG	N010926	002	Apr CAHN
	@	25MG	N010926	001	Apr CAHN
TABLET; ORAL					
PROMETHAZINE HYDROCHLORIDE					
AB	HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008 Mar CAHN
AB		25MG	A040673	002	Mar 05, 2008 Mar CAHN
AB		50MG	A040673	003	Mar 05, 2008 Mar CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL					
PROPAFENONE HYDROCHLORIDE					
AB	WATSON LABS INC	225MG	A202688	001	Aug 24, 2015 Aug NEWA
AB		325MG	A202688	002	Aug 24, 2015 Aug NEWA
AB		425MG	A202688	003	Aug 24, 2015 Aug NEWA

PROPOFOL

INJECTABLE; INJECTION					
PROPOFOL					
>A> AB	WATSON LABS INC	10MG/ML	A205307	001	Dec 22, 2015 Dec NEWA

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL					
PYRIDOSTIGMINE BROMIDE					
	@ ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005 Aug CAHN
	@	60MG	A040512	001	Oct 08, 2003 Aug CAHN
AB	ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015 Jun NEWA
TABLET, EXTENDED RELEASE; ORAL					
MESTINON					
AB	+ VALEANT PHARMS LLC	180MG	N011665	001	Jun CFTG
PYRIDOSTIGMINE BROMIDE					
AB	ALVOGEN INC	180MG	A204737	001	Jun 26, 2015 Jun NEWA
AB	IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015 Aug NEWA

PYRIMETHAMINE

TABLET; ORAL					
DARAPRIM					
+	TURING PHARMS AG	25MG	N008578	001	Aug CAHN

QUAZEPAM

TABLET; ORAL					
DORAL					
	@ SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985 Jun DISC

QUETIAPINE FUMARATE

TABLET; ORAL					
SEROQUEL					
AB	+ ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997 May CAHN
AB		EQ 50MG BASE	N020639	007	Oct 04, 2005 May CAHN
AB		EQ 100MG BASE	N020639	002	Sep 26, 1997 May CAHN

TABLET; ORAL						
SEROQUEL						
	@	EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
AB		EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
AB	+	EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
AB		EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN
<u>QUINAPRIL HYDROCHLORIDE</u>						
TABLET; ORAL						
QUINAPRIL HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
AB		EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
AB		EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
AB		EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN
<u>QUINIDINE GLUCONATE</u>						
TABLET, EXTENDED RELEASE; ORAL						
QUINIDINE GLUCONATE						
	@ CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN
<u>QUINIDINE SULFATE</u>						
TABLET; ORAL						
QUINIDINE SULFATE						
	@ CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
	@	300MG	A085632	001		Jun CAHN
TABLET, EXTENDED RELEASE; ORAL						
QUINIDINE SULFATE						
+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN
<u>QUININE SULFATE</u>						
CAPSULE; ORAL						
QUININE SULFATE						
AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul NEWA
<u>RABEPRAZOLE SODIUM</u>						
TABLET, DELAYED RELEASE; ORAL						
RABEPRAZOLE SODIUM						
AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul NEWA
AB	BRECKENRIDGE PHARM	20MG	A204237	001	Nov 18, 2015	Nov NEWA
<u>RALOXIFENE HYDROCHLORIDE</u>						
TABLET; ORAL						
RALOXIFENE HYDROCHLORIDE						
AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan NEWA
<u>RAMELTEON</u>						
TABLET; ORAL						
RAMELTEON						
AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug NEWA
<u>RAMIPRIL</u>						
TABLET; ORAL						
RAMIPRIL						
	APOTEX INC	1.25MG	A091069	001	Dec 02, 2015	Nov CTEC
AB		1.25MG	A091069	001	Dec 02, 2015	Nov NEWA
		2.5MG	A091069	002	Dec 02, 2015	Nov CTEC
		2.5MG	A091069	002	Dec 02, 2015	Nov NEWA
AB		5MG	A091069	003	Dec 02, 2015	Nov CTEC
		5MG	A091069	003	Dec 02, 2015	Nov NEWA
	+	10MG	A091069	004	Dec 02, 2015	Nov CRLD
AB		10MG	A091069	004	Dec 02, 2015	Nov NEWA
	@ MYLAN PHARMS INC	1.25MG	A090650	001	Jun 30, 2011	Nov DISC
	@	2.5MG	A090650	002	Jun 30, 2011	Nov DISC
	@	5MG	A090650	003	Jun 30, 2011	Nov DISC
	@	10MG	A090650	004	Jun 30, 2011	Nov DISC
	@ ZYDUS PHARMS USA INC	1.25MG	A090697	001	Sep 24, 2009	Nov DISC
	@	2.5MG	A090697	002	Sep 24, 2009	Nov DISC
	@	5MG	A090697	003	Sep 24, 2009	Nov DISC
	@	10MG	A090697	004	Sep 24, 2009	Nov DISC

RANITIDINE HYDROCHLORIDEINJECTABLE; INJECTION
ZANTAC

AP	+	CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun CAHN
		TABLET; ORAL					
		RANITIDINE HYDROCHLORIDE					
		@ SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr CAHN
		@	EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr CAHN

REPAGLINIDETABLET; ORAL
REPAGLINIDE

AB		STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr NEWA
AB			1MG	A091517	002	Apr 24, 2015	Apr NEWA
AB			2MG	A091517	003	Apr 24, 2015	Apr NEWA

RIBAVIRINCAPSULE; ORAL
REBETOL

	@	MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun DISC
--	---	-------------------	-------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET; ORAL

RISEDRONATE SODIUM

AB		APOTEX INC	35MG	A090877	001	Nov 30, 2015	Nov NEWA
AB		AUROBINDO PHARMA LTD	5MG	A200296	001	Nov 30, 2015	Nov NEWA
AB			30MG	A200296	002	Nov 30, 2015	Nov NEWA
AB			35MG	A200296	003	Nov 30, 2015	Nov NEWA
AB		MACLEODS PHARMS LTD	5MG	A203533	001	Dec 09, 2015	Nov NEWA
AB			30MG	A203533	002	Dec 09, 2015	Nov NEWA
AB		MYLAN PHARMS INC	5MG	A200477	001	Nov 30, 2015	Nov NEWA
AB			30MG	A200477	002	Nov 30, 2015	Nov NEWA
AB			35MG	A200477	003	Nov 30, 2015	Nov NEWA
AB		SUN PHARMA GLOBAL	5MG	A090886	001	Nov 30, 2015	Nov NEWA
AB			30MG	A090886	002	Nov 30, 2015	Nov NEWA
AB			35MG	A090886	003	Nov 30, 2015	Nov NEWA

TABLET, DELAYED RELEASE; ORAL

ATELVIA

AB	+	WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May CFTG
		RISEDRONATE SODIUM					
AB		TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May NEWA

RISPERIDONETABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB		DR REDDYS LABS LTD	3MG	A077328	004	Nov 30, 2009	Nov NEWA
AB			4MG	A077328	005	Nov 30, 2009	Nov NEWA
AB		SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr CAHN
AB			1MG	A077542	002	Aug 06, 2010	Apr CAHN
AB			2MG	A077542	003	Aug 06, 2010	Apr CAHN
AB			3MG	A078474	001	Aug 06, 2010	Apr CAHN
AB			4MG	A078474	002	Aug 06, 2010	Apr CAHN

RIVAROXABANTABLET; ORAL
XARELTO

		JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr CRLD
--	--	----------------	------	---------	-----	--------------	----------

RIVASTIGMINEFILM, EXTENDED RELEASE; TRANSDERMAL
EXELON

AB		NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug CFTG
AB	+		9.5MG/24HR	N022083	002	Jul 06, 2007	Aug CFTG
AB			13.3MG/24HR	N022083	005	Aug 31, 2012	Aug CFTG
		RIVASTIGMINE					
AB		ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug NEWA
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug NEWA
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug NEWA
AB		ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug CAHN
AB			9.5MG/24HR	A204403	002	Sep 03, 2015	Aug CAHN
AB			13.3MG/24HR	A204403	003	Aug 31, 2015	Aug CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May NEWA
AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May NEWA
AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May NEWA
AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May NEWA

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

AB	JUBILANT GENERICS	EQ 5MG BASE	A203334	001	Oct 16, 2015	Oct NEWA
AB		EQ 10MG BASE	A203334	002	Oct 16, 2015	Oct NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar CAHN
---	--------------------	--------	---------	-----	--------------	----------

ROLAPITANT HYDROCHLORIDE

TABLET;ORAL

VARUBI

+	TESARO INC	EQ 90MG BASE	N206500	001	Sep 01, 2015	Sep NEWA
---	------------	--------------	---------	-----	--------------	----------

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr CAHN
AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr CAHN
AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr CAHN
AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr CAHN
AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr CAHN
AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr CAHN
AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

	NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul NEWA
		49MG;51MG	N207620	002	Jul 07, 2015	Jul NEWA
+		97MG;103MG	N207620	003	Jul 07, 2015	Jul NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

	BIOMARIN PHARM	500MG/PACKET	N205065	002	Oct 27, 2015	Oct NEWA
--	----------------	--------------	---------	-----	--------------	----------

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar CAHN
AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan NEWA
AB	+	NOVARTIS	1MG/72HR	N017874	001	Jan CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

@ G AND W LABS INC

@

@

5MG	A074537	001	Aug 02, 1996	Apr CAHN
5MG	A074744	001	Jan 27, 1997	Apr CAHN
5MG	A074756	001	Nov 25, 1998	Apr CAHN

>A>	<u>SELEXIPAG</u>								
>A>	TABLET;ORAL								
>A>	UPTRAVI								
>A>	ACTELION PHARMS LTD	0.2MG		N207947	001	Dec 21, 2015	Dec	NEWA	
>A>		0.4MG		N207947	002	Dec 21, 2015	Dec	NEWA	
>A>		0.6MG		N207947	003	Dec 21, 2015	Dec	NEWA	
>A>		0.8MG		N207947	004	Dec 21, 2015	Dec	NEWA	
>A>		1MG		N207947	005	Dec 21, 2015	Dec	NEWA	
>A>		1.2MG		N207947	006	Dec 21, 2015	Dec	NEWA	
>A>		1.4MG		N207947	007	Dec 21, 2015	Dec	NEWA	
>A>	+	1.6MG		N207947	008	Dec 21, 2015	Dec	NEWA	
	<u>SERTRALINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	SERTRALINE HYDROCHLORIDE								
	@ HIKMA PHARMS	EQ 25MG BASE		A077864	001	Aug 10, 2009	May	DISC	
	@	EQ 50MG BASE		A077864	002	Aug 10, 2009	May	DISC	
	@	EQ 100MG BASE		A077864	003	Aug 10, 2009	May	DISC	
AB	SUN PHARM INDS LTD	EQ 25MG BASE		A077977	001	Feb 06, 2007	Apr	CAHN	
AB		EQ 50MG BASE		A077977	002	Feb 06, 2007	Apr	CAHN	
AB		EQ 100MG BASE		A077977	003	Feb 06, 2007	Apr	CAHN	
		EQ 150MG BASE		A077977	004	Feb 06, 2007	Apr	CAHN	
		EQ 200MG BASE		A077977	005	Feb 06, 2007	Apr	CAHN	
	<u>SEVOFLURANE</u>								
	LIQUID;INHALATION								
	SEVOFLURANE								
AN	SHANGHAI HENGRUI	100%		A203793	001	Nov 03, 2015	Oct	NEWA	
	<u>SILDENAFIL CITRATE</u>								
	SOLUTION;INTRAVENOUS								
	REVATIO								
AP	+ PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)		N022473	001	Nov 18, 2009	Mar	CFTG	
	SILDENAFIL CITRATE								
AP	AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)		A203988	001	Apr 01, 2015	Mar	NEWA	
	TABLET;ORAL								
	SILDENAFIL CITRATE								
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE		A203963	001	Nov 18, 2015	Nov	NEWA	
	<u>SILODOSIN</u>								
	CAPSULE;ORAL								
	RAPAFLO								
	+ ACTAVIS LABS UT INC	4MG		N022206	001	Oct 08, 2008	Mar	CAHN	
		8MG		N022206	002	Oct 08, 2008	Mar	CAHN	
	<u>SIMVASTATIN</u>								
	TABLET;ORAL								
	SIMVASTATIN								
AB	BIOCON LIMITED	5MG		A078034	001	Dec 20, 2006	Oct	CAHN	
AB		10MG		A078034	002	Dec 20, 2006	Oct	CAHN	
AB		20MG		A078034	003	Dec 20, 2006	Oct	CAHN	
AB		40MG		A078034	004	Dec 20, 2006	Oct	CAHN	
AB		80MG		A078034	005	Dec 20, 2006	Oct	CAHN	
AB	SUN PHARM INDS LTD	5MG		A076285	001	Dec 20, 2006	Apr	CAHN	
AB		10MG		A076285	002	Dec 20, 2006	Apr	CAHN	
AB		20MG		A076285	003	Dec 20, 2006	Apr	CAHN	
AB		40MG		A076285	004	Dec 20, 2006	Apr	CAHN	
AB		80MG		A076285	005	Jun 23, 2006	Apr	CAHN	
	<u>SODIUM CHLORIDE</u>								
	INJECTABLE;INJECTION								
	SODIUM CHLORIDE 0.9%								
AP	EUROHLTH INTL SARL	9MG/ML		A201850	001	Jan 20, 2012	Feb	CAHN	
	SODIUM CHLORIDE 0.9%								
	EUROHLTH INTL SARL	9MG/ML		A201833	001	Sep 24, 2013	Feb	CAHN	
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
	+ LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)		N021569	001	Jul 27, 2006	Feb	CAHN	
		112.5MG/125ML (9MG/ML)		N021569	002	Jul 27, 2006	Feb	CAHN	
	+	405MG/50ML (9MG/ML)		N021569	001	Jul 27, 2006	Feb	CPOT	
		1012.5MG/125ML (9MG/ML)		N021569	002	Jul 27, 2006	Feb	CPOT	

SODIUM CHROMATE CR-51

INJECTABLE;INJECTION

SODIUM CHROMATE CR 51

>D>	@ MALLINCKRODT	100uCi/ML	N016708	001		Dec CAHN
>A>	@ MALLINKRODT NUCLEAR	100uCi/ML	N016708	001		Dec CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB	EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun CAHN
----	--------------------	------------	---------	-----	--------------	----------

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP	3D IMAGING DRUG	10-200mCi/ML	A203777	001	Oct 19, 2015	Oct NEWA
AP	CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul NEWA
AP	HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul NEWA
AP	IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug NEWA
AP	MIDWEST MEDCL	10-200mCi/ML	A204440	001	Nov 17, 2015	Nov NEWA
AP	MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul NEWA
AP	PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb NEWA
AP	SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr NEWA
AP	TRIAD ISOTOPES INC	10-200mCi/ML	A203968	001	Oct 23, 2015	Oct NEWA
AP	UIHC PET IMAGING	10-200mCi/ML	A204462	001	Nov 17, 2015	Nov NEWA
AP	UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr CAHN
>D> AA		MALLINCKRODT	100uCi	A071909	001	Feb 28, 1989	Dec CAHN
>D> AA			200uCi	A071910	001	Feb 28, 1989	Dec CAHN
>A> AA		MALLINKRODT NUCLEAR	100uCi	A071909	001	Feb 28, 1989	Dec CAHN
>A> AA			200uCi	A071910	001	Feb 28, 1989	Dec CAHN

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

>D>	@ MALLINCKRODT	0.8-100mCi	N016515	002		Dec CAHN
>D>	+	0.8-100mCi	N016517	001		Dec CAHN
>D>	@	15-100uCi	N016517	002		Dec CAHN
>A>	@ MALLINKRODT NUCLEAR	0.8-100mCi	N016515	002		Dec CAHN
>A>	+	0.8-100mCi	N016517	001		Dec CAHN
>A>	@	15-100uCi	N016517	002		Dec CAHN

SOLUTION;ORAL

SODIUM IODIDE I 131

>D>	+	MALLINCKRODT	3.5-150mCi/VIAL	N016515	001	Dec CAHN
>A>	+	MALLINKRODT NUCLEAR	3.5-150mCi/VIAL	N016515	001	Dec CAHN

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER

	@ BAXTER HLTHCARE	1.87GM/100ML	N016692	001		Sep DISC
>D>		SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER				
>D>	B BRAUN	1.87GM/100ML	N020004	001	Apr 21, 1992	Dec DISC
>A>	@	1.87GM/100ML	N020004	001	Apr 21, 1992	Dec DISC
		1.87GM/100ML	N020004	001	Apr 21, 1992	Sep CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

KALEXATE

KVK TECH

15GM/BOT

A040905	002	Apr 03, 2015	Mar NEWA
---------	-----	--------------	----------

KAYEXALATE

AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001	Apr CAHN
----	---	----------------------	-------------	---------	-----	----------

SODIUM TETRADECYL SULFATEINJECTABLE; INJECTION
SOTRADECOL

+ MYLAN INSTITUTIONAL 20MG/2ML (10MG/ML) A040541 001 Nov 12, 2004 Jul CRLD

SOMATROPIN RECOMBINANTINJECTABLE; INJECTION
NORDITROPIN FLEXPPO

NOVO NORDISK INC 30MG/3ML N021148 011 Jan 23, 2015 Jan NEWA

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC 30MG/3ML N021148 007 Mar 10, 2009 Jul DISC

30MG/3ML N021148 007 Mar 10, 2009 Mar CMFD

@ 30MG/3ML N021148 007 Mar 10, 2009 Jan DISC

NUTROPIN

@ GENENTECH 5MG/VIAL N020168 001 Nov 17, 1993 Jun DISC

@ 10MG/VIAL N020168 002 Nov 17, 1993 Jun DISC

BX + 10MG/VIAL N020168 002 Nov 17, 1993 Mar CTEC

NUTROPIN AQ

@ GENENTECH 10MG/2ML (5MG/ML) N020522 001 Dec 29, 1995 Jun DISC

NUTROPIN AQ NUSPIN

+ GENENTECH 5MG/2ML (2.5MG/ML) N020522 003 Jan 03, 2008 Jun CTNA

+ 10MG/2ML (5MG/ML) N020522 005 Jan 03, 2008 Jun NEWA

+ 20MG/2ML (10MG/ML) N020522 004 Jan 03, 2008 Jun CTNA

NUTROPIN AQ PEN

+ GENENTECH 20MG/2ML (10MG/ML) N020522 006 Jan 03, 2008 Jun NEWA

ZOMACTON

BX + FERRING 5MG/VIAL N019774 002 Jan 04, 2002 Mar CTNA

BX 10MG/VIAL N019774 003 Mar 07, 2012 Apr CRLD

BX + 10MG/VIAL N019774 003 Mar 07, 2012 Mar NEWA

SONIDEGIB PHOSPHATECAPSULE; ORAL
ODOMZO

+ NOVARTIS PHARMS CORP EQ 200MG BASE N205266 001 Jul 24, 2015 Jul NEWA

SOTALOL HYDROCHLORIDESOLUTION; INTRAVENOUS
SOTALOL HYDROCHLORIDE

+ ALTATHERA PHARMS LLC 150MG/10ML (15MG/ML) N022306 001 Jul 02, 2009 Apr CAHN

TABLET; ORAL

BETAPACE

AB1 COVIS PHARMA SARL 80MG N019865 001 Oct 30, 1992 Mar CAHN

AB1 120MG N019865 005 Apr 20, 1994 Mar CAHN

AB1 + 160MG N019865 002 Oct 30, 1992 Mar CAHN

AB1 240MG N019865 003 Oct 30, 1992 Mar CAHN

@ 320MG N019865 004 Oct 30, 1992 Mar CAHN

STERILE WATER FOR INJECTION

LIQUID; N/A

STERILE WATER FOR INJECTION

AP EUROHLTH INTL SARL 100% A206369 001 Sep 02, 2015 Aug NEWA

SUCCINYLCHOLINE CHLORIDEINJECTABLE; INJECTION
QUELICIN PRESERVATIVE FREE

@ HOSPIRA 100MG/ML N008845 004 Jun DISC

SUCRALFATETABLET; ORAL
SUCRALFATE

AB MYLAN PHARMS INC 1GM A074415 001 Jun 08, 1998 May CAHN

SUFENTANIL CITRATEINJECTABLE; INJECTION
SUFENTANIL CITRATE

AP EUROHLTH INTL SARL EQ 0.05MG BASE/ML A074413 001 Dec 15, 1995 Jun CAHN

TAPENTADOL HYDROCHLORIDE

SOLUTION; ORAL

NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May CAHN
---	-------------	-----------------	---------	-----	--------------	----------

TABLET; ORAL

NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

EQ 75MG BASE

N022304	002	Nov 20, 2008	May CAHN
---------	-----	--------------	----------

+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May CAHN
---	--	---------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May CAHN
--	-------------	--------------	---------	-----	--------------	----------

EQ 100MG BASE

N200533	002	Aug 25, 2011	May CAHN
---------	-----	--------------	----------

EQ 150MG BASE

N200533	003	Aug 25, 2011	May CAHN
---------	-----	--------------	----------

EQ 200MG BASE

N200533	004	Aug 25, 2011	May CAHN
---------	-----	--------------	----------

+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May CAHN
---	--	---------------	---------	-----	--------------	----------

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION

TECHNISCAN MAG3

>D>	+	MALLINCKRODT	N/A	N019882	001	Jun 15, 1990	Dec CAHN
-----	---	--------------	-----	---------	-----	--------------	----------

>A>	+	MALLINKRODT NUCLEAR	N/A	N019882	001	Jun 15, 1990	Dec CAHN
-----	---	---------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE; INJECTION

TECHNISCAN

>D>	+	MALLINCKRODT	N/A	N018321	001		Dec CAHN
-----	---	--------------	-----	---------	-----	--	----------

>A>	+	MALLINKRODT NUCLEAR	N/A	N018321	001		Dec CAHN
-----	---	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M PYROPHOSPHATE KIT

INJECTABLE; INJECTION

TECHNISCAN PYP KIT

>D>	AP	MALLINCKRODT	N/A	N017538	001		Dec CAHN
-----	----	--------------	-----	---------	-----	--	----------

>A>	AP	MALLINKRODT NUCLEAR	N/A	N017538	001		Dec CAHN
-----	----	---------------------	-----	---------	-----	--	----------

TECHNETIUM TC-99M RED BLOOD CELL KIT

INJECTABLE; INJECTION

ULTRATAG

>D>		MALLINCKRODT	N/A	N019981	001	Jun 10, 1991	Dec CAHN
-----	--	--------------	-----	---------	-----	--------------	----------

>A>		MALLINKRODT NUCLEAR	N/A	N019981	001	Jun 10, 1991	Dec CAHN
-----	--	---------------------	-----	---------	-----	--------------	----------

TECHNETIUM TC-99M SESTAMIBI KIT

INJECTABLE; INJECTION

TECHNETIUM TC-99M SESTAMIBI

>D>	AP	MALLINCKRODT	N/A	A078098	001	Sep 22, 2008	Dec CAHN
-----	----	--------------	-----	---------	-----	--------------	----------

>A>	AP	MALLINKRODT NUCLEAR	N/A	A078098	001	Sep 22, 2008	Dec CAHN
-----	----	---------------------	-----	---------	-----	--------------	----------

TEDIZOLID PHOSPHATE

POWDER; IV (INFUSION)

SIVEXTRO

+	CUBIST PHARMS LLC	200MG/VIAL	N205436	001	Jun 20, 2014	Sep CAHN
---	-------------------	------------	---------	-----	--------------	----------

TABLET; ORAL

SIVEXTRO

+	CUBIST PHARMS LLC	200MG	N205435	001	Jun 20, 2014	Sep CAHN
---	-------------------	-------	---------	-----	--------------	----------

TELAPREVIR

TABLET; ORAL

INCIVEK

@	VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan DISC
---	---------------	-------	---------	-----	--------------	----------

TELMISARTAN

TABLET; ORAL

TELMISARTAN

AB	AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug NEWA
----	---------------	------	---------	-----	--------------	----------

AB		40MG	A204415	002	Sep 08, 2015	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A204415	003	Sep 08, 2015	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug NEWA
----	----------------------	------	---------	-----	--------------	----------

AB		40MG	A206511	002	Sep 03, 2015	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A206511	003	Sep 03, 2015	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB	INVENTIA HLTHCARE	20MG	A205150	001	Oct 30, 2015	Oct NEWA
----	-------------------	------	---------	-----	--------------	----------

AB		40MG	A205150	002	Oct 30, 2015	Oct NEWA
----	--	------	---------	-----	--------------	----------

TABLET;ORAL							
TELMISARTAN							
AB		80MG	A205150	003	Oct 30, 2015	Oct	NEWA
<u>TEMAZEPAM</u>							
CAPSULE;ORAL							
TEMAZEPAM							
AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
AB		30MG	A201781	004	Jun 04, 2015	May	NEWA
<u>TEMOZOLOMIDE</u>							
CAPSULE;ORAL							
TEMOZOLOMIDE							
AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
AB		250MG	A203691	006	May 08, 2015	Apr	NEWA
<u>TENOFOVIR DISOPROXIL FUMARATE</u>							
TABLET;ORAL							
TENOFOVIR DISOPROXIL FUMARATE							
AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA
VIREAD							
AB	+ GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG
<u>TERBINAFINE</u>							
GEL;TOPICAL							
LAMISIL							
	@ GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug	CAHN
<u>TERBINAFINE HYDROCHLORIDE</u>							
SOLUTION;TOPICAL							
LAMISIL							
	@ GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug	CAHN
TABLET;ORAL							
TERBINAFINE HYDROCHLORIDE							
	@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC
<u>TERCONAZOLE</u>							
SUPPOSITORY;VAGINAL							
TERCONAZOLE							
AB	TARO	80MG	A077553	001	Mar 09, 2007	Sep	CMFD
<u>TESTOSTERONE</u>							
GEL;TRANSDERMAL							
ANDROGEL							
AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
AB1	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC
TESTIM							
AB2	+ AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC
TESTOSTERONE							
	@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
	@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
AB1	PAR PHARM	25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug	CMFD
AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug	CMFD
AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC
VOGELXO							
AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan	CTEC
GEL, METERED;TRANSDERMAL							
ANDROGEL							
AB	+ ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul	CFTG

GEL, METERED;TRANSDERMAL
FORTESTA

AB	+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG
		TESTOSTERONE					
AB		ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA
AB			12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA
AB		PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA

TETRABENAZINE

TABLET;ORAL
TETRABENAZINE

AB		SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
AB			25MG	A206129	002	Aug 17, 2015	Aug NEWA
		XENAZINE					
AB		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
			12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
AB	+		25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+		25MG	N021894	002	Aug 15, 2008	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL
ACHROMYCIN V

AB	+	HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD
		TETRACYCLINE HYDROCHLORIDE					
		@ CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Sep CAHN
		@	500MG	A062752	002	Aug 12, 1988	Sep CAHN
		@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
		@	500MG	A060704	002		Apr DISC

THALLOUS CHLORIDE TL-201

INJECTABLE;INJECTION
THALLOUS CHLORIDE TL 201

>D>	AP	+	MALLINCKRODT	1mCi/ML	N018150	001	Dec CAHN
>A>	AP	+	MALLINKRODT NUCLEAR	1mCi/ML	N018150	001	Dec CAHN
			INJECTABLE;INTRAVENOUS				
			THALLOUS CHLORIDE TL 201				
>D>		@	MALLINCKRODT	2mCi/ML	A077698	001	Nov 09, 2006
>A>		@	MALLINKRODT NUCLEAR	2mCi/ML	A077698	001	Nov 09, 2006

THEOPHYLLINE

TABLET;ORAL
THEOLAIR

		@ MEDICIS	125MG	A086399	001		Mar DISC
		@	250MG	A086399	002		Mar DISC
		TABLET, EXTENDED RELEASE;ORAL					
		THEOPHYLLINE					
AB		MYLAN PHARMS INC	400MG	A040560	003	Apr 21, 2006	Nov CMS1
AB	+		600MG	A040560	002	Apr 21, 2006	May CAHN

THIOTEPA

INJECTABLE;INJECTION
THIOTEPA

		+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD
--	--	---	--------------------	-----------	---------	-----	--------------	----------

TICAGRELOR

TABLET;ORAL
BRILINTA

		ASTRAZENECA LP	60MG	N022433	002	Sep 03, 2015	Sep NEWA
--	--	----------------	------	---------	-----	--------------	----------

TIGECYCLINE

INJECTABLE;IV (INFUSION)
TIGECYCLINE

AP		SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA
		TYGACIL					
AP	+	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG

TIMOLOL MALEATESOLUTION/DROPS;OPHTHALMIC
ISTALOL

AT2	+	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG
		TIMOLOL MALEATE					
AT1		AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
AT1			EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
AT1		ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
AT2		APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
AT1		BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
AT1		FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
AT1		HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
AT1		PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
AT1		WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC
		TIMOPTIC					
AT1	+	ATON	EQ 0.5% BASE	N018086	002		Apr CTEC

TINIDAZOLETABLET;ORAL
TINIDAZOLE

AB		EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul NEWA
AB			500MG	A203808	002	Aug 04, 2015	Jul NEWA

TIOTROPIUM BROMIDESPRAY, METERED;INHALATION
SPIRIVA RESPIMAT

		BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N021936	002	Sep 15, 2015	Sep NEWA
--	--	----------------------	-----------------------	---------	-----	--------------	----------

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINETABLET;ORAL
LONSURF

		TAIHO ONCOLOGY	EQ 6.14MG BASE;15MG	N207981	001	Sep 22, 2015	Sep NEWA
	+		EQ 8.19MG BASE;20MG	N207981	002	Sep 22, 2015	Sep NEWA

TOBRAMYCINSOLUTION;INHALATION
KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb CTEC
		TOBRAMYCIN					
AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun NEWA
		SOLUTION/DROPS;OPHTHALMIC					
		TOBREX					
AT	+	ALCON LABS INC	0.3%	N050541	001		Mar CAHN

TOBRAMYCIN SULFATEINJECTABLE;INJECTION
TOBRAMYCIN SULFATE

		@ IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar CAHN
		@	EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar CAHN
		@	EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar CAHN
		@	EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar CAHN
		TOBRAMYCIN SULFATE (PHARMACY BULK)					
	+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CTEC
AP	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul CRLD

TOLAZAMIDETABLET;ORAL
TOLAZAMIDE

		@ G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr CAHN
		@	250MG	N018894	002	Nov 02, 1984	Apr CAHN
		@	500MG	N018894	003	Nov 02, 1984	Apr CAHN

TOLCAPONETABLET;ORAL
TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar CFTG
		TOLCAPONE					
AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar NEWA

TOLMETIN SODIUM

TABLET; ORAL

TOLMETIN SODIUM

@ G AND W LABS INC

EQ 600MG BASE

A074399 001 Mar 28, 1996 May CAHN

@

EQ 600MG BASE

A074729 001 Feb 27, 1997 Apr CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE; ORAL

TOLTERODINE TARTRATE

AB TORRENT PHARMS LTD

2MG

A203016 001 Aug 11, 2015 Jul NEWA

AB

4MG

A203016 002 Aug 11, 2015 Jul NEWA

TABLET; ORAL

TOLTERODINE TARTRATE

AB IVAX SUB TEVA PHARMS

1MG

A077006 001 Feb 23, 2015 Feb NEWA

AB

2MG

A077006 002 Feb 23, 2015 Feb NEWA

AB MACLEODS PHARMS LTD

1MG

A203409 001 Aug 31, 2015 Aug NEWA

AB

2MG

A203409 002 Aug 31, 2015 Aug NEWA

TOPIRAMATE

TABLET; ORAL

TOPIRAMATE

AB SUN PHARM INDS LTD

25MG

A076327 001 Mar 27, 2009 Apr CAHN

AB

100MG

A076327 002 Mar 27, 2009 Apr CAHN

AB

200MG

A076327 003 Mar 27, 2009 Apr CAHN

@ WOCKHARDT USA

25MG

A090353 001 Sep 01, 2010 Apr DISC

@

50MG

A090353 002 Sep 01, 2010 Apr DISC

@

100MG

A090353 003 Sep 01, 2010 Apr DISC

@

200MG

A090353 004 Sep 01, 2010 Apr DISC

TOPIRAMATE

@ HIKMA PHARMS

25MG

A091185 001 Nov 25, 2013 May DISC

@

50MG

A091185 002 Nov 25, 2013 May DISC

@

100MG

A091185 003 Nov 25, 2013 May DISC

@

200MG

A091185 004 Nov 25, 2013 May DISC

TOPOTECAN HYDROCHLORIDE

CAPSULE; ORAL

HYCANTIN

NOVARTIS PHARMS CORP

EQ 0.25MG BASE

N020981 001 Oct 11, 2007 Mar CAHN

+

EQ 1MG BASE

N020981 002 Oct 11, 2007 Mar CAHN

INJECTABLE; INJECTION

HYCANTIN

AP + NOVARTIS PHARMS CORP

EQ 4MG BASE/VIAL

N020671 001 May 28, 1996 Mar CAHN

AP

TOPOTECAN HYDROCHLORIDE

AP CHEM WERTH INC

EQ 4MG BASE/VIAL

A201166 001 Aug 08, 2012 May CAHN

TORSEMIDE

INJECTABLE; INJECTION

TORSEMIDE

@ EUROHLTH INTL SARL

20MG/2ML (10MG/ML)

A078007 001 Jun 11, 2008 Jan DISC

@

50MG/5ML (10MG/ML)

A078007 002 Jun 11, 2008 Jan DISC

@ LUITPOLD

20MG/2ML (10MG/ML)

A090656 001 Apr 21, 2010 Jan DISC

@

50MG/5ML (10MG/ML)

A090656 002 Apr 21, 2010 Jan DISC

TRABECTEDIN

POWDER; IV (INFUSION)

YONDELIS

+ JANSSEN PRODS

1MG/VIAL

N207953 001 Oct 23, 2015 Oct NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB MACLEODS PHARMS LTD

50MG

A205702 001 Sep 25, 2015 Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB1 AUROBINDO PHARMA LTD

100MG

A204421 001 Oct 20, 2015 Oct NEWA

AB1

200MG

A204421 002 Oct 20, 2015 Oct NEWA

AB1

300MG

A204421 003 Oct 20, 2015 Oct NEWA

>A> AB1 MYLAN PHARMS INC

100MG

A205257 001 Dec 22, 2015 Dec NEWA

>A> AB1

200MG

A205257 002 Dec 22, 2015 Dec NEWA

>A> AB1

300MG

A205257 003 Dec 22, 2015 Dec NEWA

TRAMETINIB DIMETHYL SULFOXIDETABLET; ORAL
MEKINIST

	NOVARTIS PHARMS CORP	EQ 0.5MG	N204114	001	May 29, 2013	Nov	CPOT
		EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN
		EQ 1MG	N204114	002	May 29, 2013	Nov	CPOT
		EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN
+		EQ 2MG	N204114	003	May 29, 2013	Nov	CPOT
+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN

TRANEXAMIC ACIDINJECTABLE; INJECTION
TRANEXAMIC ACID

AP	FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD
AB	MYLAN	650MG	A205133	001	Sep 21, 2015	Sep	NEWA

TRANLYCYPROMINE SULFATETABLET; ORAL
PARNATE

AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN
----	---	----------------------	--------------	---------	-----	--------------	-----	------

TRAVOPROSTSOLUTION/DROPS; OPHTHALMIC
IZBA

	@	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul	DISC
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA

TRAZODONE HYDROCHLORIDETABLET; ORAL
DESYREL

	@	PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN
	@		100MG	N018207	002		May	CAHN
	@		150MG	N018207	003	Mar 25, 1985	May	CAHN
	@		300MG	N018207	004	Nov 07, 1988	May	CAHN

TRETINOINCREAM; TOPICAL
RENOVA

	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr	CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr	CAHN
AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr	CAHN
AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul	CTEC
AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul	NEWA

TRIAMCINOLONE ACETONIDECREAM; TOPICAL
TRIAMCINOLONE ACETONIDE

AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr	CMFD
AT			0.1%	A089798	001	May 31, 1991	Apr	CMFD
AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar	NEWA
AT			0.5%	A088042	003	Mar 25, 2015	Mar	NEWA
AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar	CMFD
AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar	CMFD
AT			0.1%	N011600	001		Mar	CMFD
AT		G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug	CMFD

OINTMENT;TOPICAL									
TRIAMCINOLONE ACETONIDE									
AT		0.1%		A089796	001	Dec 23, 1988		Aug	CMFD
SPRAY;TOPICAL									
KENALOG									
AT	+	RANBAXY	0.147MG/GM	N012104	001			Mar	CFTG
AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001			Aug	CAHN
TRIAMCINOLONE ACETONIDE									
AT		PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015		Mar	NEWA
<u>TRIAMTERENE</u>									
CAPSULE;ORAL									
DYRENIUM									
		CONCORDIA PHARMS INC	50MG	N013174	001			Apr	CAHN
	+		100MG	N013174	002			Apr	CAHN
<u>TRIMIPRAMINE MALEATE</u>									
CAPSULE;ORAL									
SURMONTIL									
AB	+	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002			Jun	CRLD
AB			EQ 100MG BASE	N016792	003	Sep 15, 1982		Jun	CRLD
<u>TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)</u>									
CREAM;VAGINAL									
VAGILIA									
		@ G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987		Jul	CAHN
<u>TRIPTORELIN PAMOATE</u>									
INJECTABLE;INTRAMUSCULAR									
TRELSTAR									
	+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000		Jan	CAHN
	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001		Jan	CAHN
	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010		Jan	CAHN
<u>TROSPIMUM CHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
TROSPIMUM CHLORIDE									
AB		ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012		Jun	CRLD
AB	+		60MG	A091289	001	Oct 12, 2012		May	CRLD
AB		SANDOZ INC	60MG	A091635	001	Apr 29, 2015		Apr	NEWA
TABLET;ORAL									
TROSPIMUM CHLORIDE									
AB		GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010		Jun	CRLD
AB	+		20MG	A091575	001	Aug 13, 2010		May	CRLD
<u>UNOPROSTONE ISOPROPYL</u>									
SOLUTION/DROPS;OPHTHALMIC									
RESCULA									
	+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000		May	CAHN
	+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000		Jan	CAHN
<u>URIDINE TRIACETATE</u>									
GRANULE;ORAL									
VISTOGARD									
>A>									
>A>	+	WELLSTAT THERAP	10GM/PACKET	N208159	001	Dec 11, 2015		Dec	NEWA
		XURIDEN							
	+	WELLSTAT THERAP	2GM/PACKET	N208169	001	Sep 04, 2015		Sep	NEWA
<u>URSODIOL</u>									
CAPSULE;ORAL									
ACTIGALL									
		@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987		Mar	CAHN
AB	+		300MG	N019594	002	Dec 31, 1987		Mar	CAHN
<u>VALACYCLOVIR HYDROCHLORIDE</u>									
TABLET;ORAL									
VALACYCLOVIR HYDROCHLORIDE									
AB		HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015		Mar	NEWA
AB			EQ 1GM BASE	A203047	002	Apr 08, 2015		Mar	NEWA
AB		SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007		Apr	CAHN
AB			EQ 1GM BASE	A076588	002	Jan 31, 2007		Apr	CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan CAHN
	CAPSULE, DELAYED RELEASE;ORAL					
	STAVZOR					
	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

>A>	AB	AMNEAL PHARMS	40MG	A204011	001	Jan 11, 2016	Dec NEWA
>A>	AB		80MG	A204011	002	Jan 11, 2016	Dec NEWA
>A>	AB		160MG	A204011	003	Jan 11, 2016	Dec NEWA
>A>	AB		320MG	A204011	004	Jan 11, 2016	Dec NEWA
>A>	AB	IVAX PHARMS	40MG	A077530	001	Jan 04, 2016	Dec NEWA
>A>	AB		80MG	A077530	002	Jan 04, 2016	Dec NEWA
>A>	AB		160MG	A077530	003	Jan 04, 2016	Dec NEWA
>A>	AB		320MG	A077530	004	Jan 04, 2016	Dec NEWA
	AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May NEWA
	AB		80MG	A204821	002	Jun 09, 2015	May NEWA
	AB		160MG	A204821	003	Jun 09, 2015	May NEWA
	AB		320MG	A204821	004	Jun 09, 2015	May NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan NEWA

INJECTABLE;INJECTION

VANCOLED

@ EUROHLTH INTL SARL EQ 500MG BASE/VIAL
 @ EQ 1GM BASE/VIAL
 @ EQ 2GM BASE/VIAL
 @ EQ 5GM BASE/VIAL
 @ EQ 10GM BASE/VIAL

A062682	001	Jul 22, 1986	Jun CAHN
A062682	002	Mar 30, 1988	Jun CAHN
A062682	003	May 11, 1988	Jun CAHN
A062682	004	May 11, 1988	Jun CAHN
A062682	005	May 11, 1988	Jun CAHN

VANCOMYCIN HYDROCHLORIDE

>A>	AP	CUSTOPHARM INC	EQ 5GM BASE/VIAL	A204125	001	Dec 28, 2015	Dec NEWA
>A>	AP		EQ 10GM BASE/VIAL	A204125	002	Dec 28, 2015	Dec NEWA
>A>	AP		EQ 500MG BASE/VIAL	A204107	001	Dec 28, 2015	Dec NEWA
>A>	AP		EQ 1GM BASE/VIAL	A204107	002	Dec 28, 2015	Dec NEWA
>A>	AP	TEVA PHARMS USA	EQ 500MG BASE/VIAL	A201251	001	Dec 23, 2015	Dec NEWA
>A>	AP		EQ 1GM BASE/VIAL	A201251	002	Dec 23, 2015	Dec NEWA
>A>	AP		EQ 5GM BASE/VIAL	A201250	001	Dec 23, 2015	Dec NEWA
>A>	AP		EQ 10GM BASE/VIAL	A201250	002	Dec 23, 2015	Dec NEWA
	AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug NEWA
	AP		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug NEWA
>A>	AP		EQ 5GM BASE/VIAL	A206243	001	Dec 23, 2015	Dec NEWA
>A>	AP		EQ 10GM BASE/VIAL	A206243	002	Dec 23, 2015	Dec NEWA

POWDER;IV (INFUSION)

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

>A>	SAMSON MEDCL	EQ 100GM BASE	A091532	001	Jan 06, 2016	Dec NEWA
-----	--------------	---------------	---------	-----	--------------	----------

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+ BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG
	VARDENAFIL HYDROCHLORIDE					
AB	WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB	YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
----	------------------	--------------	---------	-----	--------------	----------

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB		EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB		EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB		EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB	RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB		180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB		240MG	N019614	002	May 29, 1990	Apr CAHN
	+	360MG	N019614	004	May 10, 1996	Apr CAHN
	VERELAN PM					
AB	RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB		200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+	300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

CALAN

@ EXELA PHARMA SCS LLC 2.5MG/ML

N018925 001 Mar 30, 1984 Aug CAHN

ISOPTIN

@ MT ADAMS 2.5MG/ML

N018485 001 Apr CAHN

TABLET;ORAL

ISOPTIN

@ MT ADAMS 40MG

N018593 003 Nov 23, 1987 Apr CAHN

@ 80MG

N018593 001 Mar 08, 1982 Apr CAHN

@ 120MG

N018593 002 Mar 08, 1982 Apr CAHN

VERAPAMIL HYDROCHLORIDE

AB	HERITAGE PHARMS INC	40MG	A071881	002	Oct 14, 2015	Oct NEWA
----	---------------------	------	---------	-----	--------------	----------

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN
--	---	--------------------	-----------	---------	-----	--------------	----------

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
			20MG	N022567	002	Jan 21, 2011	Mar CAHN
			40MG	N022567	003	Jan 21, 2011	Mar CAHN

VINORELBINE

INJECTABLE;INJECTION

VINORELBINE

>D>							
>D>	AP	MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Dec CTNA

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

	AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Sep CAHN
>A>	AP	MYLAN LABS LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Dec CTNA

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug NEWA
AB		200MG	A203503	002	Sep 02, 2015	Aug NEWA

XENON XE-133

GAS; INHALATION

XENON XE 133

>D>	@	MALLINCKRODT	10mCi/VIAL	N018327	001	Mar 09, 1982	Dec CAHN
>D>	@		20mCi/VIAL	N018327	002	Mar 09, 1982	Dec CAHN
>A>	@	MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982	Dec CAHN
>A>	@		20mCi/VIAL	N018327	002	Mar 09, 1982	Dec CAHN

ZAFIRLUKASTTABLET; ORAL
ACCOLATE

AB	PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+	20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZIPRASIDONE HYDROCHLORIDE>D> SUSPENSION; ORAL
>D> GEODON

>D>	+	PFIZER INC	EQ 10MG BASE/ML	N021483	001	Mar 29, 2006	Dec DISC
>A>	@		EQ 10MG BASE/ML	N021483	001	Mar 29, 2006	Dec DISC

ZOLEDRONIC ACIDINJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

>A>	AP	APOTEX INC	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Dec NEWA
	AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr NEWA
	AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar NEWA
	AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul CAHN
	AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar CPOT
>A>		SOLUTION; IV (INFUSION)					
>A>		ZOLEDRONIC ACID					
>A>		HOSPIRA INC	EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML)	N204016	001	Dec 28, 2015	Dec NEWA

ZOLMITRIPTANTABLET; ORAL
ZOLMITRIPTAN

AB	ALEMBIC PHARMS LTD	2.5MG	A204232	001	Sep 30, 2015	Sep NEWA
AB		5MG	A204232	002	Sep 30, 2015	Sep NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A203772	001	Sep 30, 2015	Sep NEWA
AB		5MG	A203772	002	Sep 30, 2015	Sep NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
ZOLMITRIPTAN

AB	JUBILANT GENERICS	2.5MG	A202956	001	Sep 17, 2015	Sep NEWA
AB		5MG	A202956	002	Sep 17, 2015	Sep NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A204336	001	Oct 22, 2015	Oct NEWA
AB		5MG	A204336	002	Oct 22, 2015	Oct NEWA

ZOLPIDEM TARTRATESPRAY, METERED; ORAL
ZOLPIMIST

+	AMHERST PHARMS LLC	5MG/SPRAY	N022196	001	Dec 19, 2008	Sep CAHN
---	--------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

ZOLPIDEM TARTRATE

	@	HIKMA	5MG	A078129	001	Apr 30, 2008	Mar DISC
	@		10MG	A078129	002	Apr 30, 2008	Mar DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr CAHN	
AB		10MG	A078055	002	Apr 23, 2007	Apr CAHN	

TABLET; SUBLINGUAL
INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May CFTG

ZOLPIDEM TARTRATE

AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May NEWA

ZONISAMIDECAPSULE; ORAL
ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

@ J AND J CONSUMER INC 120MG

N017756 002

Aug CAHN

@ 650MG

N017756 001

Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

SUN PHARM INDS LTD 650MG

A078569 001

Dec 14, 2011

Apr CAHN

@ 650MG

A090205 001

Nov 18, 2009

Apr CAHN

TYLENOL

+ J AND J CONSUMER INC 650MG

N019872 001

Jun 08, 1994

Aug CAHN

+ 650MG

N019872 002

Jan 11, 2001

Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

+ BAYER HEALTHCARE LLC 3%;7.5%;3%

N020045 001

Dec 07, 1992

Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+ ASTRAZENECA PHARMS 0.032MG/SPRAY

N020746 003

Mar 23, 2015

Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

+ BAYER HEALTHCARE LLC 1%

N021307 001

Dec 07, 2001

Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

+ J AND J CONSUMER INC 800MG;10MG;165MG

N020958 001

Oct 16, 2000

Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BANNER LIFE SCIENCES 5MG

N022429 001

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 004

Jul 23, 2009

Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BANNER LIFE SCIENCES 5MG

N022429 003

Jul 23, 2009

Jan CAHN

+ 10MG

N022429 002

Jul 23, 2009

Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

+ J AND J CONSUMER INC 5MG/5ML

N022155 002

Nov 16, 2007

Aug CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

+ J AND J CONSUMER INC 5MG/5ML

N022155 001

Nov 16, 2007

Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA LTD 5MG

A090760 001

Aug 05, 2015

Jul NEWA

10MG

A090760 003

Aug 05, 2015

Jul NEWA

SUN PHARM INDS LTD 5MG

A077498 001

Dec 27, 2007

Apr CAHN

10MG

A077498 002

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

SUN PHARM INDS LTD 5MG

A077498 003

Dec 27, 2007

Apr CAHN

10MG

A077498 004

Dec 27, 2007

Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

AUROBINDO PHARMA LTD 5MG

A090760 002

Aug 05, 2015

Jul NEWA

10MG

A090760 004

Aug 05, 2015

Jul NEWA

ZYRTEC ALLERGY

J AND J CONSUMER INC 5MG

N019835 003

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 004

Nov 16, 2007

Aug CAHN

ZYRTEC HIVES RELIEF

J AND J CONSUMER INC 5MG

N019835 005

Nov 16, 2007

Aug CAHN

+ 10MG

N019835 006

Nov 16, 2007

Aug CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

JUBILANT GENERICS 5MG

A091116 001

Feb 19, 2015

Feb NEWA

10MG

A091116 002

Feb 19, 2015

Feb NEWA

SANDOZ 5MG

A078692 001

Feb 14, 2008

Feb CTNA

TABLET, CHEWABLE;ORAL				
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY				
+	10MG	A078692	002	Feb 14, 2008 Feb CTNA
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF				
	JUBILANT GENERICS 5MG	A091116	003	Feb 19, 2015 Feb NEWA
	10MG	A091116	004	Feb 19, 2015 Feb NEWA
CHILDREN'S ZYRTEC ALLERGY				
@	J AND J CONSUMER INC 5MG	N021621	003	Nov 16, 2007 Aug CAHN
@	10MG	N021621	004	Nov 16, 2007 Aug CAHN
CHILDREN'S ZYRTEC HIVES RELIEF				
@	J AND J CONSUMER INC 5MG	N021621	005	Nov 16, 2007 Aug CAHN
@	10MG	N021621	006	Nov 16, 2007 Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL				
CETIRIZINE HYDROCHLORIDE ALLERGY				
	PAR PHARM INC 10MG	A205490	001	Sep 02, 2015 Aug NEWA
ZYRTEC ALLERGY				
+	J AND J CONSUMER INC 10MG	N022578	001	Sep 03, 2010 Aug CAHN
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>				
TABLET, EXTENDED RELEASE;ORAL				
ZYRTEC-D 12 HOUR				
+	J AND J CONSUMER INC 5MG;120MG	N021150	002	Nov 09, 2007 Aug CAHN
<u>CHLORPHENIRAMINE MALEATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
@	BAYER HEALTHCARE LLC 8MG	N007638	001	Mar CAHN
+	12MG	N007638	002	Mar CAHN
<u>CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE</u>				
TABLET, EXTENDED RELEASE;ORAL				
CHLOR-TRIMETON				
+	BAYER HEALTHCARE LLC 8MG;120MG	N018397	001	Mar CAHN
<u>CLEMASTINE FUMARATE</u>				
TABLET;ORAL				
CLEMASTINE FUMARATE				
@	ANI PHARMS INC 1.34MG	A073282	002	Dec 03, 1992 Jul CAHN
<u>CLOTTRIMAZOLE</u>				
CREAM;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 1%	N018052	002	Nov 30, 1990 Mar CAHN
GYNE-LOTRIMIN 3				
+	BAYER HEALTHCARE LLC 2%	N020574	001	Nov 24, 1998 Mar CAHN
CREAM, TABLET;TOPICAL, VAGINAL				
GYNE-LOTRIMIN COMBINATION PACK				
+	BAYER HEALTHCARE LLC 1%,100MG	N020289	002	Apr 26, 1993 Mar CAHN
TABLET;VAGINAL				
GYNE-LOTRIMIN				
+	BAYER HEALTHCARE LLC 100MG	N017717	002	Nov 30, 1990 Mar CAHN
<u>DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN</u>				
TABLET, EXTENDED RELEASE;ORAL				
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE				
	ACTAVIS LABS FL INC 30MG;600MG	A091070	001	Aug 31, 2015 Aug NEWA
	60MG;1.2GM	A091070	002	Aug 31, 2015 Aug NEWA
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN</u>				
CAPSULE;ORAL				
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE				
	BANNER LIFE SCIENCES 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010 Jan CAHN
<u>ESOMEPRAZOLE MAGNESIUM</u>				
TABLET, DELAYED RELEASE;ORAL				
NEXIUM 24HR				
+	ASTRAZENECA LP EQ 20MG BASE	N207920	01	Nov 23, 2015 Nov NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr CAHN
	20MG	A090283	002	Nov 17, 2009	Apr CAHN
PEPCID AC					
J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995	Jul CAHN
+	20MG	N020325	002	Sep 23, 2003	Jul CAHN
PEPCID AC					
J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999	Aug CAHN
TABLET, CHEWABLE; ORAL					
PEPCID AC					
@ J AND J CONSUMER INC	10MG	N020801	001	Sep 24, 1998	Aug CAHN
+	20MG	N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug NEWA
	180MG	A204507	003	Sep 16, 2015	Aug NEWA
FEXOFENADINE HYDROCHLORIDE HIVES					
SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug NEWA
	180MG	A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG; 120MG	A090818	001	Jan 29, 2015	Jan NEWA
-------------------	-------------	---------	-----	--------------	----------

GUAIFENESIN

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN

ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug NEWA
---------------------	-------	---------	-----	--------------	----------

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG; 60MG	A091071	001	May 27, 2015	May NEWA
	1.2GM; 120MG	A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN
----------------------	---------------------------------------	---------	-----	--------------	----------

MIDOL LIQUID GELS

+	BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan CAHN
---	----------------------	-------	---------	-----	--------------	----------

SUSPENSION; ORAL

CHILDREN'S MOTRIN

+	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995	Aug CAHN
---	----------------------	-----------	---------	-----	--------------	----------

SUSPENSION/DROPS; ORAL

CHILDREN'S MOTRIN

+	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996	Aug CAHN
---	----------------------	---------	---------	-----	--------------	----------

TABLET; ORAL

IBUPROFEN

@ ANI PHARMS INC	200MG	A071144	001	Jan 20, 1987	Oct CAHN
@	200MG	A072901	001	Dec 19, 1991	Aug CAHN
@	200MG	A072903	001	Dec 19, 1991	Aug CAHN

JUNIOR STRENGTH MOTRIN

J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug CAHN
----------------------	-------	---------	-----	--------------	----------

MOTRIN IB

+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	Aug CAHN
---	----------------------	-------	---------	-----	--------------	----------

MOTRIN MIGRAINE PAIN

>D>	+	J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000	Dec DISC
-----	---	----------------------	-------	---------	-----	--------------	----------

>A>	@	200MG	N019012	004	Feb 25, 2000	Dec DISC
-----	---	-------	---------	-----	--------------	----------

+		200MG	N019012	004	Feb 25, 2000	Aug CAHN
---	--	-------	---------	-----	--------------	----------

NUPRIN

@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug CAHN
------------------------	-------	---------	-----	--------------	----------

@	200MG	N019012	002	Jul 29, 1987	Aug CAHN
---	-------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL
CHILDREN'S MOTRIN

J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug CAHN
JUNIOR STRENGTH MOTRIN					
+ J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Aug CAHN

IBUPROFEN SODIUM

TABLET;ORAL

IBUPROFEN SODIUM

PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015	Jul NEWA
-----------------	---------------	---------	-----	--------------	----------

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S MOTRIN COLD

+ J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug CAHN
------------------------	--------------------	---------	-----	--------------	----------

TABLET;ORAL

SINE-AID IB

J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992	Aug CAHN
----------------------	------------	---------	-----	--------------	----------

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

ALAWAY

BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb NEWA
-----------------	----------------	---------	-----	--------------	----------

LANSOPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
LANSOPRAZOLE

>A> NATCO PHARMA LTD	15MG	A203306	001	Jan 13, 2016	Dec NEWA
----------------------	------	---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

ATHENTIA NEXT

AUROBINDO PHARMA LTD	1.5MG	A206867	001	Dec 08, 2015	Nov NEWA
----------------------	-------	---------	-----	--------------	----------

LEVONORGESTREL

LOTUS PHARM CO LTD	1.5MG	A202246	001	Jun 05, 2015	May NEWA
--------------------	-------	---------	-----	--------------	----------

OC PHARMA	1.5MG	A202380	001	May 29, 2015	May NEWA
-----------	-------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan CAHN
----------------------	-----	---------	-----	--------------	----------

+	2MG	N021855	002	Aug 04, 2005	Jan CAHN
---	-----	---------	-----	--------------	----------

SOLUTION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988	Aug CAHN
------------------------	---------	---------	-----	--------------	----------

SUSPENSION;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug CAHN
------------------------	-----------	---------	-----	--------------	----------

TABLET;ORAL

IMODIUM A-D

+ J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989	Aug CAHN
------------------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE

AUROBINDO PHARMA LTD	2MG	A206548	001	Dec 15, 2015	Nov NEWA
----------------------	-----	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

IMODIUM A-D EZ CHEWS

+ J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Aug CAHN
------------------------	-----	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000	Aug CAHN
------------------------	-----------	---------	-----	--------------	----------

LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	Apr CAHN
--------------------	-----------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

IMODIUM MULTI-SYMPTOM RELIEF

+ J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Aug CAHN
------------------------	-----------	---------	-----	--------------	----------

LORATADINE

CAPSULE;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 10MG	N021952	001	Jun 16, 2008	Mar	CAHN
-----------------------------	---------	-----	--------------	-----	------

SYRUP;ORAL

CLARITIN

+ BAYER HEALTHCARE LLC 1MG/ML	N020641	002	Nov 27, 2002	Mar	CAHN
-------------------------------	---------	-----	--------------	-----	------

CLARITIN HIVES RELIEF

@ BAYER HEALTHCARE LLC 1MG/ML	N020641	003	Nov 19, 2003	Mar	CAHN
-------------------------------	---------	-----	--------------	-----	------

LORATADINE

TARO

1MG/ML

A201865	001	Jul 31, 2015	Jul	NEWA
---------	-----	--------------	-----	------

TABLET;ORAL

LORATADINE

SUN PHARM INDS LTD

10MG

A076134	001	Aug 18, 2003	Apr	CAHN
---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

CHILDREN'S CLARITIN

+ BAYER HEALTHCARE LLC 5MG	N021891	001	Aug 23, 2006	Mar	CAHN
----------------------------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN REDITABS

+ BAYER HEALTHCARE LLC 5MG	N021993	001	Dec 12, 2006	Mar	CAHN
----------------------------	---------	-----	--------------	-----	------

LORATADINE REDIDOSE

SUN PHARM INDS LTD

10MG

A077153	001	Apr 11, 2007	Apr	CAHN
---------	-----	--------------	-----	------

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

CLARITIN-D

+ BAYER HEALTHCARE LLC 5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN
----------------------------------	---------	-----	--------------	-----	------

CLARITIN-D 24 HOUR

+ BAYER HEALTHCARE LLC 10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN
-----------------------------------	---------	-----	--------------	-----	------

LORATADINE AND PSEUDOEPHEDRINE SULFATE

SUN PHARM INDS LTD

10MG;240MG

A076557	001	Sep 22, 2004	Apr	CAHN
---------	-----	--------------	-----	------

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BANNER LIFE SCIENCES EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN
--------------------------------------	---------	-----	--------------	-----	------

TABLET;ORAL

NAPROXEN SODIUM

SUN PHARM INDS LTD

EQ 200MG BASE

A091183	001	May 20, 2011	Apr	CAHN
---------	-----	--------------	-----	------

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

@ IVAX SUB TEVA PHARMS EQ 2MG BASE

A076880	001	Feb 18, 2009	Mar	DISC
---------	-----	--------------	-----	------

@ EQ 4MG BASE

A077850	001	Feb 18, 2009	Mar	DISC
---------	-----	--------------	-----	------

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE MAGNESIUM

PERRIGO R AND D

EQ 20MG BASE

A204152	001	Jul 30, 2015	Jul	NEWA
---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN
-----------------------------------	---------	-----	--------------	-----	------

FOR SUSPENSION;ORAL

ZEGERID OTC

+ BAYER HEALTHCARE LLC 20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN
--	---------	-----	--------------	-----	------

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

BAYER HEALTHCARE LLC

0.025%

N018471	001	May 30, 1986	Mar	CAHN
---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350FOR SOLUTION;ORAL
MIRALAX

+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar CAHN
	POLYETHYLENE GLYCOL 3350					
	ANI PHARMS INC	17GM/SCOOPFUL	A202850	001	Dec 15, 2015	Nov NEWA
	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan CAHN

PSEUDOEPHEDRINE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
PSEUDOEPHEDRINE HYDROCHLORIDE
SUN PHARM INDS LTD 120MG
SUDAFED 24 HOUR

+	J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992	Aug CAHN
---	----------------------	-------	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDETABLET;ORAL
RANITIDINE HYDROCHLORIDE
@ SUN PHARM INDS LTD EQ 75MG BASE
@ WOCKHARDT EQ 75MG BASE

A075132	001	Jan 14, 2000	Apr CAHN
A078884	001	Jul 31, 2008	Jan DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2015

NO DECEMBER 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020977 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE - ZIAGEN</u>						
N 020978 001					D-147	Mar 23, 2018
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	6417191	Mar 28, 2016	DP U-1572			
	6417191*PED	Sep 28, 2016				
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>						
N 021652 001	6417191	Mar 28, 2016	DP U-257			
	6417191*PED	Sep 28, 2016				
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	8980319	Dec 21, 2030	DP			
	8992975	May 16, 2032	DP			
	9050335	May 16, 2032	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9056100	Jul 07, 2020	DP U-1263			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	7223387	Jul 24, 2021	DP U-1006			
	7223387	Jul 24, 2021	DP U-1484			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8936800	Dec 23, 2022	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
	8703820	Mar 12, 2023	U-1078			
	8729127	Mar 12, 2023	U-1078			
	8785420	Dec 23, 2022	U-1078			
	8909305	Dec 23, 2022	U-1078			
	8936800	Dec 23, 2022	DP U-1078			
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
	6701917	Jun 23, 2021	DP			
	6718972	Jun 23, 2021	DP			
	6748947	Jun 23, 2021	DP			
	6871646	Jun 23, 2021	DP			
	7540282	May 06, 2023	DP			
	8006690	Jun 23, 2021	DP			
	8651103	Mar 26, 2028	DP			
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	8664215	Dec 23, 2027	U-1493			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	>A> 9126931	May 29, 2031	DS		>A> NCE	Dec 11, 2020
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jun 04, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jun 04, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8946262	Feb 12, 2030	U-1655			
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 001	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
<u>AMBRISENTAN - LETAIRIS</u>						
N 022081 002	8377933	Dec 11, 2027	U-1754		I-716	Oct 02, 2018
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 001	>A> 6696481	Apr 15, 2023	DS DP U-3			
	>A> 7846961	Oct 05, 2029	DS DP U-3			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 002	>A> 6696481	Apr 15, 2023	DS DP U-3			
	>A> 7846961	Oct 05, 2029	DS DP U-3			
<u>AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA</u>						
N 205003 003	>A> 6696481	Apr 15, 2023	DS DP U-3			
	>A> 7846961	Oct 05, 2029	DS DP U-3			
<u>AMOXICILLIN - MOXATAG</u>						
N 050813 001	8778924	Dec 08, 2026	DS DP U-897			
<u>AMPHETAMINE - DYANA VEL XR</u>						
N 208147 001	8062667	Mar 29, 2029	DP		NP	Oct 19, 2018
	8597684	Mar 15, 2027	DP			
	8747902	Mar 15, 2027	DP			
	8883217	Mar 15, 2027	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	6967208	Feb 03, 2023	DS DP U-1167			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			
	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
	6967208	Feb 03, 2023	DS DP U-1501			
	6967208	Feb 03, 2023	DS DP U-1502			
	6967208	Feb 03, 2023	DS DP U-1729			
	6967208	Feb 03, 2023	DS DP U-1730			
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6413980	Dec 22, 2019	DS DP U-1200			
	6413980	Dec 22, 2019	DS DP U-1301			
	6413980	Dec 22, 2019	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1200			
	6967208	Feb 03, 2023	DS DP U-1301			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	6967208	Feb 03, 2023	DS DP U-1302			
	6967208	Feb 03, 2023	DS DP U-1323			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9018243	Mar 19, 2023	U-1505			
	9018243	Mar 19, 2023	U-1595			
<u>APREPITANT - EMEND</u>						
N 021549 001	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 002	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 021549 003	6096742	Jul 01, 2018	DS DP U-745		NPP	Aug 28, 2018
	6096742	Jul 01, 2018	DS DP U-1743			
	6096742	Jul 01, 2018	DS DP U-1744			
	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1743			
<u>APREPITANT - EMEND</u>						
N 207865 001					>A> NPP	Aug 28, 2018
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-761			
	5006528*PED	Apr 20, 2015				
	6977257	Apr 24, 2022	DP			
	6977257*PED	Oct 24, 2022				
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
	9125939	Jul 28, 2026	U-1749			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005					ODE	Dec 12, 2021
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021866 001	5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
	5006528	Oct 20, 2014	DS DP U-763			
	5006528*PED	Apr 20, 2015				
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Oct 20, 2014	DS DP U-543			
	5006528	Oct 20, 2014	DS DP U-1632			
	5006528*PED	Apr 20, 2015				
	8030313	Oct 19, 2024	U-543			
	8030313	Oct 19, 2024	U-1632			
	8338427	Mar 15, 2025	DP U-543			
	8338427	Mar 15, 2025	DP U-1633			
	8338428	Aug 06, 2023	DP U-543			
	8338428	Aug 06, 2023	DP U-1633			
	8399469	Jun 29, 2025	DS			
	8759351	Aug 06, 2023	DP U-1530			
	8759351	Aug 06, 2023	DP U-1633			
	8993761	Sep 25, 2022	DS			
	9089567	Jan 28, 2022	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	8431576	Oct 26, 2030	DS		NCE	Oct 05, 2020
	8796276	Jun 24, 2030	U-543			
	9034867	Nov 07, 2032	DP U-543			
	9193685	Oct 24, 2033	DP U-543			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
	5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
	7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
	7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
	8022228	Apr 06, 2026	DS DP			
	8022228*PED	Oct 06, 2026				
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9101637	Mar 23, 2022	U-1731			
	9101637	Mar 23, 2022	U-1732			
	9101637	Mar 23, 2022	U-1733			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 002	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 003	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 021567 004	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	5849911*PED	Dec 20, 2017			NPP	Sep 24, 2018
	6087383	Dec 21, 2018	DS DP		PED	Dec 02, 2017
	6087383*PED	Jun 21, 2019			PED	Mar 24, 2019
<u>ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ</u>						
N 206353 001	5849911	Jun 20, 2017	DS DP U-167			
	5849911*PED	Dec 20, 2017				
	6087383	Dec 21, 2018	DS DP			
	6087383*PED	Jun 21, 2019				
	8148374	Sep 03, 2029	DS DP U-1279			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Feb 24, 2022	DS DP U-282			
	7612087	Nov 12, 2026	DP			
	8178554	Jul 24, 2021	DS DP U-282			
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
	7700076	Sep 18, 2027	DP			
	8435498	Mar 01, 2024	U-1727			
	8722021	Oct 24, 2023	DP			
	8900554	Oct 24, 2023	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	>A> 9211259	Jan 26, 2029	U-1796			
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 001					NPP	Feb 20, 2018
					NPP	Feb 20, 2018
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO</u>						
N 022203 002	8071073	Jun 04, 2028	DP		M-129	Aug 30, 2016
	8518919	Nov 22, 2025	U-1430		NPP	Aug 30, 2016
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
	8163723	Aug 29, 2023	U-81			
	8163723	Aug 29, 2023	U-644			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-1667			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 001	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL - EDARBI</u>						
N 200796 002	9066936	Mar 26, 2028	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9066936	Mar 26, 2028	DP			
	9169238	Feb 25, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9066936	Mar 26, 2028	DP			
	9169238	Feb 25, 2030	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	>A> 8609707	Aug 11, 2031	DP U-1542			
	>A> 8791270	Jan 12, 2026	DP U-1790			
	>A> 8791270*PED	Jul 12, 2026				
	>A> 9000021	Mar 15, 2033	U-1542			
	>A> 9034908	Mar 15, 2033	U-1542			
	>A> 9144568	Mar 15, 2033	U-1542			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8895070	Jun 03, 2029	U-124			
	9078870	Jun 03, 2029	DP			
<u>BESIFLOXACIN HYDROCHLORIDE - BESIVANCE</u>						
N 022308 001	8937062	Nov 13, 2029	U-80			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR</u>						
N 207589 001	6753013	Jan 27, 2020	DP U-1761		NP	Oct 16, 2018
	9119781	Jun 10, 2031	DP U-1761			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001	6753013	Jan 27, 2020	DP U-88			
	6753013	Jan 27, 2020	DP U-193			
	6753013	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-88			
	6787529	Jan 27, 2020	DP U-193			
	6787529	Jan 27, 2020	DP U-1761			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 002	6753013	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-1761			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 002	6753013	Jan 27, 2020	DP U-1761			
	6787529	Jan 27, 2020	DP U-1761			
<u>BEXAROTENE - TARGRETIN</u>						
N 021055 001					M-164	Jul 29, 2018
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8933120	Mar 16, 2025	DP			
	8933127	Mar 16, 2025	DP			
	9155716	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	7351404	May 25, 2024	U-939	Y		
	7388029	Jan 21, 2022	U-938	Y		
	8541466	Jan 31, 2021	U-1217			
	8986715	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	5780454*PED	Nov 03, 2017			D-142	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
	6713446*PED	Jul 25, 2022			M-139	Aug 08, 2017
	6958319	Jan 25, 2022	DS DP		M-165	Sep 14, 2018
	6958319*PED	Jul 25, 2022			ODE	Oct 08, 2021
					PED	Feb 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Apr 08, 2018
					PED	Mar 14, 2019
					PED	Apr 08, 2022
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
	8349840	Apr 12, 2026	DP U-1529			
	8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA</u>						
N 204251 001	9044484	Oct 30, 2030	DP			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	9144609	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8877708	Jun 07, 2030	DP U-1706			
<u>BUDESONIDE - BUDESONIDE</u>						
A 201966 001					PC	Jan 23, 2016
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9132093	Sep 07, 2031	DP			
	9192581	Sep 07, 2031	DP U-1325			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001	5914122	Dec 19, 2015	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002 >A>	9205052	Sep 18, 2018	U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 001	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 002	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 003	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 004	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 005	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 006	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE - BELBUCA</u>						
N 207932 007	6159498	Oct 18, 2016	DP		NP	Oct 23, 2018
	7579019	Jan 22, 2020	U-1769			
	8147866	Jul 23, 2027	DP U-1769			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	8470361	May 22, 2030	DP U-1425		I-713	Aug 10, 2018
	8940330	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	8454996	Sep 24, 2019	U-1421		I-713	Aug 10, 2018
	8470361	May 22, 2030	DP U-1425			
	8658198	Dec 03, 2027	DP U-1494			
	8940330	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	8916195	Feb 02, 2030	U-1639			
	9107837	Jun 04, 2027	U-1639			
	9125868	Nov 08, 2027	U-1585			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8629128	May 26, 2026	DP U-1280			
	8629128	May 26, 2026	DP U-1767			
<u>CALCIUM ACETATE - PHOSLO GELCAPS</u>						
N 021160 003	6875445	Jul 30, 2021	DP			
<u>CALCIUM ACETATE - PHOSLYRA</u>						
N 022581 001	9089528	Jul 20, 2027	U-1469			
<u>CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPICID COMPLETE</u>						
N 020958 001	5989588	Sep 30, 2017	DP U-349			
	5989588*PED	Mar 30, 2018				
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER</u>						
N 207026 001					ODE	Jan 13, 2022
<u>CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER</u>						
N 207026 002					ODE	Jan 13, 2022
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 001	7094427	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - RYTARY</u>						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
<u>CARBIDOPA; LEVODOPA - DUOPA</u>						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001					I-712	Jul 24, 2018
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 001	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 002	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 003	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CARIPRAZINE HYDROCHLORIDE - VRAYLAR</u>						
N 204370 004	7737142	Mar 27, 2027	DS DP U-1750		NCE	Sep 17, 2020
	7943621	Dec 16, 2028	DS DP			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
<u>CELECOXIB - CELECOXIB</u>						
A 076898 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 076898 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 078857 004					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 002					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 003					PC	Jun 02, 2015
<u>CELECOXIB - CELECOXIB</u>						
A 200562 004					PC	Jun 02, 2015
<u>CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE</u>						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
	9107921	Jan 03, 2032	DP			
<u>CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR</u>						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					ODE	Mar 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					ODE	Mar 17, 2022
<u>CICLESONIDE - ALVESCO</u>						
N 021658 002	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - ALVESCO</u>						
N 021658 003	8371292	Feb 01, 2028	U-1355			
<u>CICLESONIDE - OMNARIS</u>						
N 022004 001	8371292	Feb 01, 2028	U-1356			
<u>CICLESONIDE - ZETONNA</u>						
N 202129 001	8371292	Feb 01, 2028	U-1357			
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	>A> 8318817	Apr 27, 2030	U-1792			
	>A> 9205048	Apr 21, 2029	U-1793			
	>A> 9220796	Jul 01, 2035	DP			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9149486	Sep 13, 2022	DP U-1578			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A 090898 001					PC	Jul 01, 2015
<u>CLOBETASOL PROPIONATE - OLUX E</u>						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
<u>COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX</u>						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2017				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7635704	Oct 26, 2026	DS DP U-257			
	7800788	Feb 02, 2022	U-257			
	8148374	Sep 03, 2029	DS DP U-1279			
	8633219	Apr 24, 2030	DP U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2017				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7635704	Oct 26, 2026	DS DP U-257			
	7800788	Feb 02, 2022	U-257			
	8148374	Sep 03, 2029	DS DP U-1279			
	8633219	Apr 24, 2030	DP U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	8981103	Oct 26, 2026	DS DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Apr 24, 2030	DP U-257		I-704	Dec 17, 2017
	8981103	Oct 26, 2026	DS DP			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	7803839	Feb 01, 2027	DS DP		NCE	Nov 10, 2020
	8362002	Oct 05, 2026	U-1776			
<u>COLCHICINE - MITIGARE</u>						
N 204820 001	8927607	Aug 22, 2033	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	7230098	Aug 26, 2025	DS		M-163	Sep 14, 2018
<u>CROFELEMER - FULYZAO</u>						
N 202292 001	8962680	Oct 31, 2031	U-1319			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	9192590	Jan 26, 2027	U-1399		>A> ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9173851	Jun 17, 2034	DP		NPP	Aug 14, 2018
	9192590	Jan 26, 2027	U-1399		>A> ODE	Aug 14, 2022
	9198882	Jan 26, 2027	U-1399			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	9034822	Jan 20, 2031	U-1759		M-168	Nov 20, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	9034822	Jan 20, 2031	U-1759		M-168	Nov 20, 2018
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Feb 18, 2018	DS DP U-1089		NS	Nov 20, 2018
	7866474	Aug 31, 2027	DP			
	7932273	Sep 07, 2025	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	9034822	Jan 20, 2031	U-1759			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	8703781	Oct 15, 2030	DS DP U-1713			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	8703781	Oct 15, 2030	DS DP U-1713			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002	8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
	8629171	Jun 13, 2031	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1724			
	8642025	Aug 11, 2027	DS DP U-1725			
	8900566	Aug 08, 2027	U-1724			
	8900566	Aug 08, 2027	U-1725			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001					ODE	Jul 22, 2021
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 001 >A>	9198925	Oct 04, 2020	U-493		M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL - FARXIGA</u>						
N 202293 002 >A>	9198925	Oct 04, 2020	U-493		M-157	Mar 11, 2018
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001 >A>	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002 >A>	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003 >A>	9198925	Oct 04, 2020	U-493			
<u>DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004 >A>	9198925	Oct 04, 2020	U-493			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	6037157	Jun 26, 2016	U-1635			
	6703403	Jun 26, 2016	U-1635			
	7148359	Jul 19, 2019	DP			
	7364752	Nov 10, 2020	DP			
	8188104	May 17, 2029	DS DP U-1636			
	8268349	Aug 25, 2024	DP			
	8399015	Aug 25, 2024	DP			
	8420596	Apr 10, 2031	DS DP			
	8466159	Sep 04, 2032	U-1637			
	8492386	Sep 04, 2032	U-1637			
	8501238	Sep 17, 2028	DS DP U-1636			
	8642538	Sep 10, 2029	DS DP U-1638			
	8680106	Sep 04, 2032	U-1637			
	8685984	Sep 04, 2032	U-1637			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
	9139536	Nov 09, 2028	U-1753			
<u>DEFERASIROX - EXJADE</u>						
N 021882 001					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 002					ODE	Jan 23, 2020
<u>DEFERASIROX - EXJADE</u>						
N 021882 003					ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERASIROX - JADENU</u>						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS	U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 021825 001	7049328	Jun 28, 2021		U-735		
<u>DEFERIPRONE - FERRIPROX</u>						
N 208030 001	7049328	Jun 28, 2021		U-735	NCE	Oct 14, 2016
	8703156	Oct 29, 2029	DP	U-735	ODE	Oct 14, 2016
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	7622130	Dec 10, 2027		U-1690		
	7754230	Dec 10, 2027		U-1690		
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025		U-1690		
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP	U-1690		
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025		U-1690		
	8883770	Feb 21, 2028	DP			
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 001					PC	May 16, 2015
<u>DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE</u>						
A 200653 002					PC	May 16, 2015
<u>DESONIDE - VERDESO</u>						
N 021978 001	8962000	Aug 31, 2025	DP	U-1412		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 003	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
	8269040	Jul 05, 2027	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
>A>	9192511	Jan 09, 2023	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				
	8648106	Jan 04, 2032	DP			
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					PC	Aug 01, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					PC	Dec 19, 2015
<u>DICHLORPHENAMIDE - KEVEYIS</u>						
N 011366 002					ODE	Aug 07, 2022
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8999387	Apr 23, 2030	U-55			
	9017721	Apr 23, 2030	DP			
	9173854	Apr 23, 2030	DP			
	9180095	Apr 23, 2030	U-55			
	9180096	Apr 23, 2030	DP			
	9186328	Apr 23, 2030	U-55			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N 022165 001	8927604	Jun 16, 2026	U-436			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001	6407079	Jun 18, 2019	DP			
	8946292	Mar 22, 2027	U-1659			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9066913	Oct 17, 2027	DP U-1488			
	9101591	Oct 17, 2027	DP U-1488			
	9132110	Oct 17, 2027	U-1488			
	9168304	Oct 17, 2027	DP			
	9168305	Oct 17, 2027	U-1488			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	9155718	Jan 17, 2022	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001 >A>	8940786	Sep 30, 2033	DP U-1789			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002 >A>	8940786	Sep 30, 2033	DP U-1789			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003 >A>	8940786	Sep 30, 2033	DP U-1789			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001					M-166	Jul 30, 2018
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	5061703	Apr 11, 2015	U-1641			
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-1641			
	8039009*PED	Sep 24, 2029				
	8058291	Dec 05, 2029	U-1641			
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641			
	8283379*PED	May 22, 2026				
	8293794	Nov 22, 2025	DP			
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8338485	Nov 22, 2025	DP			
	8338486	Nov 22, 2025	U-1641			
	8362085	Nov 22, 2025	U-1641			
	8362085*PED	May 22, 2026				
	8580858	Nov 22, 2025	U-1641			
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	9107898	May 01, 2028	DP U-620			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 002	9107898	May 01, 2028	DP U-620			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE HYCLATE - DOXTERIC</u>						
N 050795 006	6958161	Dec 15, 2022	DP U-918			
	8715724	Feb 03, 2028	DP			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N 022425 001 >A>	9107900	Apr 16, 2029	U-1726			
>A>	9107900	Apr 16, 2029	U-1728			
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090694 003					PC	Jan 11, 2016
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
>A>	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
>A>	9149532	Mar 28, 2028	DP			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
>A>	9149532	Mar 28, 2028	DP			
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	9018192	Jun 13, 2026	U-750			
	9018192	Jun 13, 2026	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-714			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-1714			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704	May 24, 2021	U-1714			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293	May 21, 2023	U-1714			
	7795293*PED	Nov 21, 2023				
	8052993	Aug 01, 2027	DP U-1714			
	8052993*PED	Feb 01, 2028				
	8052994	Aug 01, 2027	DP U-1714			
	8052994*PED	Feb 01, 2028				
	8062665	Aug 01, 2027	DP U-1714			
	8062665*PED	Feb 01, 2028				
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8071129	Aug 01, 2027	DP U-1714			
	8071129*PED	Feb 01, 2028				
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
	8828430	Aug 01, 2027	DP U-1714			
	8828430*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		D-149	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1306		I-711	Jun 11, 2018
	6280959	Oct 30, 2018	DS DP U-1575		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1714		PED	Dec 11, 2018
	6280959*PED	Apr 30, 2019			PED	Dec 11, 2018
	7160870	Nov 20, 2022	DS DP U-930		PED	Feb 26, 2022
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-1714			
	7160870*PED	May 20, 2023				
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7332481	May 24, 2021	U-1714			
	7332481*PED	Nov 24, 2021				
	7452874	May 24, 2021	DS DP U-1714			
	7452874*PED	Nov 24, 2021				
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	7473686	May 24, 2021	DS DP U-1575			
	7473686	May 24, 2021	DS DP U-1714			
	7473686*PED	Nov 24, 2021				
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7547719*PED	Jan 13, 2026				
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7790704*PED	Nov 24, 2021				
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	7795293*PED	Nov 21, 2023				
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
	8052995*PED	Feb 01, 2028				
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 207027 001	6280959	Oct 30, 2018	DS DP U-1736		D-149	Jun 11, 2018
	7160870	Nov 20, 2022	DS DP U-1736		I-711	Jun 11, 2018
	7332481	May 24, 2021	U-1736		ODE	Nov 20, 2015
	7452874	May 24, 2021	DS DP		PED	Dec 11, 2018
	7473686	May 24, 2021	DS DP U-1736		PED	Dec 11, 2018
	7547719	Jul 13, 2025	DS DP U-1736			
	7790704	May 24, 2021	U-1736			
	7795293	May 24, 2023	U-1736			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
>A>	9205076	Mar 14, 2025	U-1709			
<u>ELUXADOLINE - VIBERZI</u>						
N 206940 002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
	7786158	Mar 14, 2025	DS			
	8344011	Mar 14, 2025	U-1709			
	8609709	Mar 14, 2025	DS			
	8691860	Jul 07, 2028	DS U-1709			
	9115091	Jul 07, 2028	DS DP U-1738			
>A>	9205076	Mar 14, 2025	U-1709			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	8981103	Oct 26, 2026	DS DP			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	8981103	Oct 26, 2026	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001					M-160	Jun 26, 2018
					M-161	Jun 26, 2018
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002					M-160	Jun 26, 2018
					M-161	Jun 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
	9173859	May 04, 2027	DP U-1772			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP		NP	Aug 26, 2018
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	7125879	Aug 09, 2022	DS DP U-257			
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	9126941	May 15, 2026	U-1588			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	8920377	Nov 23, 2024	DP			
	8926594	Mar 31, 2026	DP			
	9056170	Nov 23, 2024	DP			
	9149579	Jul 19, 2025	U-1758			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9119876	Mar 13, 2035	DP			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6214865	Jul 20, 2023	DS			
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
	5747498*PED	May 08, 2019			PED	Nov 14, 2016
	6900221	Nov 09, 2020	DS DP U-659			
	6900221	Nov 09, 2020	DS DP U-875			
	6900221	Nov 09, 2020	DS DP U-1046			
	6900221	Nov 09, 2020	DS DP U-1403			
	6900221*PED	May 09, 2021				
	7087613	Nov 09, 2020	U-659			
	7087613	Nov 09, 2020	U-1045			
	7087613	Nov 09, 2020	U-1403			
	7087613*PED	May 09, 2021				
	RE41065	Nov 08, 2018	DS DP			
	RE41065*PED	May 08, 2019				
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2016	DS DP U-1451		D-150	Aug 27, 2018
	5753646	Jun 27, 2016	DS DP U-1746		I-715	Aug 27, 2018
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1509			
	5714504*PED	Aug 03, 2015				
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1509			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1509			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1509			
	6428810*PED	May 03, 2020				
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 207920 01	>A> 5900424	May 04, 2016	DS U-1783			
	>A> 5900424*PED	Nov 04, 2016				
	>A> 6369085	May 25, 2018	DS DP U-1784			
	>A> 6369085*PED	Nov 25, 2018				
	>A> 6428810	Nov 03, 2019	DP U-1785			
	>A> 6428810*PED	May 03, 2020				
	>A> 7411070	May 18, 2018	DS			
	>A> 7411070*PED	Nov 18, 2018				
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
	9198888	May 31, 2022	U-1781			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8945621	Oct 17, 2031	U-1661			
	9161920	May 31, 2022	U-1760			
	9198888	May 31, 2022	U-1781			
<u>ESTRADIOL - MINIVELLE</u>						
N 203752 005	6841716	Apr 27, 2020	DP			
	8231906	Jul 04, 2030	DS DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025	DS DP U-1368			
	8410131*PED	May 01, 2026				
	9006224	Jul 01, 2028	U-1681			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001					M-162	Sep 24, 2018
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 001	9107912	Sep 08, 2031	U-1346			
<u>FEBUXOSTAT - ULORIC</u>						
N 021856 002	9107912	Sep 08, 2031	U-1346			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 001	9173847	Oct 01, 2024	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N 022118 002	9173847	Oct 01, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001	9078814	Jan 08, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002	9078814	Jan 08, 2024	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001	5697896	Dec 16, 2016	DP			
	6169920	Jan 02, 2018	DP U-736			
	6181963	Nov 02, 2019	DP			
	8301238	Sep 30, 2031	DP			
	8428708	May 21, 2032	U-736			
	8428709	Jun 11, 2032	DP U-736			
	8781571	Mar 31, 2032	DP U-736			
	9095706	Feb 03, 2033	DP			
<u>FERRIC CITRATE - AURYXIA</u>						
N 205874 001	8901349	Feb 18, 2024	U-1577			
	9050316	Feb 18, 2024	U-1577			
<u>FERRIC PYROPHOSPHATE CITRATE - TRIFERIC</u>						
N 206317 001	6689275	Dec 31, 2016	U-1656			
	6779468	Dec 31, 2016	U-1656			
	7816404	Apr 17, 2029	DP U-1656			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY</u>						
N 201373 001	8933097	Aug 16, 2032	DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES</u>						
N 201373 002	8933097	Aug 16, 2032	DP			
<u>FINAFLOXACIN - XTORO</u>						
N 206307 001	6133260	Apr 12, 2017	DS DP			
	6432948	Apr 12, 2017	DS DP			
	8536167	Aug 08, 2031	U-1679			
	9119859	Jul 02, 2030	U-1679			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FINGOLIMOD - GILENYA</u>						
N 022527 001	9187405	Jun 25, 2027	U-1086			
<u>FLIBANSERIN - ADDYI</u>						
N 022526 001	7151103	May 09, 2023	U-1734		NCE	Aug 18, 2020
	7420057	Aug 01, 2022	DS DP			
	8227471	May 09, 2023	U-1734			
<u>FLUOROURACIL - TOLAK</u>						
N 022259 001	7169401	Jul 18, 2023	DP		NP	Sep 18, 2018
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Apr 14, 2027	DS DP U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Apr 14, 2027	DS DP U-336			
	8916131	Sep 16, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	6537983	Aug 03, 2021	DP U-1401		I-708	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1401			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1401			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1401			
	7439393	Sep 11, 2022	DS DP U-1691			
	8511304	Jun 14, 2027	DP U-1424			
	8511304	Jun 14, 2027	DP U-1691			
	RE44874	Mar 23, 2023	DS DP U-1548			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	5873360	Feb 23, 2016	DP		NP	Apr 30, 2018
	6537983	Aug 03, 2021	DP U-1691			
	6759398	Aug 03, 2021	DP U-1691			
	7101866	Aug 03, 2021	DS DP U-1691			
	7439393	Sep 11, 2022	DS DP U-1691			
	7629335	Aug 03, 2021	DP			
	7776895	Sep 11, 2022	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8511304	Jun 14, 2027	DP U-1691			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
	RE44874	Mar 23, 2023	DS DP U-1691			
<u>FLUTICASONE PROPIONATE - CUTIVATE</u>						
N 021152 001					NPP	Jan 16, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 001					M-155	Mar 27, 2018
<u>GADOXETATE DISODIUM - EOVI</u>						
N 022090 002					M-155	Mar 27, 2018
<u>GATIFLOXACIN - ZYMAR</u>						
N 021493 001	>A> 6333045	Aug 20, 2019	DP	Y		
	>A> 6333045*PED	Feb 20, 2020				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GEFITINIB - IRESSA</u>						
N 206995 001	5770599	May 05, 2017	DS DP U-1755		NP ODE	Jul 13, 2018 Jul 13, 2022
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	8969302	Aug 19, 2030	U-441			
	9155776	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	9095559	Mar 09, 2032	U-1383			
<u>GLYCOPYRROLATE - GLYCOPYRROLATE</u>						
A 091182 002					>A> PC	Jun 18, 2016
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6521260	Jan 31, 2016	DP		NP	Oct 29, 2018
	6528678	Apr 24, 2018	DP			
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8182838	Oct 20, 2028	DP			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8956661	Jun 27, 2021	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6521260	Jan 31, 2016	DP		NP	Oct 29, 2018
	6582678	Apr 24, 2018	DP			
	6878721	Oct 10, 2020	DS DP U-1773			
	7229607	Apr 09, 2021	U-1773			
	7736670	Jun 27, 2021	DP			
	7820694	Jun 02, 2020	DP U-1773			
	8029768	Apr 09, 2021	U-1773			
	8048451	Jun 27, 2021	DP			
	8067437	Jun 02, 2020	U-1773			
	8182838	Oct 20, 2028	DP			
	8283362	Jun 02, 2020	DP U-1773			
	8303991	Jun 27, 2021	DP			
	8435567	Jun 27, 2021	DP			
	8479730	Oct 11, 2028	DP			
	8580306	Jun 27, 2021	DP			
	8658673	Jun 02, 2020	DP U-1773			
	8796307	Jun 02, 2020	DP			
	8956661	Jun 27, 2021	DP			
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 001					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 002					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 003					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE</u>						
A 200881 004					PC	May 30, 2015
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001					M-154	Mar 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003					M-154	Mar 18, 2018
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004					M-154	Mar 18, 2018
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001	8962028	Jun 19, 2033	DP U-1775			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9132096	Sep 12, 2034	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
>A>	9198863	Oct 30, 2021	DP			
>A>	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
>A>	9198863	Oct 30, 2021	DP			
>A>	9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
>A>	9198863	Oct 30, 2021	DP			
>A>	9205056	Oct 30, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	>A> 9198863	Oct 30, 2021	DP			
	>A> 9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	>A> 9198863	Oct 30, 2021	DP			
	>A> 9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	>A> 9198863	Oct 30, 2021	DP			
	>A> 9205056	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
	>A> 9198863	Oct 30, 2021	DP			
	>A> 9205056	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
	9125889	Jun 03, 2031	U-1745			
	9181257	Dec 28, 2026	DS DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8871810	Sep 30, 2029	U-1599		D-152	Nov 20, 2018
	9012508	Sep 14, 2030	U-981		NPP	Nov 20, 2018
	9114068	Sep 30, 2029	U-1735			
	9138404	Sep 30, 2029	U-1756			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	9149477	May 12, 2025	U-1757			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
	9138432	Sep 30, 2025	U-1737			
	9157121	Apr 05, 2030	U-1674			
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	8658673	Jun 02, 2020	DS DP U-1168			
	8796307	Jun 02, 2020	DS DP			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8992982	Apr 23, 2030	DP			
	9089471	Apr 23, 2030	U-55			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	>A> 6432452	Aug 19, 2018	U-68		>A> M-169	Nov 19, 2018
	>A> 6787161	Aug 19, 2018	U-68			
	>A> 6844013	Dec 13, 2018	U-1221			
	>A> 7410656	Aug 19, 2018	U-1222			
	>A> 8278292	Jul 06, 2027	DP			
	>A> 8372827	Dec 18, 2026	DP			
	>A> 8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	>A> 6432452	Aug 19, 2018	U-68		>A> M-169	Nov 19, 2018
	>A> 6787161	Aug 19, 2018	U-68			
	>A> 6844013	Dec 13, 2018	U-1221			
	>A> 7410656	Aug 19, 2018	U-1222			
	>A> 8278292	Jul 06, 2027	DP			
	>A> 8372827	Dec 18, 2026	DP			
	>A> 8372828	Dec 18, 2026	DP			
	8377919	Dec 18, 2026	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30</u>						
N 203313 001	5866538	Jun 20, 2017	DP		NCE	Sep 25, 2020
	6899699	Jan 02, 2022	DP			
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 001	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DEGLUDEC - TRESIBA</u>						
N 203314 002	6899699	Jan 02, 2022	DP		NCE	Sep 25, 2020
	7615532	May 25, 2025	DS DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>INSULIN GLARGINE - BASAGLAR</u>						
N 205692 001					>A> NP	Dec 16, 2018
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
	7918833*PED	Mar 23, 2028				
	8512297	Sep 15, 2024	DP			
	8556864	Mar 03, 2024	DP			
	8603044	Mar 02, 2024	DP			
	8679069	Apr 12, 2025	DP			
	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8992486	Jun 05, 2024	DP			
	9011391	Mar 26, 2024	DP			
<u>INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN</u>						
N 205747 001	6034054	Jun 11, 2018	DP U-1707			
	6034054	Jun 11, 2018	DP U-1708			
	6551992	Jun 11, 2018	DP U-1707			
	6551992	Jun 11, 2018	DP U-1708			
	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			
	>A> 9192675	Jun 12, 2029	DP U-1788			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	7943572	Aug 10, 2026	U-1539			
	8424518	Oct 17, 2031	DP			
	8623817	Sep 18, 2029	U-1537			
	8729019	Dec 26, 2028	DP			
	8912193	Jun 12, 2029	DP U-1538			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002 >A>	9192675	Jun 12, 2029	DP U-1788			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
	6652885	Jun 29, 2020	U-1535			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP U-1697			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Dec 26, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
	8889099	Jun 29, 2020	DP U-1621			
	8912193	Jun 12, 2029	DP U-1538			
>A>	9192675	Jun 12, 2029	DP U-1788			
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527 001	8474447	Jan 17, 2030	DP			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	8147867	Aug 29, 2028	DS DP		NP	Oct 22, 2018
	8329213	May 02, 2025	DS DP			
	8703181	May 02, 2025	U-1434			
	8992970	May 02, 2025	DS DP			
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>ISOTRETINOIN - ABSORICA</u>						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
	9089534	Sep 21, 2021	DP			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVABRADINE HYDROCHLORIDE - CORLANOR</u>						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001 >A>	8927595	Oct 12, 2027	U-1782			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
>A>	7687662	Aug 06, 2027	DS DP			
>A>	8003819	Aug 06, 2027	DS DP U-1780			
>A>	8530694	Aug 06, 2027	DS DP U-1780			
>A>	8546608	Aug 12, 2024	DS			
>A>	8859504	Jun 16, 2029	DS DP			
>A>	8871745	Aug 06, 2027	U-1779			
>A>	9175017	Jun 16, 2029	U-1778			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
>A>	7687662	Aug 06, 2027	DS DP			
>A>	8003819	Aug 06, 2027	DS DP U-1780			
>A>	8530694	Aug 06, 2027	DS DP U-1780			
>A>	8546608	Aug 12, 2024	DS			
>A>	8859504	Jun 16, 2029	DS DP			
>A>	8871745	Aug 06, 2027	U-1779			
>A>	9175017	Jun 16, 2029	U-1778			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	7442830	Aug 06, 2027	DS DP U-1780		NCE	Nov 20, 2020
>A>	7687662	Aug 06, 2027	DS DP			
>A>	8003819	Aug 06, 2027	DS DP U-1780			
>A>	8530694	Aug 06, 2027	DS DP U-1780			
>A>	8546608	Aug 12, 2024	DS			
>A>	8859504	Jun 16, 2029	DS DP			
>A>	8871745	Aug 06, 2027	U-1779			
>A>	9175017	Jun 16, 2029	U-1778			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8946281	May 28, 2024	U-1662			
<u>KETOROLAC TROMETHAMINE - ACUVAIL</u>						
N 022427 001	8992952	Aug 05, 2024	DP			
>A>	9192571	Mar 07, 2028	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	9066856	Oct 23, 2033	DP			
<u>LAMIVUDINE - LAMIVUDINE</u>						
A 203564 001					PC	Sep 01, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
<u>LAMIVUDINE - EPIVIR</u>						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
<u>LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS</u>						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022		U-1663		
	7435734	Oct 21, 2022		U-1663		
	7754731	Mar 11, 2029	DS DP	U-1663		
	7820660	Apr 25, 2023	DS			
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 001					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 002					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 003					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMOTRIGINE</u>						
A 200828 004					PC	Sep 28, 2015
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 005					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL</u>						
N 020241 006					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 003					M-159	May 18, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL CD</u>						
N 020764 004					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	9144547	Sep 22, 2023	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003					M-159	May 18, 2018
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004					M-159	May 18, 2018
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 001	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734 002	8980327	Dec 01, 2030	DP			
	9023397	Dec 01, 2030	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001	8821927	Sep 18, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9085573	Mar 21, 2028	DS DP U-1470		D-153	Nov 12, 2018
					I-718	Nov 12, 2018
					I-719	Nov 12, 2018
					I-720	Nov 12, 2018
					NPP	Nov 12, 2018
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	9101622	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	5635517	Oct 04, 2019	DS	U-1211	I-706	Feb 17, 2018
	9056120	Apr 11, 2023		U-1215	ODE	Feb 17, 2022
	9101621	May 15, 2023		U-1216		
	9101622	May 15, 2023		U-1216		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LENAVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
	7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
	9006256	Jul 27, 2027		U-1695		
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001					>A> NCE	Dec 22, 2020
<u>LEUPROLIDE ACETATE - LUPRON DEPOT</u>						
N 020517 003	7429559	Jan 13, 2019	DP			
	8815801	Jun 28, 2022	DP			
	8921326	Feb 05, 2031	DP	U-1666		
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 001					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 002					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 003					M-151	Jan 22, 2018
<u>LEVALBUTEROL HYDROCHLORIDE - XOPENEX</u>						
N 020837 004					M-151	Jan 22, 2018
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001					M-156	Mar 12, 2018
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 001	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002	6471992	Feb 20, 2018	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003	6471992	Feb 20, 2018	DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004	6471992	Feb 20, 2018	DP			
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 001					PC	Oct 20, 2015
<u>LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM</u>						
A 203563 002					PC	Oct 20, 2015
<u>LEVONORGESTREL - LILETTA</u>						
N 206229 001					NP	Feb 26, 2018
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 001	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 002	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM</u>						
N 202231 003	9006289	Oct 03, 2032	DP			
	9168238	Aug 29, 2032	DP			
	9168239	Aug 29, 2032	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	>A> 7304036	Aug 30, 2026	DS DP U-1278			
	>A> 7304036	Aug 30, 2026	DS DP U-1516			
	8933030	Feb 17, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	>A> 7304036	Aug 30, 2026	DS DP U-1278			
	>A> 7304036	Aug 30, 2026	DS DP U-1516			
	8933030	Feb 17, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	May 04, 2027	U-1503			
	8853156	Mar 05, 2031	U-1642			
	9173859	May 04, 2027	DP U-1503			
	9173859	May 04, 2027	DP U-1768			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	May 04, 2027	U-1503			
	9155705	May 21, 2030	DP			
	9173859	May 04, 2027	DP U-1503			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINEZOLID - LINEZOLID</u>						
A 078061 001					PC	Dec 19, 2015
<u>LINEZOLID - LINEZOLID</u>						
A 200222 001					PC	Jul 04, 2015
<u>LINEZOLID - ZYVOX</u>						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LINEZOLID - ZYVOX</u>						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	8846618	Jun 27, 2022	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 26, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 001	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 002	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 003	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 004	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 005	7105486	Feb 24, 2023	U-842		I-703	Jan 30, 2018
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 006	7105486	Feb 24, 2023	U-727		I-703	Jan 30, 2018
	7105486	Feb 24, 2023	U-842			
	7223735	Feb 24, 2023	DP			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP U-842			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007	7223735	Feb 24, 2023	DP		I-703	Jan 30, 2018
	7655630	Feb 24, 2023	DS			
	7659253	Feb 24, 2023	DS DP U-727			
	7659254	Feb 24, 2023	U-1034			
	7662787	Feb 24, 2023	DS			
	7662788	Feb 24, 2023	U-727			
	7671030	Feb 24, 2023	DP U-727			
	7671031	Feb 24, 2023	U-727			
	7674774	Feb 24, 2023	DP U-842			
	7678770	Feb 24, 2023	U-842			
	7678771	Feb 24, 2023	DP			
	7687466	Feb 24, 2023	DP			
	7687467	Feb 24, 2023	DP U-842			
	7700561	Feb 24, 2023	DP			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2016	DS	U-1317	NCE	Dec 21, 2017
	6492365	Dec 10, 2019		U-1318	ODE	Dec 21, 2019
	7932268	Aug 19, 2027		U-1316		
	8618135	Mar 07, 2025		U-1316		
<u>LORATADINE - CLARITIN</u>						
N 020641 002	6132758	Jun 01, 2018	DP			
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025		U-1252		
	8980881	Dec 20, 2025		U-1253		
	8980881	Dec 20, 2025		U-1254		
	8980881	Dec 20, 2025		U-1255		
	8999970	Feb 07, 2033		U-1688		
	8999970	Feb 07, 2033		U-1689		
	8999970	Feb 07, 2033		U-1692		
	9169213	Dec 06, 2032		U-1762		
	9169213	Dec 06, 2032		U-1763		
	9169213	Dec 06, 2032		U-1764		
	9169213	Dec 06, 2032		U-1765		
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP	U-540		
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9174975	Jun 25, 2026		U-1770		
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9174975	Jun 25, 2026		U-1770		
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9174975	Jun 25, 2026		U-1770		
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9174975	Jun 25, 2026		U-1770		
	RE45573	Jun 23, 2025	DS			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9174975	Jun 25, 2026		U-1770		
	RE45573	Jun 23, 2025	DS			
<u>MEGESTROL ACETATE - MEGACE ES</u>						
N 021778 001	9040088	Apr 22, 2024		U-755		
	9101540	Apr 22, 2024	DP	U-755		
	9101549	Apr 22, 2024		U-755		
	9107827	Apr 22, 2024		U-755		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM - VIVLODEX</u>						
N 207233 001					NP	Oct 22, 2018
<u>MELOXICAM - VIVLODEX</u>						
N 207233 002					NP	Oct 22, 2018
<u>MESALAMINE - CANASA</u>						
N 021252 002	8217083	Jun 06, 2028	DP			
<u>MESALAMINE - ASACOL HD</u>						
N 021830 001	9089492	Nov 15, 2021	DP			
<u>MESALAMINE - APRISO</u>						
N 022301 001	8940328	Apr 20, 2018	DP			
	8956647	Apr 20, 2018	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9101660	Jan 22, 2027	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	9060941	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	9060941	Sep 19, 2023	DP			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	8945063	Mar 19, 2030	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	8945063	Mar 19, 2030	DP U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	9180125	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	9034370	Oct 07, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	9034370	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	9000038	Jul 31, 2017	U-666			
	9000038	Jul 31, 2017	U-1693			
	9000038*PED	Jan 31, 2018				
	9029416	Jul 31, 2017	DP U-666			
	9144549	Jul 31, 2017	U-1747			
	9144549	Jul 31, 2017	U-1748			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8956649	Feb 15, 2031	DP U-1665			
	9040083	Feb 15, 2031	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 001	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 002	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 003	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 004	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 005	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 006	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR</u>						
N 205831 007	6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
	7083808	Dec 16, 2019	DP			
	7247318	Dec 16, 2019	DP			
	7438930	Dec 16, 2019	DP			
	8580310	Dec 16, 2019	DP			
	9066869	Dec 16, 2019	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	>A> 8202537	Mar 15, 2027	DP			
	>A> 8287903	Feb 15, 2031	DP			
	>A> 8999386	Apr 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	>A> 8202537	Mar 15, 2027	DP			
	>A> 8287903	Feb 15, 2031	DP			
	>A> 8999386	Apr 14, 2033	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	>A> 8202537	Mar 15, 2027	DP			
	>A> 8287903	Feb 15, 2031	DP			
	>A> 8999386	Apr 14, 2033	DP			
<u>METRONIDAZOLE - NUVESSA</u>						
N 205223 001	7893097	Feb 19, 2028	DP			
	8658678	Jun 27, 2028			U-1682	
	8877792	Feb 02, 2028	DP			
	8946276	Jun 28, 2032			U-1664	
	9198858	Jun 28, 2032			U-1664	
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	8921348	Aug 27, 2028			U-1643	
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9084802	May 12, 2031			U-282	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N 050781 001	7699609	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 004 >A>	9192615	Nov 17, 2031	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 005 >A>	9192615	Nov 17, 2031	DP			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002	6946120	Apr 20, 2019	DP U-702			
<u>MITOMYCIN - MITOSOL</u>						
N 022572 001 >A>	9205075	Jul 19, 2026	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9072781	Mar 12, 2034	DP			
	>A> 9192608	Mar 12, 2034			U-43	
	>A> 9192608	Mar 12, 2034			U-55	
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9072781	Mar 12, 2034	DP			
	>A> 9192608	Mar 12, 2034			U-43	
	>A> 9192608	Mar 12, 2034			U-55	
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9072781	Mar 12, 2034	DP			
	>A> 9192608	Mar 12, 2034			U-43	
	>A> 9192608	Mar 12, 2034			U-55	
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9072781	Mar 12, 2034	DP			
	>A> 9192608	Mar 12, 2034			U-43	
	>A> 9192608	Mar 12, 2034			U-55	
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9072781	Mar 12, 2034	DP			
	>A> 9192608	Mar 12, 2034			U-43	
	>A> 9192608	Mar 12, 2034			U-55	
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	8623418	Nov 07, 2029	U-1640			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	8623418	Nov 07, 2029	U-1640			
<u>MOXIFLOXACIN HYDROCHLORIDE - MOXEZA</u>						
N 022428 001	9114168	May 29, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	9161914	Jan 31, 2033	U-540			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7056500	Jun 29, 2024	DP U-1185			
	9012469	Apr 02, 2032	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	8926594	Mar 31, 2026	DP			
	8939943	Feb 28, 2031	DP			
	9022022	Feb 28, 2031	DP			
	9056170	Nov 23, 2024	DP			
<u>NALOXONE HYDROCHLORIDE - NARCAN</u>						
N 208411 001	9211253	Mar 16, 2035	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	May 10, 2022	DP U-1556			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	8969369	May 10, 2022	DP U-1556			
	9056051	May 10, 2022	DP U-1556			
	9073933	Mar 30, 2025	DS			
	9084729	May 10, 2022	DP U-1556			
	9161937	May 10, 2022	DP U-1556			
	9168252	May 10, 2022	DP U-1556			
	9205082	May 10, 2022	DP U-1556			
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 001	6060499	Aug 14, 2017	DP U-867			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-867			
	6586458*PED	Feb 14, 2018				
	7332183	Oct 02, 2025	DP U-867			
	7332183*PED	Apr 02, 2026				
	8022095	Aug 14, 2017	DP U-867			
	8022095*PED	Feb 14, 2018				
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
	5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
	6060499	Aug 14, 2017	DP U-1719			
	6060499*PED	Feb 14, 2018				
	6586458	Aug 14, 2017	DP U-1719			
	6586458*PED	Feb 14, 2018				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET</u>						
N 021926 002	7332183	Oct 02, 2025	DP U-1719			
	7332183*PED	Apr 02, 2026				
<u>NEPAFENAC - ILEVRO</u>						
N 203491 001	8921337	Mar 31, 2032	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	8951969	Nov 18, 2030	DP			
	9186357	Nov 18, 2030	U-528			
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8999379	Feb 13, 2020	U-1686			
>A>	9205059	Dec 15, 2019	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8999379	Feb 13, 2020	U-1686			
>A>	9205059	Dec 15, 2019	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8999379	Feb 13, 2020	U-1686			
>A>	9205059	Dec 15, 2019	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 001	8940772	Apr 30, 2029	DP			
<u>NICOTINE POLACRILEX - NICORETTE</u>						
N 022360 002	8940772	Apr 30, 2029	DP			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 001	7989474	Apr 06, 2024	U-1677			
<u>NINTEDANIB ESYLATE - OFEV</u>						
N 205832 002	7989474	Apr 06, 2024	U-1677			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-167	Oct 09, 2018
<u>OLAPARIB - LYNPARZA</u>						
N 206162 001	7151102	Apr 29, 2022	DS DP		ODE	Dec 19, 2021
	7449464	Oct 11, 2024	DS DP			
	7981889	Oct 11, 2024	DS DP			
	8143241	Aug 12, 2027	U-1634			
	8247416	Sep 24, 2028	DS			
	8859562	Aug 04, 2031	U-1634			
	8912187	Mar 12, 2024	U-1634			
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	5964416	Oct 04, 2016	DP		NC	May 21, 2018
	6149054	Dec 19, 2016	DP		NCE	Jul 31, 2019
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	7220742	May 12, 2025	DS DP U-1703			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1702			
	8044046	Nov 10, 2023	U-1702			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP U-1702			
<u>OLOPATADINE HYDROCHLORIDE - PAZEO</u>						
N 206276 001	8791154	May 19, 2032	DP U-1680		NP PED	Jan 30, 2018 Jul 30, 2018
<u>OMBITASVIR; PARITAPREVR; RITONAVIR - TECHNIVIE</u>						
N 207931 001	6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
	6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
	6703403	Jun 26, 2016	U-1635			
	6703403*PED	Dec 26, 2016				
	7148359	Jul 19, 2019	DP			
	7148359*PED	Jan 19, 2020				
	7364752	Nov 10, 2020	DP			
	7364752*PED	May 10, 2021				
	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
	8399015	Aug 25, 2024	DP			
	8399015*PED	Feb 25, 2025				
	8420596	Apr 10, 2031	DS DP			
	8420596*PED	Oct 10, 2031				
	8642538	Sep 10, 2029	DS DP U-1638			
	8686026	Jun 09, 2031	DP			
	8691938	Apr 13, 2032	DS DP			
	9006387	Jun 10, 2030	U-1687			
	9044480	Apr 10, 2031	U-1638			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	9012501	Feb 07, 2025	DP U-1511			
	9050308	Jan 04, 2033	U-1511			
	9050309	Jan 04, 2033	DS			
	9132112	Feb 07, 2025	DP U-1511			
<u>OMEPRazole - OMEPRazole</u>						
N 022032 001	9023391	Aug 16, 2025	DP			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID OTC</u>						
N 022283 001	5840737	Jul 15, 2016	U-1025			
	6780882	Jul 15, 2016	DP			
	7399772	Jul 15, 2016	U-1025			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 001	9095577	Jul 13, 2030	DP			
<u>ONDANSETRON - ZUPLENZ</u>						
N 022524 002	9095577	Jul 13, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2016	DS DP U-1569			
<u>OSELTAMIVIR PHOSPHATE - TAMIFLU</u>						
N 021246 002	5763483	Aug 23, 2016	DS DP U-1113			
	5763483*PED	Feb 23, 2017				
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	8946235	Aug 08, 2032	DS DP U-1777		NCE	Nov 13, 2020
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Jul 09, 2028	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9119791	Apr 13, 2027	U-1298			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9119791	Apr 13, 2027	U-1298			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	8920392	Mar 26, 2031	U-1644			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
	9073933	Mar 30, 2025	DS		NPP	Aug 13, 2018
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	7820788	Oct 27, 2024	DP U-1092			
	7820788	Oct 27, 2024	DP U-1290			
	7820788	Oct 27, 2024	DP U-1434			
	8853260	Oct 10, 2020	DP U-1092			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	8853260	Oct 10, 2020	DP U-1290			
	8853260	Oct 10, 2020	DP U-1434			
	9101543	Feb 21, 2026	U-1434			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
	7208489	Jan 16, 2023	DS DP			
	7456168	Jan 16, 2023	U-1658			
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALIPERIDONE PALMITATE - INVEGA TRINZA</u>						
N 207946 004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
	6077843*PED	Nov 12, 2017				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9125905	Jan 30, 2024	DP			
	9173942	Jan 30, 2024	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9125905	Jan 30, 2024	DP			
	9173942	Jan 30, 2024	DP			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 001 >A>	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 002 >A>	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 003 >A>	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 004 >A>	9198871	Feb 07, 2030	DP U-1787			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N 020725 005 >A>	9198871	Feb 07, 2030	DP U-1787			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PANOBINOSTAT LACTATE - FARYDAK</u>						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 001	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 002	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
<u>PATROMER SORBITEX CALCIUM - VELTASSA</u>						
N 205739 003	7556799	Feb 27, 2025	U-1766		NCE	Oct 21, 2020
	8147873	Mar 11, 2026	DP			
	8216560	Mar 14, 2027	U-1766			
	8282913	Mar 11, 2026	DP			
	8287847	Mar 30, 2024	U-1766			
	8337824	May 29, 2030	DS U-1766			
	8475780	Mar 30, 2024	U-1766			
	8778324	Mar 30, 2024	U-1766			
	8889115	Mar 30, 2024	U-1766			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002					I-710	Jun 19, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005					I-710	Jun 19, 2018
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006					I-710	Jun 19, 2018
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7696236	Dec 18, 2027	U-1601			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	RE40640	Oct 14, 2016	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					I-707	Apr 23, 2018
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					I-707	Apr 23, 2018
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	9029533	Dec 22, 2026	U-836			
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698			
<u>PREDNISONE - RAYOS</u>						
N 202020 001	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 002	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
<u>PREDNISONE - RAYOS</u>						
N 202020 003	9040085	Apr 23, 2024	U-1362			
	9186332	Apr 23, 2024	U-1362			
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9045519	Jun 22, 2019	DP			
	9085601	Feb 02, 2027	DP			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Feb 16, 2031	DS DP			
	8680124	Jun 02, 2030	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
	6861053	Aug 11, 2019	U-1708			
	7452857	Aug 11, 2019	U-1707			
	7452857	Aug 11, 2019	U-1708			
	7605240	Aug 11, 2019	U-1707			
	7605240	Aug 11, 2019	U-1708			
	7718608	Aug 11, 2019	U-1707			
	7718608	Aug 11, 2019	U-1708			
	7915275	Feb 23, 2025	U-1707			
	7915275	Feb 23, 2025	U-1708			
	7935799	Aug 11, 2019	U-1707			
	7935799	Aug 11, 2019	U-1708			
	8193196	Sep 02, 2027	DS DP U-1707			
	8193196	Sep 02, 2027	DS DP U-1708			
	8309569	Jul 18, 2029	U-1707			
	8309569	Jul 18, 2029	U-1708			
	8741904	Feb 27, 2026	DS U-1526			
	8741904	Feb 27, 2026	DS U-1707			
	8741904	Feb 27, 2026	DS U-1708			
	8946252	Jul 24, 2029	U-1481			
	8969398	Oct 02, 2029	U-1481			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Aug 09, 2022	DS DP U-1153		NPP	Aug 26, 2018
	7125879	Aug 09, 2022	DS DP U-1307			
	7125879	Aug 09, 2022	DS DP U-1740			
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 001					PC	Nov 28, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 002					PC	Nov 28, 2015
<u>RISEDRONATE SODIUM - RISEDRONATE SODIUM</u>						
A 077132 003					PC	Nov 28, 2015
<u>RIVASTIGMINE - RIVASTIGMINE</u>						
A 204403 003					PC	Feb 29, 2016
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	5712298	Jan 27, 2020	DS DP U-1115			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Dec 08, 2023	DS DP U-1741		NCE	Sep 01, 2020
	7563801	Apr 04, 2027	DP			
	7981905	Apr 04, 2027	U-1741			
	8178550	Apr 04, 2027	DS DP			
	8361500	Oct 09, 2029	DP			
	8404702	Oct 09, 2029	U-1741			
	8470842	Jan 18, 2029	U-1741			
	8796299	Dec 17, 2022	U-1741			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		NPP	Nov 20, 2018
	6858618	Dec 17, 2021	U-1032			
	6858618*PED	Jun 17, 2022				
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	9079912	Dec 12, 2026	U-1573			
	9079912	Dec 12, 2026	U-1721			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	8101659	Jan 14, 2023	DP			
	8404744	Jan 14, 2023	DP			
	8796331	Jan 14, 2023	U-1723			
	8877938	May 27, 2027	DS DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7566714	Nov 17, 2024	U-1589			
	7566714*PED	May 17, 2025				
	7612073	Nov 17, 2024	U-1010			
	8067416	Nov 17, 2024	U-1589			
	8067416*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1590			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007					>A> NCE	Dec 21, 2020
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008					>A> NCE	Dec 21, 2020
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	9040562	Jul 28, 2026	DS DP U-1467		D-151 I-717	Oct 05, 2018 Oct 05, 2018
<u>SIROLIMUS - RAPAMUNE</u>						
N 021083 001					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 001					ODE	May 28, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 002					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 003					ODE	May 28, 2022
<u>SIROLIMUS - RAPAMUNE</u>						
N 021110 004					ODE	May 28, 2022
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8952062	Dec 22, 2019	U-1101			
	8952062	Dec 22, 2019	U-1102			
	9050302	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9085573	Mar 21, 2028	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 011	5849700	Dec 15, 2015	U-1041			
	5849704	Dec 15, 2015	DS DP U-1041			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
	8920383	Jul 17, 2026	DP			
	9108002	Jan 20, 2026	DP			
	9132239	Feb 01, 2032	DP			
<u>SONIDEGIB PHOSPHATE - ODOMZO</u>						
N 205266 001	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	8178563	Feb 06, 2029	DS U-1722			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8124630	Jan 12, 2020	U-1459			
	8841330	Jan 12, 2020	U-1696			
<u>SPINOSAD - NATROBA</u>						
N 022408 001	6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	>A> 6949527	Jan 27, 2021	U-1795			
	>A> 7265009	Aug 07, 2020	U-1795			
	>A> RE44733	Jan 27, 2021	DS DP U-1794			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	>A> 6949527	Jan 27, 2021	U-1795			
	>A> 7265009	Aug 07, 2020	U-1795			
	>A> RE44733	Jan 27, 2021	DS DP U-1794			
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	8983594	Nov 19, 2030	DP U-1328			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 001	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 002	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
<u>TACROLIMUS - ENVARUSUS XR</u>						
N 206406 003	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
	8486993	Aug 30, 2024	DP U-1752			
	8586084	Aug 30, 2024	U-1752			
	8591946	Aug 30, 2024	DP			
	8617599	Aug 30, 2024	DP			
	8623410	Aug 30, 2024	DP			
	8623411	Aug 30, 2024	U-1752			
	8664239	May 30, 2028	U-1752			
	8685998	May 30, 2028	DP U-1752			
	8889185	Aug 30, 2024	U-1752			
	8889186	Aug 30, 2024	U-1752			
	9161907	Aug 30, 2024	DP U-1752			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 001	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 002	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 003	8536130	Sep 22, 2028	U-1739			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 004	8536130	Sep 22, 2028	U-1739			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N 200533 005	8536130	Sep 22, 2028	U-1739			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	9060995	Jan 25, 2033	U-1710			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2016	DS DP U-1320			
	9060992	Nov 01, 2025	U-1320			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001 >A>	9186346	Feb 04, 2034	U-1786			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002 >A>	9186346	Feb 04, 2034	U-1786			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9132089	Aug 30, 2020	U-490			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	9125816	Aug 30, 2020	U-1103			
	9132089	Aug 30, 2020	U-1103			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8435944	Sep 27, 2027	U-1390			
	8993520	Jun 02, 2026	U-1390			
	9180194	Jun 02, 2026	U-1390			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-714	Sep 03, 2018
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	6251910	Jul 15, 2018	DS		NCE	Jul 20, 2016
	6525060	Dec 02, 2019	DS DP U-1171		NS	Sep 03, 2018
	7250419	Dec 02, 2019	DS DP U-1171			
	7265124	Jul 09, 2021	DS DP U-1171			
	8425934	Apr 17, 2030	DP			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	8975242	Oct 24, 2028	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	5964416	Oct 04, 2016	DP		NP	Sep 15, 2018
	6149054	Dec 16, 2016	DP			
	6176442	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8733341	Dec 16, 2029	DP			
	9027967	Mar 31, 2027	DP			
	RE39820	Jan 30, 2018	DS DP			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001	5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	6479500	Mar 16, 2020	U-1751			
	7799783	Dec 16, 2026	U-1751			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002	5744475	Mar 28, 2016	DS DP U-1751		NCE	Sep 22, 2020
	6479500	Mar 16, 2020	U-1751			
	7799783	Dec 16, 2026	U-1751			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8298576	Apr 04, 2028	DP U-106			
	8992989	Nov 16, 2027	DP U-1675			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	9101545	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	9101545	Mar 19, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	9101545	Mar 19, 2033	DP			
<u>TRAJECTEDIN - YONDELIS</u>						
N 207953 001	8895557	Jan 07, 2028	DP		NCE	Oct 23, 2020
					>A> ODE	Oct 23, 2022
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8703781	Oct 15, 2030	DS DP U-1712			
	9155706	Jan 28, 2032	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8703781	Oct 15, 2030	DS DP U-1712			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8703781	Oct 15, 2030	DS DP U-1712			
	9155706	Jan 28, 2032	DP			
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8957113	Mar 04, 2025	DP U-1182			
	9060939	Mar 04, 2025	DP			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8178582	Oct 10, 2029	DP			
	9144561	Mar 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 001	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 002	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 003	8133893	Mar 13, 2029	DS DP			
<u>TRAZODONE HYDROCHLORIDE - DESYREL</u>						
N 018207 004	8133893	Mar 13, 2029	DS DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	9199908	May 24, 2024	U-1771			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
<u>TRETINOIN - RETIN-A-MICRO</u>						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8512745	Jun 02, 2030	DP			
	8962603	Jun 12, 2030	U-1657			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001	>A> 5968914	Oct 19, 2016	U-1791		>A> NCE	Sep 04, 2020
	>A> 6258795	Jul 10, 2018	DP		>A> NP	Dec 11, 2018
	>A> 7776838	Aug 17, 2027	U-1791			
<u>URIDINE TRIACETATE - XURIDEN</u>						
N 208169 001	6258795	Jul 10, 2018	DP		NCE ODE	Sep 04, 2020 Sep 04, 2022
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 021304 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VALGANCICLOVIR HYDROCHLORIDE - VALCYTE</u>						
N 022257 001					D-148 NPP	Apr 23, 2018 Apr 23, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002					D-146	Mar 16, 2018
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003					D-146	Mar 16, 2018
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	003				NPP	Jun 12, 2018
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450	004				NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>